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Abstract 
 
NK cell cytotoxic functions are under the control of a large array of inhibitory and 
activating cell surface receptors. One class of inhibitory receptors are the MHC class I 
specific Killer Immunoglobulin-like Receptors (KIRs). Different KIRs recognise 
different groups of HLA molecules. KIR2DL2 and KIR2DL3 segregate as alleles of 
the same locus and recognise the same HLA-C group 1 allotypes (HLA-C1).   Loss of 
an inhibitory signal is one mechanism by which NK cells might recognise an infected 
cell. 
 
KIR-Ig proteins were generated to study the direct binding of KIR2DL2 and 
KIR2DL3 to HLA-C1: peptide complexes. The TAP-deficient T2 cell line expresses 
HLA-Cw*0102 (HLA-C1) and can be loaded with exogenous peptide to generate 
stable peptide: MHC class I complexes. Using an endogenous peptide, VAPWNSLSL 
as a template, known to bind to HLA-Cw*0102, a panel of seven peptides with 
mutations at residues 7 and 8 was studied to assess KIR binding. A peptide hierarchy 
was defined for KIR2DL2 and KIR2DL3 binding; peptides that mediated strong, 
intermediate or weak recognition of KIR to HLA-Cw*0102 were identified. A similar 
peptide hierarchy was observed to inhibit NK cells in CD107a assays. We showed 
that KIR2DL3 binds more strongly to HLA-Cw*0102: peptide than KIR2DL2, 
although in CD107a assays, KIR2DL2+ NK cells were not more inhibited than 
KIR2DL3+ NK cells. The peptide hierarchy was used to generate in vitro peptide 
repertoires containing strong and weak KIR-binding peptides.  We observed that the 
weak KIR-binding peptide VAPWNSDAL can abrogate the inhibition of NK cells by 
the strong KIR-binding peptide VAPWNSFAL, despite levels of HLA-C remaining 
constant.  This loss of NK cell inhibition in the presence of VAPWNSDAL occurred 
at more than 1 log higher concentration of VAPWNSFAL than in the absence of 
VAPWNSDAL. These data indicate that changes in peptide repertoire are 
significantly more efficient than class I down-regulation at releasing NK cells from 
inhibition.   
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Chapter 1. Introduction 
 
1.1 First description of Natural Killer (NK) cells 
 
The discovery of Natural Killer (NK) cells occurred in the early 1970s during 
research on the well-characterised ability of T-lymphocytes to lyse tumour cells 
against which they had been previously immunised.  Tumour cell lines were used to 
investigate tumour-specific cell-mediated cytotoxicity (Baldwin et al, 1973; Bubenik 
et al, 1971; Leventhal et al, 1972; O’Toole et al, 1974), and surprisingly it was 
observed that cells from non-immunised animals as well as healthy donors exhibited 
reactivity in levels comparable to those observed in immunised animals and cancer 
patients (Takasugi et al, 1973).  Further studies of cytotoxicity revealed that 
lymphocytes from healthy donors were able to spontaneously lyse tumour cells in 
vitro in the absence of prior sensitisation (Labowskie et al, 1974; Mathews et al, 1975; 
Peter et al, 1975; Ortaldo et al, 1977; Karre et al, 1986; Ljunggren et al, 1989). This 
non-adaptive, non-MHC restricted cell-mediated cytotoxicity was defined as “natural” 
cytotoxicity, and the effector cells mediating natural cytotoxicity were functionally 
defined as Natural Killer cells (Kiessling et al, 1975a,b; Herberman et al, 1975a,b).  
 
NK cells were initially described as non-phagocytic large granular lymphocytes 
(Timonen et al, 1979) that expressed the receptors for Fc fragments of 
Immunoglobulin G (IgG), but were complement receptor negative (Perlmann et al, 
1975; Perussia et al, 1983). The use of monoclonal antibodies (mAbs) to NK cell 
surface markers greatly contributed to progress in the phenotypic and functional 
identification and characterisation of NK cells as a discrete lymphocyte population 
(Zarling et al, 1981; Fleit et al, 1982; Strassmann et al, 1983; Lanier et al, 1983). 
Human NK cells were phenotypically defined by the absence of CD3 antigen or any 
of the known T cell receptor (TCR) chains, expression of the low-affinity receptor for 
IgG Fc, and expression of CD56, the 140-kDa isoform of neural adhesion molecule 
(NCAM) found on NK cells and a minority of T cells (Perussia et al, 1983; Perussia et 
al, 1984; Lanier et al, 1989; Ritz et al, 1988).  
 
The functional importance of NK cells was demonstrated by the finding that NK cell 
activity correlated with the in vivo resistance to tumour growth in murine models 
 16 
(Kiessling and Wigzell, 1979). Furthermore, work by Karre et al (1986) highlighted 
the important role of NK cells in the recognition and elimination of cells that failed to 
express normal self markers, and identified the concept of the “missing self” 
hypothesis.  
 
1.2 Overview of NK cells 
 
NK cells are now regarded as central players in the immune system not only as 
effector cells able to kill a wide variety of target cells, but by their ability to shape 
immune responses through cytokine production and direct interaction with other 
immune cells. Human NK cells represent a lymphoid population that, in contrast to T 
or B lymphocytes, do not express clonally distributed receptors for antigen, or express 
cognate receptors generated by recombination (Moretta et al, 1994; Trinchieri, 1989). 
They are bone marrow-derived large granular lymphocytes that comprise 10-15% of 
circulating lymphocytes. Under normal conditions, NK cells are mostly confined to 
peripheral blood, bone marrow and spleen (Ferlazzo et al, 2004) but can be recruited 
to inflamed tissue in response to proinflammatory cytokines and chemokines due to 
the expression of chemokine receptors on their cell surface (Robertson, 2002). 
 
NK cells mediate essential functions in innate immunity, playing a key role in anti-
viral and anti-tumour innate responses (Biron et al, 1999), due to their early 
production of cytokines, and their ability to directly destroy infected or transformed 
cells. NK cells constitutively express a lytic machinery able to kill target cells in the 
absence of previous activation that causes the target cell to die by apoptosis. They 
share a common killing mechanism with CD8+ Cytotoxic lymphocytes (CTL) and 
mainly mediate cytotoxicity by granule exocytosis and Fas ligand (van Dommelen et 
al, 2006). They can also mediate antibody-dependent cellular cytotoxicity (ADCC) 
initiated by the engagement of low-affinity CD16 (FcγRIIIA) by the Fc portion of 
antibodies bound to cell-associated antigens (Mota et al 2004, Leibson, 1997; Pignata 
et al, 1993). NK cells can be triggered to produce cytokines including gamma 
interferon (IFN-γ); a key cytokine in successful resolution of infection, tumour 
necrosis factor-α (TNF-α), granulocyte/macrophage colony stimulation factor (GM-
CSF),  regulatory cytokines including transforming growth factor (TGF)-β, and can 
produce the beta chemokines macrophage inflammatory protein-1 β (MIP-1β) and the 
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factor regulated on activation-normal T cell expressed and secreted (RANTES) (Biron 
et al, 1999). Through the production of cytokines, as well as their interaction with T 
cells and dendritic cells (DCs), NK cells participate in the shaping, magnitude and 
quality of adaptive immune responses (Fernandez et al, 1999; Mailliard et al, 2003).  
 
Control of NK cell activation is now understood to be a highly complex system of 
diverse inhibitory and activating receptor-ligand interactions. NK cells achieve 
inhibition mainly through interaction with major histocompatability (MHC) class I 
molecules via NK cell receptors that suppress rather than activate NK cell function. 
These receptors mediate a regulatory mechanism that is thought to protect normal 
cells from autologous NK cell attack. Lack of engagement of inhibitory receptors, 
along with engagement of activating receptors by activating ligands on potential 
target cells results in target cell killing (Ljunggren and Karre, 1990; Karre et al, 1986; 
Moretta et al, 1993). NK cells are therefore programmed to kill target cells that have 
lost, or express low levels of MHC class I, that can occur during viral infection or 
tumour transformation.  
 
1.3 NK cell subsets 
  
The total NK cell population is phenotypically and functionally heterogenous; in 
humans, NK cells can be subdivided based on the expression of CD56 and CD16 
(Cooper et al, 2001).  The majority of NK cells in the blood and spleen 
(approximately 90%) are characterised by a low surface density or dim expression of 
CD56 and express CD16 (CD56dimCD16+). These cells are highly cytotoxic and 
produce IFN-γ upon stimulation. CD56brightCD16- NK cells make up approximately 
10% of human NK cells. They have poor cytotoxic capacity, but upon stimulation 
release large amounts of IFN-γ (Cooper et al, 2001). Although originally thought to 
belong to separate lineages, it is now believed that these two NK cell subsets 
represent different stages of maturation with CD56bright NK cells being less mature 
than CD56dim NK cells (Chan et al, 2007; Romagnani et al, 2007).   
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1.4 Cytokine-mediated regulation of NK cell function 
 
The development and functional activity of NK cells are regulated by many cytokines, 
including Interleukin (IL)-2, IL-15, IL-12, IL-21, IL-23, IL-18 and IFNα/β. These 
proinflammatory cytokines differentially promote the expression of activation 
markers on NK cells, such as CD69, secretion of IFN-γ and/or trigger NK cell-
mediated cytotoxicity (Biron et al, 1999). IL-2 enhances NK cytotoxicity, and IL-12 
stimulates IFN-γ production by NK cells. IL-2 and IL-15 have been shown to promote 
the development of human CD56+ NK cells from hematopoietic progenitor cells 
(Mrozek et al, 1996). More recently, IL-15 has been shown to promote NK cell 
development and differentiation of CD56bright NK cells with low cytotoxic capacity 
into CD56dim NK cells with potent cytotoxic capacity in vivo (Huntington et al, 2008). 
 
1.5 The “missing self” hypothesis 
 
Early studies indicated that NK-cell responses were induced by the absence of MHC 
class I molecules on the surface of target cells (Ljunngren and Karre, 1990; Moretta et 
al, 1992). In 1986, Kärre and colleagues reported that NK cells rejected an MHC class 
I-deficient tumour cell line (RMA-S) but did not reject the same cell if it expressed 
MHC class I (RMA). This pivotal study invoked the “missing self” hypothesis as the 
central concept in NK cell recognition and postulated that engagement of inhibitory 
receptors by self MHC class I molecules is necessary to inhibit NK cell activation. 
Thus cells that lost self MHC class I became susceptible to NK-mediated lysis. 
Conversely, an induction of self MHC class I molecules on such a target cell should 
be sufficient to prevent rejection mediated by NK cells. Important validations of the 
“missing self” hypothesis were shown in studies by Storkus et al (1989) where 
susceptible target cells were rescued by NK cell-mediated lysis when transfected with 
DNA encoding HLA class I molecules, and Quillet et al (1988) where transfection of 
the human β2-microglobulin (β2-m) gene into the β2-m-deficient Daudi cell line 
rescued HLA class I expression and a decreased NK cell sensitivity was observed. 
Further support for the “missing self” hypothesis was shown in studies reporting the 
rejection of class I MHC-deficient bone marrow cells by NK cells from MHC-
matched mice (Bix et al, 1991) and the rejection of normal T cells from β2-m-
deficient mice by normal NK cells (Liao et al, 1991).  In addition, the in vivo 
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phenomenon of “hybrid resistance”, observed when (A x B)F1 offspring rejects the 
bone marrow of a parent homozygous for MHC class I is known to be dependent on 
NK cells (Kiessling et al, 1977). 
 
Two models were proposed by Kärre and colleagues (1990) to account for the 
inhibitory effect of target MHC class I expression on NK cell triggering. Firstly the 
“receptor inhibition” model stated that a receptor specific for MHC class I would 
transmit an inhibitory signal that will turn off NK activation. Secondly, the “target 
interference” model suggested that ligands on target cells that can trigger NK cells are 
masked by MHC class I and prevent NK cell activation. Despite evidence supporting 
both models, neither was conclusive at that time. 
 
It is now apparent that NK cells sense abnormal cells that lack MHC class I, or over-
express ligands for activating NK cell receptors. NK cells are able to eliminate cells 
when a sufficiently potent activating receptor is stimulated despite expression of self-
MHC class I on these cells (Cerwenka et al, 2001). The contemporary update 
therefore of the “missing self” hypothesis incorporates lack of MHC class I 
expression with the expression and binding of activating ligands. In the absence of 
inhibitory signals, NK cell cytotoxicity must be activated by a set of triggering 
receptors. The failure of NK cells to respond to a target can either be due to active 
inhibition or the absence of sufficient activating signals to initiate a response. An 
example of this situation may be represented upon interaction with erythrocytes with 
circulating peripheral blood NK cells. Human erythrocytes do not express MHC class 
I but are not susceptible to NK attack. One explanation is that erythrocytes lack 
activating ligands capable of engaging NK cell activating receptors (Lanier, 2005). 
Figure 1.1 shows a graphic representation of possible outcomes of target-NK cell 
interactions.  
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 Adapted from Lanier L. Ann Rev Immunol 2005 
 
Figure 1.1 The “missing self” hypothesis 
Encounters of NK cells with potential targets and the possible outcomes. The update of the 
“missing self” model incorporates lack of MHC class I expression with the expression and 
binding of activating ligands. a. NK cells that encounter potential target cells that lack 
expression of MHC class I or activating ligands for NK activating receptors are not activated. 
Healthy cells expressing normal levels of MHC class I on their cell surface in the absence of 
NK activating ligands are protected from NK cell lysis (b). Down-regulation of MHC class I 
during viral infection or tumour transformation along with upregulation of activating ligands 
become susceptible to NK lysis (c). d. NK cells expressing activating and inhibitory receptors 
may encounter potential target cells that express MHC class I and NK activating ligands. The 
NK cell response is determined by the balance of signals between the two receptors. 
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1.6 NK cell self-tolerance and “licensing” by self MHC class I molecules 
 
NK cell inhibitory receptors for target cell MHC class I molecules play major roles in 
controlling the NK cell reaction to potential target cells. How these receptors are 
related to self-tolerance however is still incompletely understood. Several hypotheses 
have been proposed. In the “at least one” receptor model, it is proposed that every NK 
cell in a given individual expresses at least one receptor with self-specificity for MHC 
class I. This model would firstly account for self-tolerance, and secondly would 
maximise that number of NK cells that can attack autologous cells that have 
downregulated self-MHC class I. This hypothesis was based on an analysis of human 
NK clones derived from two individuals (Valiante et al, 1997). Each NK cell clone 
derived from a given donor expressed at least one known inhibitory receptor specific 
for one of the donor’s MHC class I molecules, and each clone was inhibited from 
lysing autologous target cells (Valiante et al, 1997). This study however used cloned 
NK cells from only two donors, and did not conclusively demonstrate that all of the 
NK cells present in the donors expressed self-specific receptors. 
 
Although it seemed likely that class I specific inhibitory receptors were involved in 
NK cell self-tolerance, this was confounded by several observations. The “missing 
self” hypothesis implies that in MHC class I-deficient hosts, there should be overt NK 
cell autoreactivity. However, NK cells are not spontaneously active in humans with 
MHC class I deficiencies (Furukawa et al, 1999; Vitale et al, 2002) or in mice 
deficient in β2-microglobulin or transporter associated with antigen processing 
(TAP); two proteins which are required for stable cell-surface expression of MHC 
class I (Bix et al, 1991; Dorfman et al, 1997; Ljunggren et al, 1994). In fact, the 
opposite was found; NK cells from MHC class I-deficient mice are unable to kill 
MHC class I-deficient targets and cannot reject bone marrow grafts that are rejected 
by normal NK cells even though these NK cells appear normal in number, tissue 
distribution and expression levels of activating receptors (Bix et al, 1991; Ljunggren 
et al, 1994). Similar observations were found in humans with deficiencies in TAP. NK 
activity against targets lacking MHC class I was not induced (Furukawa et al, 1999). 
These studies indicated that NK cell function is influenced by the host MHC class I 
environment, but how these receptors related to these observations was not 
understood. 
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1.6.1 NK cell “licensing” by host MHC class I 
 
A number of experiments in the mouse have established the role of MHC class I to 
render NK cell function (Dorfman and Raulet, 1996; Olsson et al, 1995). Recently a 
study by Fernandez and colleagues (2005) observed that a subset of NK cells are 
present in the mouse that lack all known self-MHC-specific inhibitory receptors, yet 
achieve self tolerance by acquisition of a hyporesponsive functional phenotype. 
Engagement of inhibitory Ly49 receptors by self MHC class I molecule “licenses” or 
“educates” NK cells to become functionally competent (Kim et al, 2005). Studies 
performed in humans with MHC class I deficiencies (Furukawa et al, 1999; Vitale et 
al, 2002) have also shown an influence of MHC class I on the acquisition of NK cell 
function; NK cells derived from patients deficient in TAP are not able to lyse MHC 
class I-deficient target cells. A study by Anfossi et al (2006) showed that human NK 
cells also undergo an education process, which is dependent upon the inhibitory MHC 
class I receptors they express. It was suggested that recognition of self MHC class I 
by inhibitory MHC class I-specific receptors during a developmental stage is involved 
in the calibration of NK cell effector capacities, which subsequently allows the 
recognition of the absence of self MHC class I during interaction with target cells.  
 
To explain the data observed in both human and mice, it has been proposed that the 
engagement of inhibitory receptors with self MHC class I provides a positive signal 
during NK cell development that leads to “licensing” of fully competent peripheral 
NK cells (Kim et al, 2005) that can sense and lyse autologous cells that lose self 
MHC. In the absence of an inhibitory receptor-class I MHC ligand interaction, NK 
cells are unlicensed and represent a hyporesponsive subset that fail to respond to a 
number of stimuli (Anfossi et al, 2006). Thus these data suggest that there are two 
major types of self-tolerant NK cells with respect to host MHC. Under non-
inflammatory conditions in any MHC environment, licensed NK cells are tolerant 
because they possess inhibitory receptors for self MHC. Unlicensed cells are also self-
tolerant because they are not functionally competent. Licensing provides a model for 
NK cell self-tolerance and may account for appropriate pairing of inhibitory receptors 
with their cognate self-MHC class I ligands. 
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Two models of NK cell licensing have been proposed by Raulet and Vance (2006) as 
mechanisms of NK cell self tolerance to explain the existence of hyporesponsive NK 
cells (Figure 1.2). In the arming model, immature NK cells receive positive signals 
through self-MHC class I-specific inhibitory receptors through engagement of self-
MHC class I on healthy cells, which promotes the functional maturation of NK cells. 
This model is somewhat paradoxical as engagement of inhibitory receptors on mature 
NK cells inhibits NK cell functions.  NK cells that cannot interact with MHC class I-
expressing target cells, for example due to lack of inhibitory receptor expression, 
remain unarmed and hyporesponsive. In the disarming model, NK cells that lack 
inhibitory receptors specific for self could be “disarmed”, i.e. enter a state of 
hyporesponsiveness, through chronic stimulation of NK cell activating receptors by 
self cells expressing NK activating ligands. Whereas the “arming” model applies to 
immature NK cells, the “disarming” model could apply to immature or mature NK 
cells. Chronic stimulation of immature NK cells lacking MHC class I-inhibitory 
receptors for self could block maturation signals, retaining cells in an immature 
hyporesponsive state, whilst chronic stimulation could induce loss of responsiveness 
in mature NK cells, analogous to T cell anergy.  
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                Adapted from Raulet and Vance; Nat Rev Immunol 2006 
 
Figure 1.2 Arming and disarming models of NK cell self-tolerance 
a. In the arming model, immature NK cells receive positive signals from self-MHC specific 
inhibitory receptors from self-MHC-expressing cells to induce functional maturation and 
“arming” of NK cells. In the absence of inhibitory signals, NK cells remain unarmed and 
unresponsive. b. In the disarming model, NK cells expressing activating and inhibitory 
receptors interact with self cells. NK cells where inhibitory and activating signals are 
balanced retain or acquire responsiveness. NK cells chronically stimulated through activating 
receptors are “disarmed” and are hyporesponsive. Immature or mature NK cells could be 
disarmed. 
Normal 
cell NK cell
Inhibitory receptor
MHC class I Positive signal induced 
maturation
ARMED NK CELL
Responsive
Activating 
receptor
No net stimulation
Responsive
Activating 
ligand
Responsiveness 
maintained
DISARMED NK 
CELL
Hyporesponsive
Induced 
hyporesponsiveness
UNARMED NK 
CELL
Hyporesponsive
a. Arming model
b. Disarming model
 25 
1.7 NK cell Inhibitory Receptors 
 
NK cells express a repertoire of inhibitory receptors that regulate their activation. 
Some inhibitory NK receptors are specific for MHC class I, whereas others bind non-
MHC ligands. The most frequently studied inhibitory immune receptors bind MHC 
class I, and for humans include the highly polymorphic Killer Immunoglobulin-like 
receptors (KIRs), that recognise allelic determinants of classical HLA class I 
molecules, the non-polymorphic CD94/NKG2A receptor, recognising HLA-E, and 
the leukocyte immunoglobulin-like receptors (LILRs) that recognise a large number 
of HLA class I alleles (Moretta et al, 1993; Moretta et al, 1995; Litwin et al, 1994; 
Dohring et al, 1996; Braud et al, 1998; Brooks et al, 1998; Cosman et al, 1997; 
Chapman et al, 1999; Vitale et al, 1999;). Although NK inhibitory receptors are 
diverse in their extracellular domains, they share a common signalling immuno-
receptor tyrosine-based inhibition motif (ITIM) in their cytoplasmic regions. Initiation 
of the inhibitory signal upon ligand binding requires the phosphorylation of two 
tyrosine residues within the ITIMs. A summary of human NK cell inhibitory receptors 
and their ligands is shown in Table 1.1 
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Table 1.1 Human NK cell Inhibitory receptors and their ligands 
 
Inhibitory Receptor Ligand 
KIR2DL1 HLA-C2 (N77/K80) 
KIR2DL2 HLA-C1 (S77/N80) 
KIR2DL3 HLA-C1 (S77/N80) 
KIR3DL1 HLA-Bw4 
KIR3DL2 HLA-A3, HLA-A11 
KIR3DL3 ? 
KIR2DL5A/KIR2DL5B ? 
CD94/NKG2A HLA-E 
LILR-1/ILT-2 HLA-A, -B, -C, -E, -F, -G; UL18 
2B4/CD244 CD48 
KLRG1 E-Cadherin, N-Cadherin, R-cadherin 
CAECAM1 CD66 
LAIR-1 Collagen 
SIGLEC7 α-2,8 disialic acid 
SIGLEC9 Sialic acid 
SIRPα CD47 
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1.7.1 Killer Immunoglobulin-like receptors (KIRs) 
 
KIRs are type I transmembrane glycoproteins that have two (KIR2D) or three 
(KIR3D) extracellular C2-type immunoglobulin (Ig) domains (Wagtmann et al, 
1995a; D’Andrea et al, 1995). They exist as either inhibitory or activating forms 
(Moretta et al, 1993; Moretta et al, 1995; Litwin et al, 1994; Dohring et al, 1996). 
Inhibitory receptors have a longer cytoplasmic tail containing two consecutive ITIMs. 
Ligation of inhibitory KIRs by their HLA ligands on healthy cells inhibits NK cell 
activation and protects the healthy cell from NK cell-mediated lysis through 
recruitment of Src homology (SH)2-containing protein tyrosine phosphatase-1  (SHP-
1) (Lanier, 1998; Long, 1999). Activating forms of the receptors have short 
cytoplasmic tails and contain a charged lysine residue in their transmembrane domain 
that allows interaction with the immunoreceptor tyrosine-based activation motif 
(ITAM)-containing adaptor protein DAP-12 that transmits the activating signal to NK 
cells (Lanier et al, 1998). The known ligands for KIRs are all MHC class I molecules, 
and the specificity of the inhibitory KIR have been clearly defined for several 
receptors. Inhibitory KIR recognise HLA-C allotypes, some HLA-A and HLA-B 
allotypes, and in the case of KIR2DL4, HLA-G (Rajagopalan and Long, 1999). 
Human KIRs are expressed by a majority of NK cells, γδ T cells and a small 
proportion of memory CD8+ αβ T cells (Uhrberg et al, 2001; Parham, 2004a).  
 
1.7.1.1 KIR nomenclature 
 
A generally accepted nomenclature has been adopted to categorise the KIRs 
according to the number of Ig domains present in each gene and whether they possess 
long or short cytoplasmic tails (Valiante et al, 1997). The acronym KIR is followed by 
a suffix that describes the molecule. Receptors with either two or three Ig extracellular 
domains are designated 2D or 3D respectively. The D is followed by either an L, 
indicating a long cytoplasmic tail, or an S, indicating a short cytoplasmic tail. The 
extracellular KIR Ig domains are the sites of ligand recognition. The Ig domains have 
been designated D0, D1 and D2. The D0 domain of KIR3D is the membrane distal 
domain followed by the D1 and D2 domains. KIR2D receptors are subdivided into 
Type I KIR2DL, that have D1 and D2 domains whereas type II KIR2DL (KIR2DL4 
and KIR2DL5) possess D0 and D2 domains (Figure 1.3) 
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Figure 1.3 Structure of KIR receptors 
Members of the KIR family have either two (KIR2D) or three (KIR3D) extracellular Ig 
domains. KIR3D receptors have 3 Ig-like domains (D0, D1 and D2), Type I KIR2D receptors 
have D1 and D2 domains, and Type II KIR2D receptors have D0 and D2 domains. KIR 
members are divided into inhibitory or activating receptors; those with a long cytoplasmic tail 
(KIR2DL; KIR3DL) contain two ITIM motifs which operate together to mediate inhibition of 
NK cells through recruitment of SHP-1 upon binding to their cognate class I ligand. KIR 
members with a short cytoplasmic tail are activating receptors, designated by an S (KIR2DS; 
KIR3DS). They contain a charged lysine residue in their transmembrane (TM) region, 
allowing association with the ITAM-containing adaptor protein DAP12. KIR2DL4 is a 
unique receptor, containing only one ITIM and a charged arginine in the TM region that 
allows association with FcεR1γ. KIR2DL4 is an activating receptor that may also have 
inhibitory function.  
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1.7.1.2 Mechanisms of KIR diversity 
 
The gene family encoding the KIRs forms part of the Leukocyte Receptor Complex 
(LCR) on human chromosome 19 (Wilson et al, 1997; Trowsdale, 2001). The KIR 
locus is highly diverse in humans. KIR haplotypes vary in the number and type of KIR 
genes they contain, and the individual genes exhibit allelic polymorphism (Uhrberg et 
al, 1997; Wilson et al, 2000). All of the KIR genes in an individual’s genotype are 
expressed by some of that individual’s NK cells, and the probability that two KIRs are 
expressed simultaneously on a given NK cell equals the product of the individual 
frequencies of these two KIRs in the respective NK cell pool (Valiante et al, 1997). 
KIRs are expressed clonally such that the expression of KIR is highly heterogenous 
due to the expression of different numbers of KIR genes and different combinations 
of KIR genes (Valiante et al, 1997; Vilches and Parham, 2002). Whether a KIR gene 
is expressed on a given NK cell clone is determined during NK cell maturation, and 
once acquired the pattern of expression remains stable (Valiante et al, 1997). NK cells 
express other receptors, and like KIR some of these receptors are expressed by sub-
populations of NK cells. Together, the clonal distribution of these receptors creates an 
NK cell repertoire of receptor expression to which KIR make a major contribution.  
 
At the level of the human population, two groups of KIR haplotypes have been 
defined that can be distinguished that occur at relatively even frequency: groups A 
and B (Uhrberg et al, 1997; Wilson et al, 2000). Group A and B haplotypes express 
comparable genes for inhibitory KIR, but differ in the activating KIR gene content. 
Group A haplotypes have only six genes; the four main inhibitory KIR (KIR2DL1, 
KIR2DL2/KIR2DL3, KIR3DL1 and KIR3DL2), one activating KIR (KIR2DS4),  and 
a structurally divergent KIR (e.g. KIR2DL4). Group B haplotypes express more genes 
(up to 14) encoding between two and five activating KIR. Group A haplotypes were 
previously thought not to vary in gene content, but showing extensive variability on 
the allelic level (Shilling et al, 2002). However, a recent study by Martin et al (2008) 
to determine the extent of KIR haplotypic variability among 59 families of Northern 
European descent identified a total of 20 unique haplotypes differing in gene content, 
the most common of which was the previously defined Group A haplotype. Some of 
these unusual haplotypes were suggested to have arisen through unequal crossover 
and linkage disequilibrium between several pairs of genes. Group B haplotypes 
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exhibit variation in gene content and also allelic polymorphism (Yawata et al, 2002). 
Currently more than 40 different Group B haplotypes have been described based on 
segregation analysis (Khakoo and Carrington, 2006). Immunogenetic analyses of 
different ethnic populations show significant differences in the frequency distribution 
of A and B haplotypes (Yawata et al, 2002; Toneva et al, 2001). Selection by 
pathogens and genetic drift are likely to contribute to these differences observed.  
 
Sequence analysis of KIR cDNA has shown the KIR genes are highly polymorphic. 
This is likely generated by point mutation and homologous recombination (Shilling et 
al, 2002; Gardiner et al, 2001; Chwae et al, 1999; Kwon et al, 2000; Shilling et al, 
1998). Allelic polymorphism has been described for all KIR genes, but it appears most 
extensive for KIR3DL1 and KIR3DL2. Allelic diversity can be difficult to differentiate 
from diversity at the KIR locus. KIR3DL1 and KIR3DS1 have been shown to occupy 
the same position on different haplotypes, and segregation analysis has indicated that 
they are alleles of a single locus (Gardiner et al, 2001). KIR2DL2 and KIR2DL3 also 
segregate as alleles of the same locus (Keaney et al, 2004), and it has been proposed 
that KIR2DL2 arose from non-reciprocal recombination between KIR2DL1 and 
KIR2DL3 based on sequence similarity patterns (Wilson et al, 2000). The functional 
consequence of KIR polymorphism is not completely understood. 
 
Studies of KIR diversity have shown that variation in gene content and allelic 
diversity is likely to affect NK cell function, as the absence of KIR genes is associated 
with loss of specificity, whereas allelic variation can affect expression levels of a 
given KIR without changing its specificity (Shilling et al, 2002). KIRs and their HLA 
ligands are highly polymorphic and their genes segregate independently on different 
chromosomes (Becker et al, 2003). The number of KIR ligands depends on a person’s 
HLA type, therefore it is possible that an individual does not express the correct HLA 
class I ligands for the inhibitory KIRs they express (Gumperz et al, 1996; Uhrberg et 
al, 1997). Although KIR and HLA segregate independently, recent evidence of co-
evolution of KIR and their HLA ligands was provided for KIR3DL1. Norman et al 
(2007) showed positive selection acting on HLA-Bw4 (the ligand for KIR3DL1), and 
suggested that this was a result of its interaction with KIR3DL1 on NK cells.  
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1.7.1.3 MHC Class I ligands for KIR  
 
KIR receptors are able to distinguish between HLA class I molecules with specific 
structural features. The specificity of the inhibitory KIR for HLA allotypes has been 
clearly defined for several receptors (Table 1.2).  KIR2DL1 binds the subset of HLA-
C allotypes with lysine at position 80 of the heavy chain, known as Group 2 HLA-C 
allotypes (HLA-C2). KIR2DL2 and KIR2DL3 bind the remaining Group 1 HLA-C 
allotypes (HLA-C1) with asparagine at position 80 of the heavy chain (Wagtmann et 
al, 1995b; Colonna et al, 1993). KIR3DL1 recognises HLA-B allotypes with the 
serologically-defined Bw4 motif (Cella et al, 1994; Gumperz et al, 1995), which 
represents approximately 40% of HLA-B alleles. No KIR has yet been shown to bind 
allotypes containing Bw6, the alternative to Bw4 positive allotypes. KIR3DL2 binds 
the HLA-A alleles; HLA-A3 and HLA-A11, (Pende et al, 1996; Dohring et al, 1996), 
and KIR2DL4 binds HLA-G (Kikuchi-Maki et al, 2003).  The receptor-ligand 
interaction can be modulated by the peptide bound to HLA (Malnati et al, 1995; 
Peruzzi et al, 1996; Rajagopalan et al, 1997; Kim et al, 1997; Zappacosta et al, 1997; 
Maenaka et al, 1999). Compared to the inhibitory receptors, the specificities of the 
activating KIR have been harder to define, as they seem to have a much lower affinity 
for their putative HLA ligands. Based on sequence similarity, it is expected that 
KIR2DS1 and KIR2DS2 should have the same HLA class I ligands as KIR2DL1 and 
KIR2DL2/KIR2DL3 respectively. However, KIR2DS1 only binds HLA-C weakly 
whereas consistent binding of KIR2DS2 to HLA-C has not been shown (Biassoni et 
al, 1997; Winter et al, 1998; Vales-Gomez et al, 1998a; Stewart et al, 2005). 
KIR2DS4 has been observed to bind to interact with cells expressing HLA-Cw4 (Katz 
et al, 2001). The activating receptor KIR3DS1 shares >97% sequence similarity to 
KIR3DL1 in the extracellular domain, and is expected to bind HLA-Bw4. However 
its cell surface expression and ligand specificity has not been definitely established.  
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Table 1.2 Defined KIR specificities of human MHC class I ligands 
 
KIR receptors Inhibitory/Activating HLA class I ligands 
KIR2DL1 Inhibitory HLA-C2; p80 lysine 
KIR2DS1 Activating HLA-C2; p80 lysine 
KIR2DL2 Inhibitory  HLA-C1; p80 arginine 
KIR2DL3 Inhibitory  HLA-C1; p80 arginine 
KIR3DL1 Inhibitory  HLA-Bw4 
KIR3DL2 Inhibitory HLA-A3 and HLA-A11 
KIR2DL4 Inhibitory/Activating HLA-G 
KIR2DS4 Activating HLA-Cw4 
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1.7.1.4 Specificity of Inhibitory KIR2DL 
 
MHC class I molecules were first implicated as potential ligands of NK cell receptors 
when an inverse relationship was observed between the susceptibility of target cells to 
NK-cell mediated lysis and the level of expression of class I molecules on target cells 
(Karre et al, 1986; Storkus et al, 1987). Evidence for the involvement of multiple 
receptors that recognised distinct HLA class I molecules came from studies 
examining the specificity of cloned NK cells against different allogeneic target cells 
In 1990, work by Morretta and colleagues (1990a, 1990b) led to the identification of 
two 58kDa proteins confined to human NK cells, originally termed p58, that were 
candidate inhibitory receptors for MHC class I molecules, suggested by their ability to 
regulate the cytolytic function of human NK cells against different allogeneic tumour 
target cells (Moretta et al, 1990b). Single members of this family were identified by 
two monoclonal antibodies (mAbs); GL183 (Moretta et al, 1990a) and EB6 (Moretta 
et al, 1990b), which were later defined as KIR2DL2/KIR2DL3 and KIR2DL1 
respectively. The expression of these p58 molecules correlated with the allospecificity 
of cloned NK cells for target cells (Ciccone et al, 1992a).  
 
A series of experiments by Ciccone et al (1992b) and Moretta et al (1993) showed 
specific interaction between the NK cell p58 receptors and HLA-C. Transfection of 
HLA-Cw3 into the murine P815 target cell, a target known to be lysed efficiently by 
NK cells regardless of their allospecificity, was shown to confer selective protection 
against lysis by NK clones that reacted with both GL183 and EB6 (GL183+EB6+) 
mAbs (Ciccone et al, 1992). P815 cells transfected with other class I alleles including 
HLA-A2, -A3 and –A24 were not protected from lysis by this group of clones, and  
NK clones displaying specificities other than the GL183+EB6+ phenotype efficiently 
lysed HLA-Cw3-transfected P815 target cells. These observations were confirmed by 
Moretta et al (1993); NK clones characterised by the GL183+EB6dull phenotype were 
unable to lyse target cells expressing HLA-Cw3 and related alleles, whilst NK cells 
expressing EB6, but not GL183, failed to lyse cells expressing HLA-Cw4 and related 
alleles, but were lysed by GL183+EB6dull NK clones. 
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Later studies using monoclonal antibodies directed to EB6 and GL183 revealed that in 
fact EB6-reactive receptors were responsible for the recognition of HLA-Cw4 and 
other related alleles, while the GL183-reactive receptors alone recognised HLA-Cw3 
and related C alleles (Vitale et al, 1995). This finding was observed when a group of 
p58+ NK clones were identified that failed to lyse all normal allogeneic cells 
expressing HLA-C. The ability of this clone to recognise all HLA-C alleles was 
consequent to the independent function of the two p58 receptors expressed by these 
cells. In the case of HLA-Cw4+ target cells, anti-EB6 but not anti-GL183 mAbs could 
reconstitute lysis, whereas anti-GL183 but not anti-EB6 mAbs could reconstitute lysis 
of HLA-Cw3+ targets. The previously identified GL183+EB6dull NK clone by Ciccone 
et al (1992b) and Moretta et al (1993) that conferred protection against HLA-Cw3+ 
but not HLA-Cw4+ targets in fact were later found to only express GL183-reactive 
receptors, whereas the NK clone identified by Vitale et al (1995) that could lyse all 
HLA-C-expressing cells expressed a GL183+EB6bright phenotype. 
 
Molecular cloning of the p58 family of NK receptors revealed them as members of 
the Ig superfamily, possessing two extracellular Ig-like domains (Colonna and 
Samaridis, 1995; Wagtmann et al, 1995a). The expression of these p58 receptors 
correlated with allospecificity of cloned NK cells for target cells (Ciccone et al, 
1992a). Specific recognition of HLA-C alleles by p58 receptors was demonstrated by 
direct binding using soluble recombinant p58-Ig fusion proteins (Wagtmann et al, 
1995b, Fan et al, 1996). p58-Ig fusion proteins reactive with GL183 specifically 
bound to cells transfected with HLA-Cw3, whereas p58-Ig fusion proteins reactive 
with EB6 specifically bound to cells transfected with HLA-Cw4 (Wagtman et al, 
1995b). KIR2DL1 was shown to directly bind to a soluble HLA-Cw4 refolded with 
β2-microglobulin and a HLA-Cw4-specific peptide, in a 1:1 complex independent of 
the presence of zinc (Zn2+) (Fan et al, 1996). p58 receptors have two zinc-binding 
motifs in their extracellular domains that are thought to be required for inhibitory KIR 
function but not necessary for binding to HLA-C (Rajagopalan et al, 1995; 
Rajagopalan et al, 1998; Vales-Gomez et al, 2001).  
 
In addition to the identified p58 receptors, 50kDa molecular forms of EB6- or GL183- 
binding proteins were identified that displayed the same HLA-C specificity of the 
corresponding p58 receptors but mediate NK cell triggering rather than inhibition 
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(Moretta et al, 1995). These data suggested that p58 and p50 receptors could be 
homologous in their extracellular domains, but different in their intracellular portion. 
Indeed, cloning of several homologous p58 receptors showed that different from p58 
receptors that possess a long cytoplasmic tail, the activating p50 receptors have a 
short cytoplasmic tail associated with a transmembrane region containing the charged 
residue lysine, and are know as KIR2DS receptors (Biassoni et al, 1996). KIR2DS 
and KIR2DL receptors exhibit high sequence homology in their extracellular domains 
but not in their transmembrane or cytoplasmic portions.  
 
1.7.1.5 Allotypic recognition of HLA-C by KIR2DL 
 
 NK cells are able to discriminate between HLA-C allotypes that are grouped 
according to the amino acid residues at positions 77 and 80 on the α1 helix of the 
class I heavy chain. KIR2DL1+ NK cells are unable to kill target cells expressing 
HLA-C alleles with Asparagine (Asn) at position (p) 77 and Lysine (Lys) at p80 
(HLA-C2 allotypes), whereas KIR2DL2+ and KIR2DL3+ NK cells are unable to kill 
target cells expressing HLA-C alleles with serine (Ser) at p77 and Asn at p80 (HLA-
C1 allotypes) (Vitale et al, 1995). Substitution of the amino acid at residues 77 and 80 
typical of the HLA-Cw3 allele with those present at the same residues in HLA-Cw4 
results in a HLA-Cw3 mutant that is no longer recognised by NK clones expressing 
KIR2DL2 or KIR2DL3 but recognised by KIR2DL1+ NK clones (Biassoni et al, 
1995). Mutagenesis studies indicated that a methionine at position 44 of KIR2DL1 
confers specificity for HLA-Cw4 and related alleles, whilst lysine at position 44 of 
KIR2DL2 and KIR2DL3 confers specificity for HLA-Cw3 and related alleles (Winter 
and Long, 1997). Other mutagenesis studies indicated that clusters of polymorphic 
KIR residues contribute to the specificity for different HLA-C allotypes (Winter and 
Long, 1997; Biassoni et al, 1997; Richardson et al, 2000). 
 
Understanding of the allelic specificity of KIR2D receptors for HLA-C comes from 
crystallographic studies both in free form (Fan et al, 1997; Snyder et al, 1999; 
Maenaka et al, 1999a), and bound to their respective HLA-C ligands; KIR2DL2 
bound to HLA-Cw3 and associated peptide (Boyington et al, 2000), and KIR2DL1 
bound to HLA-Cw4 and associated peptide (Fan et al, 2001). 
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Overall, the KIR fold is similar to the C2-type Ig-like folds that resemble the 
hematopoietic growth factor receptor fold (Fan et al, 1997). KIR2D molecules have 
two tandem N-terminal domains (D1 and D2) connected by a linker of 3-5 amino 
acids. Two anti-parallel β-sheets form each domain, and the hinge angle between the 
D1 and D2 varies from about 60° (KIR2DL1) to 80° (KIR2DL2 and KIR2DL3) in 
different KIR2D receptors, despite a relatively conserved set of hydrophobic residues 
at the D1-D2 interface. An interdomain salt bridge conserved in all KIR family 
sequences restricts the hinge angle. The crystal structures of KIR2DL2 bound to 
HLA-Cw3 (Boyington et al, 2000) and KIR2DL1 bound to HLA-Cw4 (Fan et al, 
2001) show that KIR binds HLA-C in a 1:1 stoichiometry, and bind the α1 and α2 
helices of HLA-C. In both complexes, three loops from the D1 and D2 domains of 
KIR2D bind with approximately orthogonal orientation to the α1 and α2 helix of 
HLA-C respectively and make direct contact with the associated peptide. KIR2DL2 
interacts with residues 7 and 8 of the peptide, and KIR2DL1 interacts with residue 8 
of the associated peptide. There does not seem to be any conformational changes in 
either KIR2D receptors or their respective HLA-C ligands when the complexed 
structure is compared to the uncomplexed components. This suggests a rigid body 
association which is consistent with both the rapid binding kinetics observed in 
KIR/MHC interactions (Maenaka et al, 1999b). The KIR/HLA interface is highly 
charged and comprises a number of salt bridges that are critical for binding.  
 
The allelic specificity of KIR2DL receptors is readily explained by the structure of 
KIR2DL2 bound to HLA-Cw3: peptide (Boyington et al, 2000) and KIR2DL1 bound 
to HLA-Cw4: peptide (Fan et al, 2001). The KIR2DL2/HLA-Cw3 interface contains 
twelve residues from HLA-Cw3, eleven of which are invariant across all HLA-C 
alleles, despite their location within the polymorphic region of the class I heavy chain. 
The only variable residue is that at residue 80. Of the 16 KIR2DL2 residues that 
contact HLA-Cw3, only those at position 44 and position 70 differ in KIR2DL1. In 
the KIR2DL2/HLA-Cw3: peptide complex, lysine 44 of KIR2DL2 forms a hydrogen 
bond with Asn at position 80 of HLA-Cw3 (Figure 1.4), which determines the 
allotype specificity. By contrast, KIR2DL1 uses a different mechanism to achieve 
allelic specificity. In the KIR2DL1/HLA-Cw4 complex, the side chain of HLA-Cw4 
residue 80 Lysine is situated in a negatively charged pocket formed by a channel 
between D1 and D2 of KIR2DL1. This pocket includes the methionine at p44 of 
 37 
KIR2DL1 that forms both hydrophobic and polar interactions with Lys80 of HLA-
Cw4. Substitution of residues in KIR2DL1 or HLA-C2 with residues present in 
KIR2DL2/L3 or HLA-C1 would  be expected to result in charge repulsion and steric 
hindrance, leading to loss of binding.  
 
Peptide preferences have been demonstrated for KIR2D binding to HLA-C molecules 
(Rajakopalan and Long, 1997; Zappacosta et al, 1997). Consistent with the finding 
that the KIR binding site is centred near the C-terminal residues 7 and 8 of the 
peptide, the KIR-HLA interface is most sensitive to substitutions at these two 
residues. Comparatively TCRs, which exhibit greater peptide selectivity than KIRs 
focus on the central portions of the MHC-bound peptide at residues 4-6 (Garcia et al, 
1996). In the KIR2DL2-HLA-Cw3 complex, glutamine (Gln) at residue 71 of 
KIR2DL2 is hydrogen bonded to the main-chain nitrogen atom of p8 Ala (Boyington 
et al, 2000) which is thought to restrict the size of the side chain that can be 
accommodated. Indeed, there is a preference for the small amino acid residues alanine 
or serine in the P8 position (Boyington et al, 2000). In the KIR2DL1/HLA-Cw4 
complex, the surface of KIR2DL1 around Lys at p8 of the peptide is electronegatively 
charged; substitution of p8 of the peptide with negatively charged residues abolishes 
binding (Fan et al, 2001).  
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Figure 1.4 Crystal structure of KIR2DL2 bound to HLA-Cw3: GAVDPLLAL 
KIR2DL2 (green) is bound across both the α1 and α2 helices of HLA-Cw3 (red) and directly 
contacts positions 7 and 8 of the peptide (yellow). Both the D1 and D2 domains of KIR2DL2 
make contact with HLA-C. The KIR/HLA binding interface contains 12 residues from HLA-
Cw3, eleven of which are invariant across all HLA-C alleles. Amino acid 80 is the only 
variable residue contributing to the receptor interface. Allotype specificity is determined by a 
hydrogen bond (dotted red line) between Lys 44 of KIR2DL2 (K44) and Asn 80 (Q80) of 
HLA-Cw3 (red). The KIR2DL2 interface residues are completely conserved in KIR2DL3; 
both receptors recognise the same HLA class I alleles.  
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1.7.1.6 Cross-reactivity of KIR2DL-HLA-C recognition 
 
Some studies have shown weak to moderate cross-reactivity of KIR2DL receptors 
with HLA-C allotypes bearing alternate epitopes (Winter et al, 1998; Moesta et al, 
2008). This cross-reactivity was first observed in a study by Winter et al (1998) to 
investigate the binding properties of three KIR2DL and two KIR2DS receptors to a 
panel of HLA-C transfectants. The functional HLA class I specificities of all three 
KIR2DL were also determined. These experiments revealed permissiveness in 
recognition of HLA-C for two of the KIR2DL receptors. To evaluate the strength of 
binding of each of the individual KIR2D receptors to HLA-C allotypes and their 
specificity, soluble KIR2D-Ig fusion proteins were generated and tested for binding to 
721.221 cells expressing single HLA-C alleles. Binding of KIR2DL1-Ig to HLA-
Cw*0401 was stronger than that observed for KIR2DL2-Ig or KIR2DL3-Ig binding to 
HLA-Cw*0304. Interestingly, binding of KIR2DL2-Ig to HLA-Cw*0304 was 
reproducibly stronger than that of KIR2DL3-Ig to HLA-Cw*0304, even though the 
KIR2DL2 and KIR2DL3 alleles used in this study differed by only five amino acids 
in their extracellular domains. KIR2DL1-Ig bound to transfected cells expressing 
Group 2 HLA-C allotypes (N77K80), and did not bind to Group 1 HLA-C allotypes 
(S77N80). In contrast the specificity of the KIR2DL2 and KIR2DL3 fusion proteins 
for HLA-C1 allotypes was less clear. KIR2DL2-Ig and KIR2DL3-Ig bound HLA-
Cw*0102, -Cw*0304 and -Cw*0702 transfectants (all Group 1 HLA-C allotypes). 
However, KIR2DL2-Ig, but not KIR2DL3-Ig bound to cells expressing HLA-
Cw*1503, an HLA-C2 allotype. To ascertain whether this recognition could be 
detected in a functional assay, a KIR negative NK cell line, NK-92, was transfected 
with KIR2DL1, KIR2DL2 or KIR2DL3 and tested for its ability to kill HLA-C 
transfectants. Binding of KIR2DL2 and not KIR2DL3 to the HLA-C2 allele HLA-
Cw*1503 was observed using fusion proteins, whereas both receptors recognised this 
allele in cytotoxicity assays. This cross-reactivity observed was confirmed by Moesta 
et al (2008). Binding and functional assessment revealed that KIR2DL2 and 
KIR2DL3 receptors interacted with HLA-C1 but also reacted with several HLA-C2 
allotypes, and KIR2DL2 was a stronger receptor than KIR2DL3. KIR2DL1 however 
did not cross-react with any HLA-C1 alleles. Binding of KIR2DL1 to HLA-C2 alleles 
therefore seems to be specific, whereas KIR2DL2 and KIR2DL3 are more 
promiscuous receptors recognising HLA-C1 allotypes and some HLA-C2 allotypes. 
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1.7.1.7 Recognition of HLA-A and HLA-B by inhibitory KIR3D receptors 
  
KIR3DL1 was described as a receptor specific for HLA-B alleles expressing the Bw4 
epitope but not HLA-B alleles expressing the Bw6 epitope (Litwin et al, 1994; Cella 
et al, 1994; D’Andrea et al, 1995; Gumperz et al, 1995; Gumperz et al, 1997). 
KIR3DL1 discrimination of Bw4 and Bw6 allotypes was subsequently confirmed and 
shown by mutagenesis studies to depend on the amino acids Thr/Ile 80, Leu 82 and 
Arg83 (Gumperz et al, 1997). Mutation at Leu82 and Arg83, residues common to 
Bw4 motifs show that although they contribute to KIR3DL1 interaction, are not 
essential. Mutagenesis studies on the receptor side have shown that all three 
extracellular Ig domains are required for binding to HLA-Bw4 alleles (Khakoo et al, 
2002), and position 139 in the D1 domain has been shown to be critical for binding.  
Similar to HLA-C recognition, KIR3DL1 binding to HLA-Bw4 alleles is affected by 
the nature of the bound peptide (Peruzzi et al, 1996a; Peruzzi et al, 1996b). KIR3DL2 
has been demonstrated to recognise only certain HLA-A alleles, HLA-A3 and HLA-
A11, and this recognition is highly peptide specific (Pende et al, 1996; Dohring et al, 
1996; Hansasuta et al, 2004).  
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1.7.1.8 The peptide preference for KIR-HLA binding 
 
The crystal structure of KIR2DL2 bound to HLA-Cw3: peptide revealed that 
KIR2DL2 makes direct contact with residues 7 and 8 of the peptide bound in the 
MHC class I groove. KIR recognition has been shown to be both dependent and 
influenced by the peptide bound to HLA, although there is no true peptide-specific 
recognition, since KIR can bind to the same HLA molecules carrying different 
peptides (Malnati et al, 1995; Correa and Raulet, 1995; Peruzzi et al, 1996a; 
Rajagopolan and Long, 1997; Zappacosta et al, 1997). Early studies to identify the 
role of peptide in KIR-mediated inhibition used cell lines deficient TAP, a protein 
responsible for importing peptides from the cytoplasm to the endoplasmic reticulum. 
Peptide unavailability due to deficiency in TAP results in inefficient MHC class I 
stabilisation on the cell surface. TAP-deficient cells can be loaded with exogenous 
peptide, stabilising the class I molecule leading to the increase in stable MHC class I 
complexes on the cell surface (Henderson et al 1992; Correa and Raulet, 1995). Initial 
studies showed that TAP-deficient cell lines loaded with exogenous peptide were 
found to inhibit NK cells, whilst in the absence of peptide, TAP-deficient cells 
become susceptible to NK lysis (Correa and Raulet, 1995). It was proposed that the 
role of peptide was to stabilise MHC class I on the cell surface, and that MHC class I 
recognition by NK cells is peptide-dependent but not peptide specific. In contrast to 
this data, NK cells have been reported to recognise empty class I molecules 
(Mandelboim et al, 1996).  
 
Functional studies have shown that the lysis of target cells by NK clones exhibits 
peptide specificity. In one such study, the ability of individual peptides bound to 
HLA-Cw*0304 to protect target cells from lysis by KIR2D-expressing NK cells was 
investigated (Zappacosta et al, 1997). HLA-Cw*0304 was isolated and a number of 
endogenously bound peptides were characterised by mass spectrometry. Complete 
sequences for eight peptides were obtained and synthesised. All peptides were 
between 8-11 amino acids in length and shared an alanine at position 2 (known to be 
an anchor residue for HLA-Cw*0304) and a C-terminal leucine. Using these peptides, 
HLA-Cw*0304 molecules were stabilised on the surface of TAP-deficient RMA-S-
Cw*0304-transfected target cells. Different degrees of peptide-mediated protection 
were observed with the eight different peptides tested; some peptides were highly 
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protective against NK cell lysis with others less protective. The ability of peptides to 
protect from lysis did not correlate with the stability of complexes as measured by a 
cell surface stability assay. These findings suggested that recognition of HLA-
Cw*0304 by NK cells is selective and dependent on the peptide bound to MHC class 
I. Furthermore, Surface Plasmon Resonance (SPR) analysis showed that the affinity 
of soluble KIR2DL3 binding to HLA-Cw7: peptide was affected by the bound peptide 
(Maenaka et al, 1999b). Studies with synthetic peptides showed that the recognition of 
HLA-Cw4 by KIR2DL1 is dependent on the presence of peptide in the groove 
(Rajagopalan and Long, 1997). A range of peptides loaded onto HLA-Cw4-
expressing RMA-S cells showed that all peptides stabilised HLA-C on the cell surface 
to an equal amount, but peptides with a negatively charged residue at position 8 
prevented recognition of HLA-Cw4 by KIR2DL1. This can be readily explained by 
the crystal structure of KIR2DL1 bound to HLA-Cw4. KIR2DL1 has an 
electronegatively charged polar surface around the peptide p8 Lys side chain (Fan et 
al, 2001). It therefore does not tolerate acid residues at this position.  
 
Recognition of HLA-B*2705 by NK cells also exhibits peptide selectivity (Malnati et 
al, 1995; Peruzzi et al, 1996a; Peruzzi et al, 1996b). Studies have demonstrated that 
certain residues at position 7 and 8 of the peptide failed to confer HLA-B27-
dependent protection from NK cell-mediated lysis. In particular, the charged residue 
lysine, arginine, and glutamine at positions 7 and 8 of the peptide rendered class I 
MHC molecules more susceptible to lysis (Peruzzi et al, 1996a; Peruzzi et al, 1996b). 
KIR3DL2 binds HLA-A3 and HLA-A11, but in binding studies using an HLA-A11 
tetramer, this was only the case when specific viral peptides were refolded with the 
HLA molecule (Hansasuta et al, 2004). Most recently, KIR2DS1 was found to 
interact with HLA-Cw4 and exhibits the same peptide dependency as KIR2DL1 with 
sensitivity to residues 7 and 8; peptide substitutions that had an effect on binding of 
KIR2DS1 had similar effects on KIR2DL1 binding (Stewart et al, 2005). 
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1.7.1.9 Kinetics of the Interaction of HLA-C ligands with KIR2D receptors 
 
Surface Plasmon Resonance analysis using soluble KIR2DL1, KIR2DL3, KIR2DS2, 
HLA-Cw6 and HLA-Cw7 molecules has permitted assessment of the specificity, 
kinetic parameters and peptide dependency of inhibitory and activating KIR-HLA 
interactions (Vales-Gomez et al, 1998b; Maenaka et al, 1999; Vales-Gomez et al, 
2000). These studies observed that KIR2DL receptors bind to HLA-C with very fast 
association and dissociation rate constants, and the binding of inhibitory KIR to HLA-
C was of a much higher affinity than the binding of activating KIRs to HLA-C 
(Vales-Gomez et al, 1998b). Although several studies using KIR-Ig fusion proteins 
have reported a hierarchy of KIR2DL binding to HLA-C (Winter et al, 1998; Moesta 
et al, 2008), direct affinity measurements showed that inhibitory KIR2DL1 and 
KIR2DL3 receptors bind to HLA-C with similar affinity, with a KD of around 10µM. 
Binding of activating KIR2DS to HLA-C was however very weak. Furthermore, the 
affinity of KIR2DL to HLA-C was dramatically altered by the bound peptide 
(Maenaka et al, 1999b). The affinity of KIR for HLA-C is in the range shown by TCR 
for the specific peptide-MHC complexes, but the kinetics of KIR-HLA-C binding and 
detachment is much faster. One implication between the rapid interaction kinetics is 
that the availability of the receptor or ligand determines whether an interaction occurs; 
i.e. the rate limiting step in this interaction is the diffusion of receptor or ligand into 
the area of cell-cell contact (Vales-Gomez et al, 2000). A second implication is that 
the rapid dissociation rate is likely to contribute to the transience of the inhibitory 
interaction; exposure to HLA molecules does not result in a sustained inhibitory state 
of the NK cell, allowing the NK cell to sample losses of HLA in the next target cell 
rapidly.  
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1.7.2 CD94/NKG2A Receptor 
 
The genes for CD94 and NKG2 are present in human, rat and mouse, and encode 
receptors that recognise non-classical MHC class Ib ligands; human HLA-E and 
mouse Qa1-b (Braud et al, 1998).  NKG2A and CD94 form heterodimers which are 
expressed on the cell surface of NK cells. Cell surface expression of NKG2A is 
dependent on the association with CD94 (Brooks et al, 1997). NKG2A has two ITIMs 
in the cytoplasmic domain that upon ligand binding can recruit SHP-1 and inhibit NK 
cytotoxicity. Therefore CD94/NKG2A heterodimers function as inhibitory receptors. 
The activating CD94/NKG2C receptor requires association with the adaptor protein 
DAP-12 for stable expression on the cell surface and for signalling.  
 
Human CD94/NKG2A and CD94/NKG2C bind HLA-E (Lee et al, 1998; Braud et al, 
1998). Unlike KIR receptors, the CD94/NKG2 receptors do not demonstrate extensive 
polymorphism. HLA-E preferentially binds peptides derived from amino acid residues 
3-11 of the signal sequence of the classical MHC class I molecules HLA-A, HLA-B 
and HLA-C and the non-classical HLA-G molecule (Braud et al, 1998), but cannot 
bind its own leader peptide. Peptides other than class I leader segments can also bind 
to HLA-E (Michaëlsson et al, 2002). Cell surface expression of HLA-E is dependent 
on TAP (Braud et al, 1998). The inhibitory CD94/NKG2A and activating 
CD94/NKG2C receptors bind the same ligands, although CD94/NKG2A has a higher 
affinity for HLA-E than its activating counterpart (Llano et al, 1998; Vales-Gomez et 
al, 1999).  
 
The nature of the bound peptide can markedly influence the affinity of the interaction 
between HLA-E and CD94/NKG2A or CD94/NKG2C receptors, and peptides bound 
to HLA-E can differentially affect recognition by the inhibitory and activating 
receptors (Llano et al, 1998; Brooks et al, 1999; Vales-Gomez et al, 1999). A 
biological consequence of this has been suggested by Michaëlsson et al (2002), who 
showed that HLA-E can present a peptide derived from the leader sequence of human 
heat shock protein-60 (hsp60), a protein induced in response to stress stimuli. HLA-E 
bound to the hsp60 peptide led to a loss of recognition by CD94/NKG2A inhibitory 
receptors, which suggests a mechanism for NK cells to detect stressed cells in a 
peptide-dependent manner.  
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1.7.3 LILRs 
 
The LILRs are monomeric type I glycoproteins of the immunoglobulin superfamily. 
LILR-1 has four extracellular-Ig like domains and its cytoplasmic tail contains four 
ITIMs that can associate with SHP-1 to inhibit NK cells upon ligand binding (Cosman 
et al, 1997; Colonna et al, 1997). LILR-1 binds a broad specificity of HLA class I 
molecules including HLA-A, -B, -C, and the non-classical HLA class I molecules 
HLA-F and HLA-G (Chapman et al, 1999; Vitale et al, 1999; Navarro et al, 1999; 
Lepin et al, 2000), and also binds with high affinity to the Human Cytomegalovirus 
(HCMV) MHC class I homolog UL18 (Cosman et al, 1997). LILR-1 binds to UL18 
with >1000-fold higher affinity than for host MHC class I, therefore even low levels 
of UL18 would be expected to compete efficiently with host class I for binding. 
LILR-1 recognises the α3 domain of both host MHC class I and viral UL18. The α3 
domain of class I proteins is relatively conserved between different alleles as 
compared with the polymorphic α1-α2 peptide-binding region. Binding of LILR-1 to 
the α3 domain of class I MHC proteins provides a rationalisation for the broad 
binding specificity of LILR-1 compared with individual KIRs that bind to an epitope 
within the highly polymorphic α1-α2 peptide-binding region. 
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1.8 The Inhibitory NK cell Immunological Synapse 
 
The encounter between an NK cell and an MHC class I+ healthy target cells results in 
the generation of the inhibitory NK cell Immunological Synapse (IS), which prevents 
NK cell activation and target cell death. The human inhibitory NK synapse was first 
described by Davis et al (1999) who showed that following contact with NK-resistant 
target cells, inhibitory KIR receptors bound to their HLA-C ligands cluster to form an 
inhibitory IS. KIR and HLA-C were found to be distributed into rings around central 
patches of intercellular adhesion molecule-1 (ICAM-1) and Lymphocyte function-
associated antigen-1 (LFA-1), and synapse formation depended upon extracellular 
Zn2+. The clustering of KIRs and associated components of the inhibitory IS has been 
termed the supramolecular inhibitory cluster (SMIC). Three-dimensional organisation 
of the SMIC has been described and shows that initially inhibitory receptors cluster in 
the centre of the SMIC (c-SMIC) while adhesion molecules localise at the periphery 
(p-SMIC). With time, inhibitory receptors migrate to the periphery of the synapse 
(Vyas et al, 2004).  
 
Ligation of inhibitory receptors results in rapid phosphorylation of ITIMs and 
recruitment of SHP-1 and SHP-2 (Burshtyn et al, 1996; Campbell et al, 1996; 
Binstadt et al, 1996; Fry et al, 1996). SHP-1 clusters at the centre of the inhibitory IS 
(Vyas et al, 2002; Almeida and Davis, 2006), disrupting cytoskeletal rearrangement 
and impairing integrin-mediated adhesion (Stebbins et al, 2003; Burshtyn et al, 2000), 
blocking activating signals, and promoting the detachment of NK cells from target 
cells. Recent observations that activating receptors accumulate and co-localise with 
KIR at the inhibitory IS suggest that inhibitory KIR do not prevent signalling by 
activating receptors by blocking their accumulation at the inhibitory synapse, but by 
blocking their ability to signal at the inhibitory synapse (Schleinitz et al, 2008). 
 
Interestingly, despite an abundance of inhibitory receptors at the inhibitory IS, 
phosphorylated KIR is confined to discrete microclusters within the aggregate of KIR 
at the IS (Treanor et al, 2006). Rather than a small fraction of KIR being 
phosphorylated homogenously across the IS, KIR phosphorylation is limited to a 
small fraction that clusters in distinct microdomains at the centre of the synapse (c-
SMIC). This spatial confinement of inhibitory receptor activation focuses inhibition at 
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the cell-cell contact site where activating signals could be triggered, providing a 
mechanism for prompt NK cell deactivation (Treanor et al, 2006), and also provides 
an explanation for the observation that a single NK cell can form activating and 
inhibitory synapses at the same time (Vyas et al, 2001). The density of cell surface 
MHC class I protein has been observed to determine its patterning at the NK cell 
inhibitory IS (Almeida and Davis, 2006). As MHC class I levels increase, the 
distribution of MHC class I changes from being multifocal, to clusters that are 
homogenous or ring-shaped (Almeida and Davis, 2006). These differences in 
patterning and segregation of proteins may influence downstream signalling, and may 
provide a mechanism by which NK cells respond to loss of MHC class I. 
 
1.8.1 Role of Bivalent Cations and KIR2DL aggregation in NK cell Inhibition 
 
The mechanism by which HLA-C binding triggers phosphorylation of KIR2DL 
ITIMs has not been fully identified. The angle between the D1 and D2 domains of 
KIR2DL1 and KIR2DL2 vary slightly upon HLA-C binding (Snyder et al, 1999; 
Boyington et al, 2000; Fan et al, 2001), but it is not clear whether this variation 
induces a conformational change that facilitates tyrosine phosphorylation of the 
ITIMs. There is experimental evidence for binding of HLA-C inducing KIR 
aggregation mediated by zinc and other bivalent cations (Rajagopalan et al, 1995; 
Rajagopalan and Long, 1998; Vales-Gomez et al, 2001). The first extracellular Ig 
domain of KIRs have two stretches of sequence, HEGVH and HFLLH that resemble 
the zinc binding motif HEXXH, that are capable of binding zinc ions (Rajagopalan et 
al, 1995; Rajagopalan et al, 1998). Mutation of histidine sites within these zinc-
binding histidine-rich motifs had no effect on KIR binding to HLA-C, but did impair 
inhibitory function (Rajagopalan et al, 1998). Surface Plasmon Resonance analysis, 
analytical ultracentrifugation and chemical cross-linking experiments have shown that 
zinc binding to KIR2D molecules induces multimerisation of KIR proteins that alters 
the kinetic of the KIR2D-HLA-C interaction (Vales-Gomez et al, 2001). In the 
absence of zinc, the interaction with HLA-C is a simple first order interaction with 
extremely fast association and dissociation rates. In the presence of zinc however, the 
association and dissociation phases of the KIR2D-HLA-C interaction became a 
mixture of fast and slow rate components (Vales-Gomez et al, 2001). Binding of 
HLA-C to KIR induces clustering of KIR, phosphorylation of KIR and SHP-1 (Faure 
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and Long, 2003), and formation of the NK cell inhibitory immune synapse (Davis et 
al, 1999). Both phosphorylation and clustering of KIR at the interface with HLA-C-
expressing targets was found to be dependent on zinc (Davis et al, 1999; Faure and 
Long, 2003). KIR2D aggregation may explain lack of saturation seen in binding 
studies using KIR2D-Fc proteins. Binding of KIR2DL-Ig to their HLA-C ligands fail 
to reach saturation even at concentrations of 100µg/ml (Winter et al, 1998).  
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1.9 NK cell Activating Receptors 
 
The effector functions of NK cells are regulated by a balance between signals derived 
from inhibitory receptors and activating receptors. A large number of structurally 
distinct activating NK cell receptors have been characterised (Table 1.3) and include 
NKG2D, the Natural Cytotoxicity Receptors (NCRs) NKp46, NKp30 and NKp44, 
and CD16 (FcγRIIIA) (Moretta et al, 1990a; Moretta et al, 1990b; Sivori et al, 1997; 
Pessino et al, 1998; Pende et al, 1999; Vitale et al, 1998; Cerwenka et al, 2001). The 
NCRs and NKG2D are the major receptors involved in NK cytotoxicity. Although the 
cellular ligands of NCRs are still unknown, NKG2D has been shown to recognise 
different ligands, such as the MHC-class I homologs MICA and MICB and the family 
of UL16-binding proteins (ULBP 1-4) (Cerwenka et al, 2001). NK cells can be 
activated to mediate ADCC through engagement of the low affinity Fc receptor for 
IgG, CD16. Engagement of this receptor through the Fc region of antibody bound to 
antigen triggers NK cell activation and target cell death. Other NK receptors play a 
role as activating coreceptors in NK-mediated cytolysis including CD244 (2B4) and 
DNAM-1 (Sivori et al, 2000; Bottino et al, 2003).  In contrast to NK inhibitory 
receptors, most activating receptors are expressed by all NK cells.  
 
Although human NK cells express numerous activating or co-activating receptors that 
can trigger NK cell functions, many induce common signalling pathways, and thus 
behave in a similar manner. Most activating receptors have short cytoplasmic domains 
that are not capable of transducing signals. They associate with adaptor proteins 
CD3ζ, FcεR1γ and DAP-12, which contain ITAMs in their cytoplasmic domain. 
Other receptors such as NKG2D use the DAP10 adaptor protein, which has the YxxM 
motif (Cerwenka et al, 2001). Upon engagement of NK activating receptors, adaptor 
proteins that associate with these receptors transmit intracellular signals resulting in 
activation of NK cell effector function. 
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Table 1.3 Human NK cell activating receptors, associated adaptor proteins and 
ligands 
 
Activating Receptor Signalling Ligand 
NKp46 FcεR1γ, CD3ζ Viral hemaglutinin ? 
NKp44 DAP-12 Viral hemaglutinin ? 
NKp30 FcεR1γ, CD3ζ ? 
NKG2D DAP-10 MICA, MICB, ULBP 1-4 
CD16 FcεR1γ / CD3ζ IgG 
CD244/2B4 SAP CD48 
DNAM-1 Protein kinase C CD112, CD155 
KIR2DS1 DAP-12 HLA-C2 N77/K80 
KIR2DS2 DAP-12 ? 
KIR2DS4 DAP-12 HLA-Cw4 
KIR3DS1 DAP-12 ? 
KIR2DL4 FcεR1γ HLA-G 
CD94/NKG2C DAP-12 HLA-E 
SLAMF7 ITSM CRACC 
SLAMF6 ITSM, SAP NTB-A 
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1.9.1 Specificity of Activating KIR  
 
In addition to the identified p58 receptors, 50kDa molecular forms of EB6- or GL183-
reactive antibodies were identified that displayed the same HLA-C specificity of the 
corresponding p58 receptors that mediate NK cell triggering rather than inhibition 
(Moretta et al, 1995). Different from p58 receptors that have a long cytoplasmic tail, 
the activating p50 receptors have a short cytoplasmic tail associated with a 
transmembrane region containing the charged residue lysine (Biassoni et al, 1996). 
Despite their homology to inhibitory KIR, very few studies have been able to 
document binding of activating KIR to HLA class I molecules. KIR2DS1 reacts with 
the mAb EB6, differing from KIR2DL1 by seven amino acids in the extracellular 
domain. KIR2DS1 has been shown to promote NK cell cytotoxicity in an HLA class 
I-independent manner (Moretta et al, 1995), and direct binding of KIR2DS1 has also 
been observed to HLA-C2 allotypes (Biassoni et al, 1997, Stewart et al, 2005). 
KIR2DS1-HLA-C interactions can activate NK cell cytotoxicity under restricted 
conditions, although interaction with cognate ligand is not always sufficient to trigger 
NK effector responses, suggesting additional costimulatory signals for activation 
(Stewart et al, 2005). Direct binding of KIR2DS2 to HLA-C1 molecules has been 
difficult to demonstrate (Winter et al, 1998). Mutational analysis of KIR2DL2, 
KIR2DL3 and KIR2DS2 has shown that only the residue at position 45 is unique to 
KIR2DS2. Substitution of the tyrosine at position 45 of KIR2DS2 with the 
corresponding KIR2DL2 residue allowed binding of KIR2DS2-Ig to HLA-Cw3, 
comparable to KIR2DL2-Ig binding (Winter et al, 1998).  
 
KIR3DS1, the short-tailed allotype of KIR3DL1 differs by only 6-12 amino acids 
from KIR3DL1 in the extracellular domain (Gardiner et al, 2001). No interaction of 
KIR3DS1 with HLA-Bw4 alleles has been observed, but inferred from both genetic 
and functional studies of HIV infection (Martin et al, 2002a; Alter et al, 2007). 
Among the other activating KIR2D receptors, KIR2DS3 and KIR2DS5 more closely 
resemble KIR2DL1 at residues implicated in HLA-C recognition, whereas KIR2DS4 
is more similar to KIR2DL2. Ligands for these activating receptors are largely 
unknown, although KIR2DS4 has been suggested to initiate NK cell cytotoxicity 
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against cells expressing HLA-Cw4 (HLA-C2) but not HLA-C1 allotypes (Katz et al, 
2001). 
 
These results fit a model in which activating and inhibitory receptors recognise the 
same sets of self-MHC class I molecules and differ only in their binding affinities. If 
activating and inhibitory receptors in similar concentrations are competing for binding 
to the same HLA-C molecules, then the signals from the inhibitory receptors are more 
likely to predominate. The role of activating receptors is not clear. It may be that 
activating receptors either recognise MHC class I molecules with a specific peptide 
related to viral or other pathological conditions or that they recognise MHC class I-
like molecules. Several reports have described an association between KIR2DS 
receptors in inflammatory conditions such as psoriatic arthritis, psoriasis vulgaris and 
rheumatoid arthritis (Martin et al, 2002b; Williams et al, 2005).  
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1.10 The Activating NK cell Immunological Synapse 
 
The induction of many NK cell effector functions requires contact with target cells. 
When an NK cell is activated by a target cell, the area between the NK cell and the 
target cell assembles into a well-organised immunological synapse, the formation of 
which is crucially dependent on the actin cytoskeleton to move molecules in and out 
of the developing synapse (Orange et al, 2003). This ensures precise targeting of the 
cytolytic granules, and cytolytic effector molecules to the interface between the NK 
cell and target cell. 
 
Formation of the activating NK cell IS is a sequential process. The first step requires 
NK cell contact and tight adhesion to the target cell. Upon initial contact, adhesion 
molecules including LFA-1 and Mac-1 rapidly segregate into a peripheral 
supramolecular activation cluster (p-SMAC) and contribute to the tight conjugation 
formed between NK cells and target cells (Orange et al, 2003; Vyas et al, 2001; Roda-
Navarro et al, 2004). LFA-1 also induces early actin polymerisation and creation of an 
F-actin ring in the p-SMAC, enabling more stable conjugation (Vyas et al, 2001). 
Activating receptors accumulate in the central supramolecular activation cluster (c-
SMAC), and the combinations of activating signals from different activating receptors 
synergise to induce NK cell responses (Bryceson et al, 2006). This receptor clustering 
at the NK-cell activating synapse is important for the induction of the signalling 
cascade, which leads to microtubule cytoskeleton rearrangement and the polarisation 
of the lytic granules to the synapse. The lytic granules aggregate around the 
microtubule organising centre (MTOC), and the MTOC begins to polarise towards the 
immunological synapse. Signals required for MTOC polarisation in NK cells include 
extracellular signal-regulated kinase (ERK) phosphorylation, Vav1 activation and 
protein tyrosine kinase 2 (PYK2) activity (Graham et al, 2006; Chen et al, 2006; 
Sancho et al, 2000). The lytic granules move along microtubules to the MTOC and 
are delivered to the c-SMAC of the activating NK cell IS. The final step of lytic 
granule exocytosis is not completely defined for NK cells, but is known to require the 
actin cytoskeleton. (Banerjee et al, 2007). Lytic granules fuse with the plasma 
membrane releasing their contents including perforin and granzyme resulting in target 
cell death. The NK cell detaches from the target cell diassembling the activating NK 
IS. 
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1.11 Signalling by NK cell Activating Receptors 
 
Activating NK cell receptors lack cytoplasmic domains capable of transducing 
signals. They associate with adaptor proteins DAP-12, CD3ζ and FcεR1γ that contain 
ITAM motifs for signal transduction upon engagement of NK activating receptors. 
The human NKG2D receptor associates with DAP-10 (Wu et al, 1999; Wu et al, 
2000). All of these adaptor molecules contain a transmembrane aspartic acid residue 
that mediate interaction with a positively charged amino acid found in the 
transmembrane domain of NK cell activating receptors. ITAM-dependent signalling 
and DAP10-dependent signalling have distinct early pathways following stimulation, 
associating with different adaptor proteins. However both pathways seem to converge 
on a common NK cell signalling pathway involving the activation of Rac. This 
sequentially leads to activation of the mitogen-activated extracellular signalling 
regulated kinase (MAPK) ERK, by way of p21-activated kinase (PAK) and mitogen-
activated or extracellular signal-regulated protein kinase kinase (MEK) (Vivier et al, 
2004). This culminates in the redistribution of intracytoplasmic granules and their 
exocytosis at the point of contact between NK cells and target cells, leading to lysis of 
the target cell (Figure 1.5 and Figure 1.6).  
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Adapted from Lanier, L. Nat Immunol 2008 
 
Figure 1.5 ITAM-dependent signalling pathways in human NK cells 
ITAM-dependent signalling is initiated upon engagement of NK cell activating receptors 
associated with the ITAM-containing adaptor proteins DAP12, FcεR1γ and CD3ζ. The 
protein tyrosine phosphatase CD45 dephosphorylates a tyrosine in the COOH terminus of Src 
family kinases including lck and fyn, which in turn phosphorylate tyrosine residues in the 
ITAMs. Phosphorylated ITAMs provide docking sites for the SH2 domains of SYKs – Syk 
and ZAP70, which induce the phosphorylation of adaptor proteins including LAT. These 
adaptor proteins provide tyrosine-phosphorylated docking sites for the SH2 domains of 
downstream effector molecules including PI3K, PLCγ1, PLCγ2 and Grb2. PI3-K activates 
Rac, possibly through Vav1. Activation of Rac induces a signalling pathway leading to 
activation of ERK1/2 shown be critical for cytotoxicity. PLCγ2 hydrolyses membrane 
phosphatidylinositols into DAG and IP3. IP3 triggers the release of Ca2+ from internal stores 
required for release for exocytosis of lytic granules. Dashed arrows suggest putative 
interactions that have not been confirmed by in vitro or in vivo studies. 
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Adapted from Lanier, L. Nat Immunol 2008 
 
Figure 1.6 DAP-10-dependent signalling pathways in human NK cells 
DAP10-dependent signalling is initiated upon engagement of NKG2D with its ligands. The 
protein tyrosine phosphatase CD45 dephosphorylates a tyrosine in the COOH terminus of Src 
family kinases including lck and fyn, which in turn phosphorylate tyrosine residues in the 
YINM motif. Phosphorylated YINM provides docking sites for the p85 subunit of PI3K, and 
Grb2. Grb2 mediates recruitment of downstream effector molecules including PLCγ2 and 
Vav1. PI3-K activates Rac, possibly through Vav1. Activation of Rac induces a signalling 
pathway leading to activation of ERK1/2 shown be critical for cytotoxicity. PLCγ2 
hydrolyses membrane phosphatidylinositols into DAG and IP3. IP3 triggers the release of 
Ca2+ from internal stores required for release for exocytosis of lytic granules. Dashed arrows 
suggest putative interactions that have not been confirmed by in vitro or in vivo studies. 
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1.12 Signalling by NK cell Inhibitory Receptors 
 
Although diverse in their extracellular domains, inhibitory NK receptors share a 
common tyrosine-containing ITIM motif in their cytoplasmic region, which, upon 
tyrosine phosphorylation recruit and activate cytoplasmic tyrosine phosphatases. 
Upon ligand binding, ITIMs of inhibitory receptors are tyrosine-phosphorylated, and 
recruit the cytoplasmic tyrosine phosphatases SHP-1 and SHP-2, which block 
activation signals (Burshtyn et al, 1996; Campbell et al, 1996; Binstadt et al, 1996; 
Fry et al, 1996). KIR receptors have two consecutive ITIMs in their cytoplasmic 
domains. Mutagenesis studies have shown that the two ITIMs have distinct roles in 
inhibiting NK cells (Bruhns et al, 1999). The membrane proximal ITIM recruits SHP-
1, which is sufficient to inhibit NK cells. The membrane-distal ITIM cannot recruit 
SHP-1 or SHP-2 alone, but is able to recruit SHP-2 in the presence of the membrane-
proximal ITIM. SHP-2 then amplifies the signal from SHP-1, and the action of both 
phosphatases inhibits NK cytotoxicity. 
 
SHP-1 and SHP-2 block conjugate formation, Ca2+ influx, degranulation, cytokine 
production and proliferation of NK cells (Burshtyn et al, 2000; Kaufman et al, 1995; 
Valiante et al, 1996). Vav1 has been identified as a key substrate of SHP-1 (Stebbins 
et al, 2003). The early dephosphorylation of Vav1 by SHP-1 blocks actin cytoskeleton 
rearrangement and provides a mechanism by which NK cellular cytotoxicity is 
inhibited through inhibitory receptor engagement. 
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1.13 NK cell Effector Functions 
 
The effector functions of NK cells, including cytotoxicity and cytokine production are 
of pathophysiological importance. The major mechanism of killing used by NK cells 
is by the release of cytotoxic granules that are preformed and stored within NK cells 
(Wulfing et al, 2003). These granules contain a number of proteins including perforin 
and granzymes, which can mediate target cell lysis. NK cells also express members of 
the TNF superfamily, including Fas and Tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL) (Screpanti et al, 2001) providing a second mechanism of 
cytotoxicity through engagement of these target cells with cell-surface death 
receptors. The end result of both these pathways is apoptotic target cell death. NK 
cells also produce cytokines such as IFN-γ that stimulate adaptive immunity (Biron et 
al, 1999).  
 
1.13.1 Perforin/Granzyme-mediated Apoptosis 
 
Perforin/granzyme-mediated apoptosis is the principal pathway used by NK cells to 
eliminate virus-infected or transformed cells (Catalfalmo et al, 2003). Cytotoxic 
granules and their constituent proteins are preformed during NK cell development and 
maturation (Screpanti et al, 2001). The cytotoxic granules package mediators of a 
diverse range of cell-death pathways that rapidly kill their targets. NK cell cytolytic 
granules are confined by an external membrane and contain internal membrane-
associated vesicles and dense cores of tightly packed proteins (Peters et al, 1991). 
Major granule proteins include perforin, a calcium-dependent pore-forming cytolytic 
protein, and granzymes, a family of structurally related pro-apoptotic serine proteases 
that enter the target cell and initiate apoptosis (Raja et al, 2002).  
 
Perforin, a Ca2+-dependent cytolytic protein of ~67kDa, is a key component of the 
cytolytic machinery. Upon secretion it binds and inserts itself into the phospholipid 
bilayer of the target cell plasma membrane, and polymerises to form a pore (Uellner 
et al, 1997). Perforin facilitates granzyme-mediated apoptosis (Pipkin and Lieberman, 
2007). Studies in perforin-deficient mice and humans with mutations in the perforin 
gene have highlighted the importance of this protein for NK and T cell-mediated 
cytotoxicity (Kagi et al, 1994; Lowin et al, 1994; Catalfamo and Henkart, 2003).  
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Granzymes are highly specific serine proteases located within the cytotoxic granules. 
Granzyme B plays a critical role in triggering apoptotic cell death either directly or 
via the activation of cellular caspases, which are central regulators of apoptosis (Barry 
et al, 2000). Delivery of granzymes into target cells was originally thought to be 
mediated by perforin, however granzyme B can be endocytosed in the absence of 
perforin (Shi et al, 1997; Penkosi et al, 1998; Froelich et al, 1996). More recently it 
has been proposed that the mannose-6-phosphate receptor aids delivery of Granzyme 
B into the target cell (Motyka et al, 2000). 
 
The core of the lytic granules is surrounded by a lipid bilayer containing lysosomal 
associated membrane glycoproteins (LAMPs) including CD107a (LAMP-1), CD107b 
(LAMP-2) and CD63 (LAMP-3) (Betts et al, 2003; Alter et al, 2004). Members of the 
LAMP family are highly glycosylated membrane proteins that represent 
approximately 50% of the proteins in the lysosomal membrane (Chen et al, 1985). 
The highly glycosylated portion of the molecule on the luminal side of the vesicle is 
thought to protect the cellular membrane from attack by lytic enzymes contained in 
the granules and therefore protects the extracellular membrane of the effector cell 
following degranulation (Betts et al, 2003). CD107a expression on the cell surface of 
CTL or NK cells can be used to measure degranulation as a marker of activation, and 
this marker correlates strongly with both cytokine secretion and lysis of target cells 
(Alter et al, 2004; Betts et al, 2003).  
 
1.13.2 Death Receptor Apoptotic Pathway 
 
Another mechanism used by NK cells to kill their targets is induction of death 
receptor-mediated apoptosis (Montel et al, 1995). Death ligands belong to the TNF 
family of ligands, a large family of membrane-bound and soluble molecules. NK cells 
can express at east three TNF-family ligands, Fas ligand (FasL), TNF, and TRAIL. 
Upon death receptor ligation, intracellular adaptor molecules are recruited, and these 
molecules can, in turn, associate with initiator caspases through death effector domain 
or caspase recruitment domain interactions leading to their activation with the final 
result of target cell death (Montel et al, 1995; Screpanti et al, 2001).  
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1.13.3 IFN-γ production 
  
NK cells secrete a number of effector cytokines including IFN-γ, which is considered 
the prototypic NK cell cytokine. NK cell secretion of IFN-γ is involved in the 
suppression of viruses and other pathogens (Biron et al, 1999) and can also contribute 
to effector functions against tumour metastases (Street et al, 2001). IFN-γ can also 
promote production of nitric oxide, antigen presentation through upregulation of 
MHC class I and II molecules on many cell types, activate DCs, and can contribute to 
the shaping, magnitude and quality of adaptive immune responses (Fernandez et al, 
1999; Mailliard et al, 2003).  
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1.14 NK cells and the anti-viral response 
 
The anti-viral mechanisms by which NK cells operate include both a direct cytotoxic 
response as well as production of cytokines and chemokines including IFNγ, TNFα, 
GM-CSF, IL-5, IL-10, and IL-13 (Biron et al, 1999) that control the growth and 
spread of pathogens and/or tumours; in particular IFNγ and TNFα. Many of the 
cytokines released by NK cells also modulate other cells of the immune system which 
affect the initiation and maintenance of adaptive immune responses. NK cells are 
activated during a wide range of viral infections by virus-induced type I interferons 
(Orange et al, 2002). Perhaps the most compelling evidence for the importance of NK 
cells in anti-viral defence mechanisms in humans comes from an NK cell-deficient 
patient who suffered from recurrent herpes virus infection (Biron et al, 1989). Other 
studies with humans who have various NK cell abnormalities have further confirmed 
the importance of NK cells in protection from herpes virus including HCMV (Biron et 
al, 1989); Epstein-Barr Virus (EBV) (Merino et al, 1986); Human Immunodeficiency 
virus (HIV) (Bonavida et al, 1986) and Hepatitis B and Hepatitis C viruses (Loh et al, 
2005). Studies in mice revealed that NK cells are critical for clearance of certain viral 
infections including murine cytomegalovirus (MCMV) infection (Orange et al, 1995). 
The importance of NK cell-produced IFNγ in antiviral defence has been definitively 
established and is produced during many viral infections including MCMV and 
influenza virus (Orange et al, 1995; Orange et al, 1996; Monteiro et al, 1998). IFNγ 
has been shown to inhibit replication of vaccinia virus, MCMV, and herpes simplex 
virus-1 through induction of nitric oxide production (Lucin et al, 1994; Karupiah et al, 
1993). 
 
Many viruses have developed an extensive array of strategies to block and/or 
modulate NK cell-specific activities, supporting the critical role for NK cells in viral 
infection (Orange et al, 2002). For example, studies have shown that the Hepatitis C 
virus (HCV) E2 envelope protein can bind to CD81 and impair both NK cytotoxicity 
and IFNγ production (Crotta et al, 2002; Tseng et al, 2002). More recently, NK cells 
from chronically infected HCV patients are both numerically and functionally 
impaired (Meier et al, 2005) and are unable to efficiently activate DCs (Jinushi et al, 
2003). 
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1.15 NK cells and the anti-tumour response 
 
NK cells were discovered because of their in vitro ability to kill tumour cells in the 
absence of prior sensitisation. The idea of the “missing self” hypothesis was in fact 
based on a study showing that NK cells were able to lyse MHC class I-negative 
murine lymphoma cells, RMA-S, but not the class I-competent parental cell line RMA 
(Karre et al, 1986). Studies in NK cell-deficient mice have demonstrated that NK cells 
are critical for suppressing tumour metastasis (Kim et al, 2000). Several in vivo 
studies have shown that control of tumours is dependent on NK cell-mediated perforin 
(Smyth et al, 1999), IFNγ (Street et al, 2001) and TNFα (Smyth et al, 1998) 
production. The activating receptor NKG2D is thought to play a central role in the 
NK cell-mediated anti-tumour response. The NKG2D-NKG2D ligand recognition 
pathway seems to be essential for the antimetastatic activity of cytokines that promote 
perforin-mediated cytotoxicity (Smyth et al, 2004). Both human and mouse NKG2D 
ligands are upregulated in tumour cell lines by genotoxic stress and can stall DNA 
replication (Gasser et al, 2005).  
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1.16 NK-DC Bidirectional crosstalk and the Adaptive Immune Response 
 
DCs are potent antigen presenting cells (APCs) that initiate and regulate immune 
responses to invading pathogens. Recent studies have demonstrated that NK cells can 
regulate aspects of innate immunity and influence the subsequent adaptive immune 
response by interacting with cells of the innate immune system, in particular DCs. A 
bidirectional crosstalk between NK cells and DCs results in activation of both cell 
types through induction of NK cell effector functions and further maturation of DCs 
(Gerosa et al, 2002). 
 
Following a study by Fernandez et al (1999) who first showed that DCs can induce 
NK cell activity against tumours in vivo, a number of studies have been directed to the 
understanding of the implications of DC ‘priming’ of NK cells. These studies have 
defined a requirement for both cytokines and cell-cell interactions in the DC-mediated 
activation of NK cells. DC-derived cytokines such as IL-12 and IL-18 can promote 
IFNγ production by NK cells in vitro, and DC production of type 1 IFNs as well as 
cell-cell contact is required for NK-cell proliferation and cytotoxicity (Osadu et al, 
2001; Yu et al, 2001; Gerosa et al, 2002; Piccioli et al, 2002; Ferlazzo et al, 2002). 
DC-mediated activation of NK cells has important functional consequences on 
adaptive responses. Activated NK cells can boost ongoing adaptive responses through 
production of IFNγ, thereby inducing Th1 polarisation of antigen-specific T cells. 
Additionally, NK cells may boost the activation and the T cell stimulatory capacity of 
DCs. A recent study by Mailliard et al (2003) demonstrated that activation of human 
DCs by NK cells results in the differentiation of DCs that are capable of inducing a 
more efficient cytotoxic T lymphocyte (CTL) response.  
 
NK cells can induce DC activation under appropriate conditions. In vitro studies have 
demonstrated that activation of DCs by NK cells is dependent on both cell-cell 
contact and production of TNFα and IFNγ by NK cells (Piccioli et al, 2002; Gerosa et 
al, 2002). Engagement of the NK cell activating receptor NKp30 has been implicated 
in driving activation of immature DCs through production of IFNγ and TNFα (Vitale 
et al, 2005). It is as yet unclear where exactly NK cells and DCs meet in vivo, 
although it is likely that interactions occur either at the local site of inflammation or in 
the lymph nodes (Andoniou et al, 2006). 
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1.16.1 Killer DCs: A link between innate and adaptive immunity? 
 
A number of reports have noted that NK cells can also function as APCs and directly 
regulate T cell activation (Hanna et al, 2004). In humans, activated NK cells express 
MHC class II, costimulatory molecules and are able to present antigen (Hanna et al, 
2004). Thus NK cells may also serve as APCs that directly prime the adaptive 
immune response through direct interaction with T cells. More recent reports have 
identified a lineage of cells demonstrating molecular expression profile of both DCs 
and NK cells (Taieb et al, 2006; Chan et al, 2006). These IFN-producing killer DCs 
(IKDCs) express many NK cell markers and kill their targets either through NK cell 
activating receptors or the death receptor TRAIL (Chan et al, 2006). Following 
activation, the cytotoxic activity of IKDCs decreases, and these cells become capable 
of presenting specific antigens. Antigen presentation is associated with decreased 
cytotoxicity and reduced expression of activating receptors and signalling molecules 
with an increase in expression of APC markers (Chan et al, 2006). Thus the recently 
identified IKDCs may not only play a role in cancer and virus immunosurveillance, 
but also may represent an important link between innate and adaptive immunity. It is 
now clear that DCs play an important role in the regulation of several aspects of 
innate immunity, in particular NK cells. Reciprocally, NK cells can influence DC 
functions.  
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1.17 Background to the Project 
 
1.17.1 The Protective effect of KIR2DL3 but not KIR2DL2 in Hepatitis C virus 
(HCV) infection 
 
Genetic studies have shown the synergistic protective effect of homozygosity for 
KIR2DL3 and HLA-C1 in HCV infection (Khakoo et al, 2004). This protective effect 
was not seen in individuals who are heterozygous for KIR2DL2/KIR2DL3 or 
homozygous for KIR2DL2. Both KIR2DL2 and KIR2DL3 bind the same HLA-C1 
allotypes with Asn at position 80 (Vitale et al, 1995), and make direct contact with the 
HLA-C1 bound peptide at residues 7 and 8 of the peptide (Boyington et al, 2001). 
KIR2DL2 and KIR2DL3 segregate as alleles of the same locus (Keaney et al, 2004), 
are similar in sequence, and vary by no more than six amino acids in their 
extracellular domains between any two allelic products (VandenBussche et al, 2006). 
The amino acid differences observed are not located within the region that interacts 
with HLA-C1 and bound peptide. The protective effect of KIR2DL3/KIR2DL3-
HLAC1C1 observed was suggested to be because of evidence that KIR2DL3 binds 
more weakly to its ligands than KIR2DL2 (Winter et al, 1998, Moesta et al, 2008). 
Binding studies using KIR2D-Ig fusion proteins have shown that KIR2DL2-Ig binds 
more strongly to 721.221 cells transfected with different HLA-C1 allotypes than 
KIR2DL3-Ig (Winter et al, 1998, Moesta et al, 2008). Moreover, KIR2DL2+ NK cells 
exerted stronger inhibition than KIR2DL3+ NK cells against the HLA-C1-transfected 
target cells (Winter et al, 1998, Moesta et al, 1998). NK cells expressing KIR2DL3 
are predicted to bind more weakly to HLA-C1 in vivo, therefore inhibitory signals 
may be more readily overcome by activating signals than if NK cells were inhibited 
by KIR2DL2, which would be a more favourable outcome in the context of viral 
infection (Khakoo et al, 2004).  
 
Although KIR2DL2 has been shown to bind more strongly than KIR2DL3 to HLA-
C1, the influence of peptides was not addressed in this study. Other studies have 
shown different degrees of peptide-mediated protection conferred by the same HLA-
C1 allele suggesting that recognition of HLA-C1 by KIR2DL2 and KIR2DL3 is both 
selective and dependent on the peptide bound to HLA-C1 (Maenaka et al, 1999; 
Zappacosta et al, 1997). The question of why KIR2DL3 is protective, but not 
 66 
KIR2DL2 which has the same ligands, is still unresolved. Despite evidence that 
KIR2DL2 binds more strongly than KIR2DL3 to HLA-C1, direct affinity 
measurements revealed that inhibitory KIR2D receptors bind to HLA-C with similar 
affinities, with a Kd of approximately 10µM (Maenaka et al, 1999b; Vales-Gomez et 
al, 2000). No direct comparison of the two receptors has been made, which is 
necessary as affinity for HLA-C can be dramatically altered by both the specific HLA 
allele studied and by the specific peptide presented by the HLA molecule.  
 
1.17.2 Peptide repertoire changes and NK cell activation 
 
The peptide selectivity observed for KIR interactions with HLA may be relevant as 
they may influence NK cell recognition of infected cells. Although some viruses 
downregulate MHC class I as a means to escape CTL attack, loss or downregulation 
of MHC class I does not always explain discrimination by NK cells; NK cell-
mediated killing of autologous human cells infected with human herpes virus 6 
(HHV-6) was observed despite no observable changes in MHC class I expression 
(Malnati et al, 1993). Furthermore, exogenously loaded viral peptides derived from 
coxsackie virus have been shown to abrogate NK cell recognition of MHC class I 
ligands, resulting in NK cell lysis of target cells (Mandelboim et al, 1997). NK cell 
killing of virally-infected cells may therefore be triggered by replacement of self 
peptide with endogenously processed viral peptides, or changes in self-peptide, such 
that MHC class I molecules are no longer recognised by inhibitory receptors 
expressed on NK cells. Indeed, HIV infection has been shown to uniquely alter the 
presentation of host-encoded peptides on MHC class I molecules (Hickman et al, 
2003), therefore viral proteins or an alteration in host protein presentation on MHC 
class I molecules may render an infected cell susceptible to NK cell lysis. Given that 
HLA-C1 can bind peptides that confer different levels of protection against NK-
mediated lysis, subtle changes in the peptide repertoire that can occur during viral 
infection or tumour transformation may be sensed by KIR2DL receptors through loss 
of recognition of MHC class I, therefore triggering NK cell activation.  
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1.18 Aims and Objectives 
 
The aim of this study is to investigate the binding of inhibitory KIR2DL receptors to 
Group 1 HLA-C allotypes. KIR-Ig binding and CD107a assays were employed to 
investigate the peptide specificities of KIR2DL2 and KIR2DL3 in binding to HLA-
C1. The effect of peptide repertoire changes on NK cell activation was also 
investigated. The specific aims of the project are to answer the following questions: 
 
1. Do KIR2DL2 and KIR2DL3 exhibit differences in binding? 
Studies have shown that KIR2DL2 binds more strongly to Group 1 HLA-C allotypes 
than KIR2DL3, and KIR2DL2+ NK cells exerted stronger inhibition than KIR2DL3+ 
NK cells against HLA-C1-expressing target cells (Winter et al, 1998; Moesta et al, 
2008). Homozygosity for KIR2DL3 and HLA-C1 was shown to be protective in HCV 
infection (Khakoo et al, 2004). KIR2DL3+ NK cells may be less inhibited than 
KIR2DL2+ NK cells in vivo, and therefore could more readily be activated than 
KIR2DL2+ NK cells; a favourable outcome in viral infection. 
 
2. Do KIR2DL2 and KIR2DL3 have different peptide specificities for binding? 
As the affinity for HLA-C can be dramatically altered by both the specific HLA-C 
allele, and by the specific peptide presented by the HLA molecule, we hypothesised 
that the observed differences between KIR2DL2 and KIR2DL3 in HCV infection may 
in part be due to the receptors exhibiting peptide selectivity. KIR2DL2 may recognise 
some peptide: MHC complexes that are not recognised by KIR2DL3. If this were the 
case KIR2DL3+ NK cells would not be inhibited by specific peptide: HLA-C1 
complexes that inhibit KIR2DL2+ NK cells, and therefore KIR2DL3+ NK cells could 
be activated through recognition of activating ligands by activating receptors. 
Recognition of peptide: MHC by KIR2DL2 however would provide inhibition for NK 
cells. Inhibitory signals delivered to NK cells are known to dominate over activating 
signals.  
 
3. Do KIR2DL2 and KIR2DL3 require a different quantity of MHC: peptide 
interactions to mediate inhibition? 
Some viral infections can downregulate MHC class I from the cell surface of target 
cells to avoid attack by CTL. This however renders them susceptible to attack by NK 
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cells. As KIR2DL2 has been shown to bind more strongly to HLA-C1 than KIR2DL3, 
we investigated whether the stronger interaction with HLA-C1 intact KIR2DL2+ NK 
cells results in a requirement for quantitatively less peptide: MHC interactions to 
inhibit NK cells than intact KIR2DL3+ NK cells. In this situation, loss of MHC class I 
that can occur during viral infection of tumour transformation may be more readily 
sensed by KIR2DL3+ NK cells. 
 
4. How much of a change in peptide repertoire is required to activate NK cells 
expressing KIR2DL2/KIR2DL3? 
Discrimination by NK cells cannot always be explained by loss of MHC class I. We 
investigated the effect of changing the peptide repertoire on activation of NK cells 
expressing KIR2DL2 or KIR2DL3. Viral infection may alter the presentation of 
peptides presented by MHC class I, and these subtle changes in the peptide repertoire 
may trigger NK activation. HLA-C molecules are expressed at a lower level than 
HLA-A and HLA-B molecules (Neisig et al, 1998), and subtle changes in peptide 
repertoire may be more relevant to HLA-C.  
 
Using KIR2DL-Ig fusion proteins, we investigated KIR2DL2 and KIR2DL3 binding 
to 721.221 cells transfected with HLA-C1 allotypes, and exploit a cell line that is 
deficient in TAP to determine the peptide specificity of these two receptors. 
Furthermore, a flow cytometry-based functional assay using a marker of 
degranulation as a correlate for NK cell activation and target cell lysis was performed 
to determine the effect of peptides differing in residues critical for KIR binding on 
NK cell activation/inhibition. This assay enables us to look at the effect of peptide on 
KIR2DL2+ and KIR2DL3+ NK cell populations. Finally, in vitro peptide repertoires 
were generated incorporating peptides that mediate strong and weak binding of HLA-
C1 to KIR2DL2 and KIR2DL3, to investigate the effect of changing the peptide 
repertoire on activation of NK cells expressing KIR2DL2 and KIR2DL3. 
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Chapter 2. Materials and Methods 
 
 
2.1 Cell lines  
 
The HLA-A, HLA-B and HLA-C negative mutant B-lymphoblastoid cell line 721.221 
and 721.221 transfectants expressing a single HLA class I allele, have been described 
(Shimizu and DeMars, 1989). The K562 cell line is an erythroleukemic human cell 
line derived from a chronic myeloid patient that lacks MHC class I, and is a highly 
sensitive NK cell target (Koeffler et al, 1980). The mutant T2 cell line is derived from 
a hybrid of the B-cell line .174, and the T-lymphoblastoid cell line CEM (Salter et al, 
1985). It fails to express normal amounts of MHC class I at the cell surface due to the 
lack of functional transporter associated with antigen processing (TAP) heterodimer. 
It synthesises HLA-A*0201, HLA-Cw*0102 and HLA-B*5101 (Andersen et al, 
1999). The COS7 cell line is an African green monkey kidney fibroblast-like cell line 
suitable for transfection by vectors requiring expression of SV40 T antigen (Gluzman 
et al, 1981). This line contains T Ag, therefore these vectors replicate to high levels. 
The KIR- NKL cell line was established from the peripheral blood of a patient with 
CD3-CD16+CD56+ large granular lymphocyte leukaemia, and has been characterised 
by Robertson et al (1996). NKL cells and NKL cells transduced to express either 
KIR2DL2 or KIR2DL3 receptors (NKL-KIR2DL2 and NKL-KIR2DL3 respectively), 
were a gift from Professor Peter Parham (Department of Structural Biology, Stanford 
University, CA; Moesta et al, 2008). 
 
2.2 Cell culture 
 
T2 cells, K562 cells, 721.221 and HLA-C-transfected 721.221 cells were cultured and 
maintained in growth medium (R10) containing RPMI medium 1640 (Biowhittaker, 
U.K.) supplemented with 10% heat-inactivated fetal calf serum (FCS), 1% Penicillin 
streptomycin (Biowhittaker, U.K.) and 2mM L-glutamine (Biowhittaker, U.K.) at 
37°C under 5% CO2. These cell lines were maintained in logarithmic phase at neutral 
pH by diluting the cultures at a 1 in 10 dilution every 72 hours. COS 7 cells were 
cultured and maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
(Biowhittaker, U.K.) supplemented with 10% FCS, 1% Penicillin streptomycin and 
2mM L-glutamine. COS 7 cells were maintained in logarithmic phase at neutral pH 
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by diluting cultures at a 1 in 4 dilution every 48 hours. NKL, NKL-KIR2DL2 and 
NKL-KIR2DL3 cells were cultured and maintained in growth medium (R10) 
containing RPMI medium 1640, supplemented with 10% heat-inactivated FCS, 1% 
Penicillin streptomycin, 2mM L-glutamine and 100Units/ml Interleukin-2 (NIH 
resource) at 37°C under 5% CO2. NKL-KIR2DL2 and NKL-KIR2DL3 were 
selectively cultured by addition of 5µg/ml Blastocidin (Invitrogen, U.K.). NKL cells 
were maintained in logarithmic phase at neutral pH by diluting the cultures at a 1 in 
10 dilution every 72 hours.  
 
2.3 Generation of KIR-Ig 
 
The KIR-Ig fusion protein KIR2DL2-Ig, KIR2DL3-Ig, and KIR2DS4-Ig (all gifts 
from Eric Long, NIAID, U.S.A.) were generated following the described method by 
Winter and Long (2000). The sequences encoding the extracellular regions of 
KIR2DL2 and KIR2DL3 were previously amplified by polymerase chain reaction 
(PCR) for cloning into the Cd51neg1 expression vector (Aruffo et al, 1990). The 
inserted DNA was in frame with the leader peptide of CD5 and an artificial splice site 
preceding the hinge, CD2 and CD3 regions of human IgG1. Mutant KIR-Ig fusion 
proteins (KIR2DL2 R16P-Ig; KIR2DL2 E35Q-Ig; KIR2DL2 C148R-Ig; KIR2DL2 
I200T-Ig and KIR2DL2 K216E-Ig) were generated by Collin Brooks by site directed 
mutagenesis. COS7 cells were transfected with 10µg DNA per 107 cells, using filter-
sterilised transfection medium containing 1M HEPES (Sigma, U.K.), DEAE-dextran 
(Sigma, U.K.) and chloroquine (Sigma, U.K.) for 4hrs, before removing the 
transfection media and incubating cells with 12mls of filter-sterilised DNA uptake 
solution (10% DMSO/PBS) for two minutes. COS7 cells were incubated with growth 
medium overnight. The following day, growth medium was removed and serum-free 
media was added. Supernatants of serum-free COS7 cells were collected on day 4 and 
day 8 after transfection and affinity purified on protein A-Sepharose using a PD-10 
Desalting column (Sephadex, U.K.). Proteins were eluted using 100mM Glycine (pH 
3) and collected in eppendorf tubes containing 1M Tris-HCl pH 7.5. The OD of the 
fractions were measured at 280nm, and samples containing protein were pooled 
together and dialysed overnight using PBS and a dialysis membrane with cut-off 
between 5-14kDa (Medicell International Ltd, U.K.).  The proteins were stored at -
20°C until use. The integrity of the purified proteins was verified by SDS-PAGE 
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using Comassie staining and samples were run under reducing and non-reducing 
conditions.  
 
2.4 Assessment of KIR-Ig reactivity by ELISA 
 
KIR-Ig reactivity was detected by ELISA for KIR2DL2-Ig and KIR2DL3-Ig using 
KIR2DS2-Ig as a standard. 96-well Maxisorb plates (Bioscience, U.K.) were coated 
with goat anti-human IgG Fc antibody (Serotec, U.K.) and detected with the 
KIR2DL2/KIR2DL3/KIR2DS2-specific DX27 antibody (BD Biosciences). Goat anti-
mouse IgG HRP (Sigma, U.K.) was used as a secondary antibody before detection 
with OPD substrate (Sigma, U.K.). The optical density (O.D) of samples were read at 
595nm. Samples were quantified using nonlinear regression analysis to obtain 
unknown samples from a standard KIR2DS2-Ig curve. 
 
2.5 MHC class I staining of HLA-C-transfected cell lines 
 
1x105 HLA class I-transfected and untransfected 721.221 cells were stained with 
IgG2a negative control antibody (Serotec, U.K.) or W6/32 antibody (Serotec, U.K.) at 
a final concentration of 2µg/ml for ½ hour (hr) at 4°C. Unbound antibody was washed 
off before addition of goat anti-mouse IgG2a-FITC human secondary antibody 
(Serotec, U.K.) for ½ hr on ice. Samples were directly analysed by flow cytometry 
using a FACSCanto analytical flow cytometer (BD, U.K.), and FACSCalibur 
analytical flow cytometer (BD, U.K.). 
 
2.6 Two-layer KIR binding assay 
 
1x105 HLA class I-transfected and untransfected 721.221 cells were incubated with 
increasing concentrations of KIR2DL2-Ig, KIR2DL3-Ig or control-Ig (KIR2DS4-Ig) 
up to 100µg/ml for 1 hr at 4°C. After washing twice, cells were incubated with FITC-
conjugated goat anti-human IgG1 antibody (Serotec, U.K.) for ½ hr at 4°C. Samples 
were analysed directly; fluorescence of 10,000 cells gated by forward and side scatter 
was analysed using a FACSCaliber analytical flow cytometer (BD, U.K.). 
Fluorescence of 10,000 cells gated by forward and side scatter was analysed using a 
FACSCaliber analytical flow cytometer (BD, U.K.). 
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2.7 Peptide stabilisation assay 
 
1x105 T2 cells were incubated in the presence or absence of 100µM peptide (Peptide 
Protein Research Ltd, U.K.) overnight at 26°C before staining with the HLA-
Cw*0102-specific antibody VP6G3 (a gift from A. Mulder; Leiden, Netherlands), for 
½ hour at room temperature. After washing twice, cells were stained with FITC-
conjugated goat anti-human IgM antibody (Serotec, U.K.) for ½ hr at room 
temperature. For experiments where stabilisation of HLA-A*0201 was assessed,  
1x105 T2 cells were stained with the HLA-A*0201-specific antibody BB7.2-FITC 
(in-house antibody) for ½ hr on ice. Samples were analysed directly using a 
FACSCaliber analytical flow cytometer (BD, U.K.). Fluorescence of 10,000 cells 
gated by forward and side scatter was analysed using a FACSCaliber analytical flow 
cytometer (BD, U.K.). 
 
2.8 One-layer KIR binding assay 
 
1x105 T2 cells were incubated in the presence or absence of 100µM peptide (Peptide 
Protein Research Ltd, U.K.) overnight at 26°C. KIR2DL2-Ig, KIR2DL3-Ig and 
KIR2DS4-Ig proteins were conjugated with protein-A Alexa 488 at a ratio of 12:1 
KIR: Alexa (Invitrogen, U.K.) overnight at 4°C (1:12 Alexa 488: KIR-Ig). The 
following day, T2 cells were stained with increasing concentrations (up to 120µg/ml) 
of KIR-Ig for 1hr at room temperature. Samples were washed twice and bound fusion 
proteins detected by flow cytometry; fluorescence of 10,000 cells gated by forward 
and side scatter was analysed using a FACSCaliber analytical flow cytometer (BD, 
U.K.). 
 
2.9 Preparation of Peripheral blood mononuclear cells (PBMCs) 
 
PBMCs were obtained from healthy donors at Southampton University. Fresh PBMCs 
were isolated using Hypaque-Ficoll (Amersham Biosciences, U.K. Biosciences) 
density centrifugation. PBMCs were frozen (90% FCS/10% DMSO) at -140°C until 
use. Each individual gave informed consent for participation in this study. HLA-C 
typing was done by Derek Middleton by sequence specific oligonucleotide 
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hybridisation (Queen’s University Belfast, Northern Ireland; Middleton and Williams, 
2003). 
 
2.10 KIR genotyping 
 
DNA extraction for PCR typing was prepared from PBMCs using the QIAamp Blood 
Kit according to manufacturer’s instructions (QIAGEN, U.K.). KIR genotyping was 
performed by sequence specific primer PCR (PCR-SSP) using the Gene GeneAmp 
PCR system 9700 (AB Applied Biosystems, U.K.) as a thermocycler. For KIR2DL2 
the primers were, sense: 3’CCA TGA TCC CCT CTC CAA A-5’ and antisense: 5’-
GCC CTG CAG AGA ACC TAC A-3’, amplifying a 1500 bp fragment, and for 
KIR2DL3 the primers were, sense 3’-CCT TCA TCG CTG GTG CTG-5’ and 
antisense: 5’-CAG GAG ACA ACT TTG GAT CA-3’, amplifying a 798 bp fragment 
(Uhrberg et al, 1997). Primers sense: 5’-CGC GAG AAG ATG ACC CAG ATC-3’ 
and antisense: 5’-TTG CTG ATC CAC ATC TGC TCC-3’ specific for a 734 bp β-
actin fragment were included in all reactions as an internal control. Amplification was 
performed in a 25 µl reaction, using the primers at a concentration of 0.5 µM 
(specific) or 0.05 µM (internal control),  each dNTP (Promega, U.K.) at a 
concentration of 2 mM, 0.625 U AmpliTaq polymerase  (Applied BiosystemS, U.K.) 
and 200 ng DNA under the following conditions: initial denaturation, 95°C 2 min; 
followed by 5 cycles at 94°C for 60 s, 62°C for 60 s and 72°C for 45 s; then 30 cycles 
at 94°C for 60 s, 60°C for 45 s and 72°C for 45 s; and then a final extension 72°C for 
5 min. Each experiment included negative and positive controls. Amplification 
products were analysed on SYBRsafe DNA gel stain (Invitrogen, U.K.) prestained 
1.2% agarose gels. 
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2.11 CD107a assay 
 
2.11.1 Effector cell preparation 
 
PBMCs were resuspended at 1x106 cells/ml in RPMI medium 1640 supplemented 
with 10% FCS, 1% Penicillin streptomycin (R10) and stimulated with 1ng/ml 
recombinant human Interleukin (IL)-15 (R&D Systems, U.K.). PBMCs were 
incubated overnight at 37°C in 5% CO2 at a final volume of 200µl.  
 
2.11.2 Target cell preparation 
 
4x104 T2 cells were incubated alone, or with increasing concentrations of peptide to a 
maximum concentration of 10-5M, at 26°C overnight. For peptide mix experiments 
target cells were simultaneously loaded with different concentrations of two peptides 
to a final concentration of either 10-5M or 10-6M peptide. 
 
2.11.3 CD107a assay 
 
The following day, the IL-15 containing media was removed from PBMCs which 
were subsequently stained with CD107a-PE antibody (BD Pharmingen) at 20µl/ml. 
As a negative control, PBMCs were stained with an isotype IgG1-PE antibody (BD 
Pharmingen, U.K.) at 20µl/ml. Peptide-containing media was removed from T2 cells 
before resuspending in fresh peptide-containing R10. PBMCs were stimulated with 
T2 cells at an effector to target (E:T) ratio of 5:1 for a total of 4 hours (best E:T ratio 
as determined by an E:T titration from 40:1 to 1:1). As a positive control, PBMCs 
were stimulated with K562 cells. For some experiments, .221 cells or HLA-Cw*0304-
transfected cells (.221-Cw3) were used as target cells. .221 cells or .221-Cw3 cells 
were incubated at different E:T for four hours at 37°C.  For each experiment, 
spontaneous expression of CD107a was determined for PBMCs in the absence of 
target cells. Cells were incubated for 1hr at 26°C in 5% CO2 after which 6µl of 
monensin (Golgi-Stop, BD Biosciences, U.K.) at a final concentration of 6µg/ml was 
added to samples before incubation for an additional 3hrs at 26°C in 5% CO2. 
Monensin prevents the acidification of endocytic vesicles avoiding the degradation of 
reinternalised CD107a proteins from the surface and allows visualisation of this 
 75 
marker following stimulation. Immediately following stimulation, PBMCs were pre-
blocked in 10% human serum (Cambrex, U.K.) in FACS buffer on ice for 20 minutes. 
PBMCs were subsequently stained for cell surface markers CD56-PECy7 (BD 
Pharmingen, U.K.) and CD3 APCCy7 (BD Pharmingen, U.K.) to identify the NK cell 
population, and for specific NK cell subsets using anti-CD158b-FITC (BD 
Pharmingen, U.K.) and anti-CD158a-APC (Beckman Coulter, U.K.). Cells were 
stained for ½ hr on ice before washing twice. Five-colour flow cytometric analysis 
was performed using a FACSCanto analytical flow cytometer (BD Biosciences, 
U.K.). A total of 10,000 NK cell events were acquired and analysed using DIVA 
software (BD Biosciences, U.K.). For some experiments, samples were analysed 
using a Cyan ADP LX9 flow cytometer (Dako, U.K.), with data analysed using the 
Dako Summit analysis program (Dako, U.K.). Analysis was performed on gated cells 
within the lymphocyte population. Expression of CD107a was determined in NK cell 
populations defined by anti-CD158b and anti-CD158a antibodies.  
 
2.12 IFN-γ Sandwich ELISA 
 
Detection of human IFN-γ in cell culture supernatants was performed using a human 
IFN-γ kit with a detection range from 4-400pg/ml, following manufacturer’s 
instructions (Mabtech, Sweden). NKL, NKL-KIR2DL2 or NKL-KIR2DL3 cells were 
either rested from IL-2 for 24hrs prior to stimulation with K562 cells or T2 cells, or 
left in IL-2 containing media. For some experiments, recombinant human Interleukin-
12 (R&D systems, U.K.) was added to NKL, NKL-KIR2DL2 or NKL-KIR2DL3 cells 
for 24hrs prior to stimulation with target cells. Different concentrations of NKL, 
NKL-KIR2DL2 and NKL-KIR2DL3 cells were co-incubated with T2 cells at 
different E:T (20:1-1:1) at 26°C. Samples were prepared in triplicate. Cell-free 
supernatants were collected at 6, 12, 24, 48 and 72 hours following stimulation. A 
human IFN- γ standard curve was run in triplicate for each experiment. IFN-γ in 
samples was detected by a biotinylated IFN-γ monoclonal antibody, followed by 
incubation with streptavidin alkaline phosphatase.  p-Nitrophenyl phosphate (pNPP) 
substrate (Sigma, U.K.) was used to detect alkaline phosphatase activity, and the O.D. 
of samples was measured at 405nm using an ELISA plate reader. The amount of 
human IFN-γ produced in samples was detected by nonlinear regression curve 
analysis from the standard curve. 
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2.13 Lactate Dehydrogenase (LDH) assay 
 
Detection of NKL cytotoxic activity to T2 cells was detected by release of LDH in 
cell culture supernatants and was performed using an LDH assay kit, following 
manufacturer’s instructions (Roche, U.K.). Optimal cell concentration for both NKL-
KIR2DL3 and T2 cells was determined by titration of cells. A maximum cell 
concentration of 1x106 cells/ml was used to determine the spontaneous LDH activity 
in these cell lines. NKL-KIR2DL3 cells were IL-2 rested for 24 hours before each 
experiment, and for some samples, NKL-KIR2DL3 were stimulated with 100ng/ml 
recombinant human IL-12. Different cell concentrations of IL-2 rested NKL-
KIR2DL3 and T2 cells, resuspended in RPMI supplemented with 1% FCS, were 
added together at different E:T ratios by adjusting the cell concentration of NKL-
KIR2DL3 cells (20:1 – 1:1). 100µl NKL-KIR2DL3 cells were added to 100µl target 
cells for 4 hours at 26°C, before cell-free supernatants were collected. 100µl 
supernatant was transferred to 96-well flat-bottomed microtiter plates, before adding 
100µl LDH reaction mix to the wells. The O.D of samples was measured at 490nm 
after 30 minutes. Samples were performed in triplicates, with spontaneous and 
maximum lysis determined for T2 cells, and spontaneous lysis determined for NKL-
KIR2DL3 at each E:T for each experiment. Maximum lysis was detected by addition 
of 1% Triton X-100 (Sigma, U.K.) to NKL-KIR2DL3 and T2 cells. Percent 
cytotoxicity of T2 cells was determined by the following calculation: 
 
(Experimental LDH–Spontaneous LDH effector)-Spontaneous LDH target)     x100 
 
(Maximum LDH target cell – spontaneous LDH target cell) 
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2.14 Chromium (51Cr) release assay  
 
2x106 T2 cells were labelled with 3.7 MBq of sodium 51chromate (MP Biomedicals, 
Invine, CA) at 37°C for 2 hours. Cell were washed and resuspended to 1x105 cells/ml. 
50µl T2 cells were transferred to 96 well U-bottom plates and incubated at 26°C 
overnight. The following day, 100µl NKL-KIR2DL3 cells were added to target cells 
at different E:T ratios (20:1 – 5:1) and incubated for 5 hours at 26°C or 37°C. After 5 
hours, plates were spun down and 50µl of cell-free supernatant was transferred to 
lumaplates, and plates were dried overnight. Radioactivity was measured in a 
microbeta counter. Spontaneous release of 51Cr was determined for target cells 
incubated alone, and maximum release was determined from target cells lysed in 1% 
Triton X-100. Percentage of lysis was calculated as the percentage of specific 51Cr 
release using the following equation: 
 
% Specific lysis = (Counts per minute (cpm)Experimental – cpmSpontaneous) / cpmMaximal – 
cpmSpontaneous) x 100 
 
2.15 Conjugate formation and cell staining 
 
T2 cells were incubated overnight at 26°C in the absence or presence of 10-5M 
peptide. The following day, 1x105 NKL or NKL-KIR2DL3 cells were co-incubated 
with T2 cells at an E:T of 2:1 for 10 minutes at 37°C. Cells were spun gently and 
resuspended in 100µl PBS before being fixed in 100 µl pre-warmed 4% PFA for ½ hr 
at 37°C. Cells were spun gently and resuspended in 0.01% Triton X-100 for 1 minute 
at room temperature. Cells were stained with 20µg/ml GL183 antibody (Abcam, 
U.K.) for 30 minutes before addition of Alexa Fluor-488 goat anti-human IgG 
antibody (Invitrogen, U.K.). Cells were washed twice and resuspended in PBS 
containing 1% BSA. Cells were imaged using a Leica SP5 resonance scanning 
microscope (Leica Microsystems, U.K.). FITC was excited using 488 laser line. 
Transmission images and FITC emission were collected in different channels. Data 
were processed using Leica Imaging software (Leica Microsystems, U.K.) and 
ImageJ. 
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2.16 Statistical analysis  
 
A number of statistical analyses were employed in this investigation. The Mann-
Whitney test is a nonparametric test that was used to compare the distributions of two 
unmatched groups (p<0.05 was significant). A probability value (p value) of less than 
0.05 (p<0.05) was deemed to be significant. One-way Analysis of Variance 
(ANOVA) test was used to determine the significance of differences between the 
means of groups tested. A probability value (p value) of less than 0.05 (p<0.05) was 
deemed to be significant. Nonlinear regression analysis was performed (GraphPad 
Prism 5, U.K.) to fit a binding curve to obtain Bmax (maximum specific binding) 
values and ½ max (concentration of ligand required to reach ½ maximum binding) 
values. A linear regression curve analysis of transformed data was used to interpolate 
graphs of transformed data to calculate unknown values (GraphPad Prism 5, U.K.). 
Analysis of Covariance (ANCOVA) was used to determine whether slopes of linear 
regression were significantly different. A p value of less that 0.05 (p<0.05) was 
deemed to be significant. 
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Chapter 3. Binding of KIR2DL2 and KIR2DL3 to Group 1 HLA-C alleles 
 
KIR receptors are able to discriminate between two groups of HLA-C allotypes that 
are grouped according to the amino acids at positions 77 and 80 in the α1 helix of the 
MHC class I heavy chain (Ciccone et al, 1992b; Moretta et al, 1993; Vitale et al, 
1995; Wagtmann et al, 1995b; Fan et al, 1996). KIR2DL1+ NK cells are unable to kill 
target cells expressing group 2 HLA-C (HLA-C2) allotypes, with Asparagine (Asn) at 
position 77 and Lysine (Lys) at p80, whereas KIR2DL2/KIR2DL3+ NK cells are 
unable to kill target cells expressing group 1 HLA-C (HLA-C1) allotypes with serine 
(Ser) at p77 and Asn at p80 (Vitale et al, 1995). The crystal structure of KIR2DL2 
bound to HLA-Cw*0304 (HLA-C1 allotype) and associated peptide showed that 
allotype specificity of KIR2DL2 for HLA-Cw*0304 is determined by a hydrogen 
bond between Lys at position 44 of KIR2DL2, and Asn at position 80 of HLA-
Cw*0304 (Boyington et al, 2000). These residues are conserved in KIR2DL3, which 
binds with similar specificity to HLA-C1 allotypes. 
 
Although initially thought to represent different genes, genomic analysis has shown 
that KIR2DL2 and KIR2DL3 segregate as alleles of the same locus (Uhrberg et al, 
2002). KIR2DL2 and KIR2DL3 differ by no more than six amino acids in their 
extracellular domains between any two allelic products, and none of the amino acid 
differences are located within the region that interacts with HLA-C1 and bound 
peptide (Snyder et al, 1999; Boyington et al, 2000; VandenBussche et al, 2006). The 
KIR2DL2 and KIR2DL3 alleles (KIR2DL2*001 and KIR2DL3*001 respectively) 
used in this study, differ by only five amino acids in their extracellular domains 
(Figure 3.1). Distinguishing the extracellular domains of KIR2DL2*001 and 
KIR2DL3*001 alleles are four polymorphic positions in the Ig-like domains: 16 and 
35 in the D1 domain and 148 and 200 in the D2 domain, and one polymorphic 
position in the stem region, position 216. 
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  D1 Domain (Residues 1-102) 
 
                                                   10                      20                       30                     40                           50 
2DL2*001 HEGVHRKPSL LAHPGRLVKS EETVILQCWS DVRFEHFLLH REGKFKDTLH 
2DL3*001 HEGVHRKPSL LAHPGPLVKS EETVILQCWS DVRFQHFLLH REGKFKDTLH 
 
 
 
                                        60                        70                        80                     90                    100 
2DL2*001 LIGEHHDGVS  KANFSIGPMM  QDLAGTYRCY GSVTHSPYQL  SAPSDPLDIV 
2DL3*001 LIGEHHDGVS  KANFSIGPMM  QDLAGTYRCY GSVTHSPYQL  SAPSDPLDIV 
 
 D2 domain (Residues 103-200) 
 
                                    110                    120                  130                      140                      150 
2DL2*001 ITGLYEKPSL SAQPGPTVLA GESVTLSCS RSSYDMYHLS RECEAHECRF                   
2DL3*001 ITGLYEKPSL SAQPGPTVLA GESVTLSCS RSSYDMYHLS REREAHECRF     
 
 
 
                                     160                    170                      180                      190             200 
2DL2*001 SAGPKBNGTF QADFPLGPAT HGGTYRCFGS FRDSPYEWSN SSDPLLVSVI   
2DL3*001 SAGPKBNGTF QADFPLGPAT HGGTYRCFGS FRDSPYEWSN SSDPLLVSVT 
 
 
 Stem (Residues 201-224)           TM (Residues 225-245)      Cyto-                
                    
                                     210                     220                    230                  240                       250   
2DL2*001 GNPSNSWPSP  TEPSSKTGNP  RHLHILIGTS  VVIILFILLF F. LLHRWCSNK   
2DL3*001           GNPSNSWPSP  TEPSSETGNP  RHLHVLIGTS VVIILFILLL FFLLHRWCCNK 
 
 
                            plasmic tail (Residues 246-327) 
                                     
                                         260                      270                      280                      290                   300   
2DL2*001 KNAAVMDQES  AGNRTANSED  SDEQDPQEVT YTQLNHCVFT QRKITRPSQR   
2DL3*001           KNAVVMDQEP AGNRTVNRED  SDEQDPQEVT YAQLNHCVFT QRKITRPSQR  
 
 
 
                                     
                                    310                   320                     330                      
2DL2*001 PKTPPTDIIV YAELPNAESR SKVVSCP  
2DL3*001           PKTPPTDIIV YTELPNAEP 
 
 
 
Figure 3.1 Sequence alignment of the polymorphisms that distinguish the amino 
acid residues of KIR2DL2*001 and KIRDL3*001 
The polymorphisms that distinguish KIR2DL2*001 and KIRDL3*001 are highlighted in red. 
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The functional importance of the polymorphisms between KIR2DL2 and KIR2DL3 
was indicated by the observation that the combination of KIR2DL3 and HLA-C1, but 
not KIR2DL2 and HLA-C1, was protective in Hepatitis C (HCV) infection (Khakoo 
et al, 2004). The synergistic protective effect of KIR2DL3/KIR2DL3-HLAC1/C1 
observed was suggested to be because of evidence that KIR2DL3 binds more weakly 
to its ligands than KIR2DL2 (Winter et al, 1998). Using KIR2D-Ig fusion proteins, 
KIR2DL2-Ig binds more strongly to 721.221 cells transfected with different HLA-C1 
allotypes than KIR2DL3-Ig (Winter et al, 1998, Moesta et al, 2008). Moreover, KIR 
proteins were overexpressed in KIR-negative NK cells using the vaccinia virus 
system, and KIR2DL2+ NK cells exerted stronger inhibition than KIR2DL3+ NK cells 
against the HLA-C1-transfected target cells (Winter et al, 1998). Explaining these 
findings in the context of HCV infection, NK cells expressing KIR2DL3 would bind 
more weakly to HLA-C1 and therefore the inhibitory signals would be more readily 
overcome by activating signals than if NK cells were inhibited by KIR2DL2.  
 
In this chapter, a comparison was made between KIR2DL2 and KIR2DL3 binding to 
HLA-C1. KIR2DL2-Ig and KIR2DL3-Ig fusion proteins were generated and used to 
stain HLA-C1-transfected cells. To ascertain whether HLA-C1 recognition could be 
detected in a functional assay, a multi-parameter flow cytometric assay was 
performed to measure NK cell activation using PBMCs as effector cells, and HLA-C1 
transfected cells as target cells. Finally, the polymorphisms in the extracellular 
domains distinguishing KIR2DL2 and KIR2DL3 were investigated to determine 
whether the polymorphisms between the two receptors could explain weaker binding 
of KIR2DL3 to HLA-C1.  
 82 
3. Results 
 
3.1 Generation of KIR-Ig fusion proteins 
 
Previous studies by Winter et al (1998) observed differential binding of soluble 
KIR2DL2-Ig and KIR2DL3-Ig proteins to 721.221 cells transfected with group 1 
HLA-C (HLA-C1) alleles. To investigate the differences in binding of KIR2DL2 and 
KIR2DL3 to HLA-C1 allotypes, soluble KIR2DL2-Ig, KIR2DL3-Ig and KIR2DS4-Ig 
fusion proteins were generated and purified. The integrity of purified proteins was 
assessed by SDS-PAGE using Comassie staining and samples were run under 
reducing and non-reducing conditions. The SDS-PAGE gel in Figure 3.2 shows two 
separate preparations of KIR2DL2-Ig and KIR2DL3-Ig. Protein preparations ran to 
the expected size of 130kDa homodimers and 65kDa monomers. Antibody reactivity 
of the KIR-Ig proteins was assessed by ELISA, and samples were quantified using a 
standard titration curve of KIR2DS2-Ig (Figure 3.3). Protein concentration was 
determined by nonlinear regression analysis. KIR-Ig protein was detected in the 
eluates. 
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Figure 3.2 SDS-PAGE gel of purified KIR-Ig proteins 
KIR-Ig fusion proteins were generated and purified as described in Materials and Methods. 
Protein integrity was verified by SDS-PAGE using Comassie staining and samples were run 
under reducing (Lanes 1-4) and non-reducing (Lanes 5-8) conditions. The gel above shows 
two separate preparations of KIR2DL2-Ig (Lanes 1, 2, 5 & 6) and KIR2DL3-Ig (Lanes 3, 4, 7 
& 8). A full range molecular weight rainbow marker (RM; Mr 12 000 – 225 000) was used to 
determine the molecular weight of KIR-Ig proteins, which ran to the expected size of 130kDa 
(homodimers) and 65kDa (monomers). 
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Figure 3.3 Antibody reactivity of KIR-Ig fusion proteins 
Antibody reactivity of KIR-Ig proteins was assessed by ELISA for KIR2DL2-Ig and 
KIR2DL3-Ig using KIR2DS2-Ig as a standard (a). KIR-Ig proteins were detected with the 
KIR2DL2/KIR2DL3/KIR2DS2-specific DX27 antibody. Unknown sample concentrations of 
KIR2DL2-Ig and KIR2DL3-Ig were quantified using nonlinear regression analysis (b). 
Protein was detected in eluates only (KIR2DL2-Ig and KIR2DL3-Ig). 
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3.2 Binding of soluble KIR2DL2 and KIR2DL3 to HLA class I-transfected cells 
 
To evaluate the differences in binding of KIR2DL2 and KIR2DL3 to HLA-C1 
allotypes, soluble KIR2DL2-Ig, KIR2DL3-Ig and KIR2DS4-Ig fusion proteins were 
incubated at increasing concentrations with the MHC class I negative cell line, 
721.221, and 721.221 cells transfected with single HLA-C alleles – HLA-Cw*0304, 
HLA-Cw*0702 and HLA-Cw*0401 (Figure 3.4). KIR2DS4-Ig was used as a 
negative control; previous studies have shown that this fusion protein does not bind to 
HLA-C-transfected cells (Winter et al, 1998). Six separate experiments were 
performed for each binding analysis. 
 
Binding of either KIR2DL-Ig fusion proteins to their HLA-C1 ligands consistently 
failed to reach saturation even at 100µg/ml. This may reflect KIR aggregation on 
binding to HLA-C. KIR2DL2-Ig and KIR2DL3-Ig as predicted bound to HLA-
Cw*0304- and HLA-Cw*0702- transfected cells (HLA-C1 allotypes), but binding of 
the soluble proteins to HLA-Cw*0401-expressing cells (HLA-C2 allotype) and 
721.221 untransfected cells was negligible. KIR2DL2-Ig reproducibly bound more 
avidly to HLA-Cw*0304 and HLA-Cw*0702 than KIR2DL3-Ig. The observed 
differences in binding of KIR2DL2-Ig and KIR2DL3-Ig to HLA-C1-transfectants 
were reproducible amongst several protein preparations (at least three different 
protein preparations for each KIR-Ig), and support previously published studies.  
 
KIR2DL2-Ig and KIR2DL3-Ig bound more avidly to HLA-Cw*0304 than HLA-
Cw*0702 at all concentrations of KIR-Ig. This may be because of an increased 
affinity of these two receptors to HLA-Cw*0304 or may reflect differences in HLA-C 
expression on transfectant cells. Staining of HLA-C-transfected cells for MHC class I 
expression using the pan MHC class I conformation-specific antibody W6/32 
consistently showed that HLA-Cw*0304 is expressed at a higher level than HLA-
Cw*0702 on 721.221 cells (Figure 3.5), which may explain the differences in binding 
observed.  
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Figure 3.4 Binding of KIR2DL2-Ig and KIR2DL3-Ig to HLA-C1-transfected 
cells 
721.221 (.221) cells or .221 cells transfected with HLA-Cw*0304 (.221-Cw3), HLA-
Cw*0702 (.221-Cw7) or HLA-Cw*0401 (.221-Cw4) were stained with KIR-Ig fusion 
proteins as described in Materials and Methods, and analysed by flow cytometry. a. 
Histogram plots for each cell line is shown following staining with KIR2DS4-Ig (black fill), 
KIR2DL2-Ig (block line) or KIR2DL3-Ig (dashed line), all at 50µg/ml. b. One experiment of 
six separate experiments is shown for KIR-Ig binding to HLA-C1 following incubation of 
HLA-C1 transfected cells with increasing concentrations of KIR2DS4-Ig, KIR2DL2-Ig 
(block line) or KIR2DL3-Ig (dashed line). Data are expressed as mean fluorescence intensity 
(MFI). 
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Figure 3.5 HLA class I expression of HLA-C transfected .221 cells 
Untransfected 721.221 cells or 721.221 cells transfected with HLA-Cw*0304, HLA-
Cw*0702 or HLA-Cw*0401 were stained with IgG2a negative control (cIg) or W6/32 at a 
final concentration of 2µg/ml and analysed by flow cytometry. a. Histogram plots of each cell 
line is shown. b. One experiment of six separate experiments is shown for W6/32 expression 
of indicated cell lines. Data are expressed as mean fluorescence intensity (MFI), and MFI 
values are written above each bar. 
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3.3 Functional recognition of HLA-C1 by KIR2DL2 and KIR2DL3 
 
To determine whether the recognition of HLA-C1 alleles by KIR2DL2 and KIR2DL3 
could be detected in a functional assay, a multi-parameter flow cytometric NK cell 
assay was performed using NK cell degranulation as a measure of NK cell activation, 
in the context of KIR interaction with peptide: MHC. CD107a is expressed on the 
membranes of cytolytic granules and has been shown to be a marker of NK cell 
activity, correlating with both a loss of perforin and target cell death (Alter et al, 
2004). This marker was used to detect NK cell activity in NK cell populations 
expressing either KIR2DL2 or KIR2DL3. 
 
3.3.1 Optimisation of CD107a assay on K562 target cells 
 
To set up and optimise this assay, the MHC class I-deficient K562 cell line, known to 
be efficiently lysed by NK cells, were used as target cells to stimulate PBMCs from 
healthy donors. PBMCs were stimulated overnight with IL-15 before co-incubation 
with K562 cells for 4 hours at 37°C in the presence of monensin and either an anti-
CD107a antibody or an isotype control antibody. After 4 hours, NK cells were 
defined by staining with anti-CD3 and anti-CD56 antibodies. The anti-CD158b 
antibody (clone CH-L) was used to detect KIR2DL2/L3+ NK cells (CD158b+). This 
antibody does not discriminate between KIR2DL2 and KIR2DL3 and also recognises 
the activating receptor KIR2DS2. The anti-CD158a (KIR2DL1/KIR2DS1) antibody 
(clone EB6B) was used to detect KIR2DL1+ NK cells (CD158a+). The frequency of 
degranulating (CD107a-expressing) NK cells was quantitated by multi-parameter 
flow cytometry. Data from one donor is shown in Figure 3.6. Analysis was performed 
on CD3-CD56+ lymphocytes, which represents NK cells. NK cells were divided into 4 
populations defined by staining with anti-CD158a and anti-CD158b antibodies. The 
gating strategy is shown in Figure 3.6a. Within the 4 NK cell sub-populations, the 
percentage of CD107a+ NK cells was determined in either PBMCs stimulated with 
IL-15 alone or PBMCs stimulated with IL-15 and K562 cells. Flow cytometry 
histogram figures for one donor are illustrated in Figure 3.6a, and show the 
percentage of CD158b+CD158a- NK cells expressing CD107a following incubation 
with an isotype control IgG1-PE antibody, and PBMCs stimulated with IL-15 
overnight either in the absence of stimulation with K562 cells or following 
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stimulation with K562 cells. For this donor, following stimulation with K562 target 
cells the frequency of degranulating CD158b+CD158a- NK cells increased from 
2.65% for PBMCs incubated with IL-15 alone to 58.94% following incubation with 
IL-15 and K562 cells. NK cells from the 4 defined NK cell sub-populations 
degranulated equally in response to K562 target cells (Figure 3.6b). 
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Figure 3.6 Degranulation assay for NK cell sub-populations 
CD107a assay was performed as described in Materials and Methods, and samples were 
analysed directly by flow cytometry. a. Analysis was performed on CD3-CD56+ NK cells. NK 
cells were separated into four populations as determined by staining with anti-CD158b and 
anti-CD158a antibodies. Flow cytometry histogram figures illustrate the percentage of 
CD107a-expressing CD158b+CD158a- NK cells following incubation with an isotype control 
IgG1-PE antibody, anti-CD107a antibody in the absence of stimulation, and anti-CD107a 
antibody following stimulation with K562 target cells at an E:T of 5:1 for one donor. b. All 
four NK cell sub-populations defined by CD158a and CD158b staining express CD107a 
upon stimulation with K562 target cells. Data is shown for one donor, and are means of 
triplicates +/- SEM. 
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To determine the optimal effector to target ratio for inducing maximal NK cell 
activation, PBMCs were stimulated with different concentrations of K562 target cells 
(Figure 3.7). Maximal CD107a expression on total NK cells was detected at an E:T 
of 5:1, therefore this E:T was used for all further experiments. 
 
To assess whether a four hour co-incubation of PBMCs and K562 target cells was 
sufficient to observe maximal CD107a expression by NK cells, the kinetics of 
CD107a expression was examined for one donor following co-incubation of PBMCs 
with K562 cells at an E:T of 5:1 (Figure 3.8). CD107a expression on the total NK cell 
population was examined between 1-6 hours following stimulation with K562 cells. 
CD107a expression was detected on NK cells as early as 1 hour after stimulation, 
with maximal expression detected after 4 hours. A further two hours did not increase 
the frequency of CD107a-expressing NK cells. Therefore, for subsequent experiments 
a 4-hour time point was employed.  
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Figure 3.7 Determining the optimal E:T ratio for CD107a expression 
CD107a assay was performed as described in Materials and Methods. Different 
concentrations of K562 cells were co-incubated with PBMCs to determine the optimal E:T 
ratio for CD107a expression. 
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Figure 3.8 Kinetics of NK cell CD107a expression following stimulation with 
K562 cells 
CD107a assay was performed as described in Materials and Methods. PBMCs stimulated with 
IL-15 were incubated either alone or in the presence of K562 target cells (K562) at an E:T of 
5:1 for different time points up until a maximum of 6 hours. Samples were analysed directly 
using a FACSCanto analytical flow cytometer.   
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3.3.2 Inhibition of CD158b+ NK cells by HLA-C1 
 
To determine whether the recognition of HLA-C1 allotypes by KIR2DL2 and 
KIR2DL3 could be detected in the described CD107a assay, the KIR2DL2 or 
KIR2DL3 type was determined for healthy donors by PCR-SSP. Two KIR2DL2 
homozygous and three KIR2DL3 homozygous donors were identified (Figure 3.9). 
PBMCs from these individuals were co-incubated with either untransfected 721.221 
cells or 721.221 cells transfected with HLA-Cw*0304 (721.221-Cw3), and the 
frequency of CD107a+ NK cells was determined for each of the four defined NK cell 
populations in response to these target cells. Similar results were obtained for all five 
donors (Figure 3.10a), with no significant differences observed. For four out of the 
five donors (Donors 2-5), approximately 40% of NK cells degranulated in response to 
.221 target cells for all four NK cell populations. For Donor 1, lower frequencies of 
degranulating NK cells following co-incubation with .221 cells were observed with 
approximately 20% of NK cells from each population responding to these targets. 
Histogram plots shown for one KIR2DL3 homozygous donor are shown in Figure 
3.10b. NK cells from all four subpopulations expressed approximately 40% of 
CD107a following co-incubation with 721.221 cells. However, the frequency of 
degranulating singly or double positive CD158b+ NK cells in response to HLA-
Cw*0304-.221 cells was low, with only 5.4% and 4.7% expressing CD107a 
respectively. No inhibition was observed in the CD158a+CD158b- or CD158b-
CD158a- NK cell population after co-incubation with HLA-Cw*0304 target cells, 
with 35.1% and 46.1% of NK cells from these populations respectively expressing 
CD107a in response to these targets. 
 
For all donors, degranulation of single or double CD158b+ populations (CD158b+a- or 
CD158b+a+ populations) was strongly inhibited following incubation with HLA-
Cw*0304-expressing target cells, and equivalent for these two populations (Table 
3.1). NK cells that do not express CD158b (CD158b-a+ or CD158b-a-) were not 
inhibited by HLA-Cw*0304-.221 cells. For these populations, the frequency of 
degranulating NK cells was comparable to degranulation in response to .221 cells. 
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Figure 3.9 PCR-SSP to determine KIR genotype of healthy donors 
The KIR genotype for 5 healthy donors was determined by PCR-SSP using primers specific 
for KIR2DL2 and KIR2DL3 as described in Materials and Methods. Two KIR2DL2 
homozygous (Lanes 1 -2) and three KIR2DL3 (Lanes 3-5) homozygous donors were 
identified. A DNA ladder was used (200bp-10,000bp) was used to detect KIR2DL2 and 
KIR2DL3 bands.  
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Figure 3.10 Functional recognition of HLA-C1 by CD158b 
a. CD3-CD56+ NK cells from 2 KIR2DL2 homozygous and 3 KIR2DL3 homozygous were 
separated into 4 populations based on CD158b and CD158a antibody staining. The frequency 
of CD107a+ NK cells is shown for each population following co-incubation with .221 or 
HLA-Cw*0304.221 targets cells. b. Histogram plots from one KIR2DL3 homozygous donor 
showing the frequency of CD107a expression on the four NK cell populations in response to 
.221 or HLA-Cw*0304-.221 
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  % CD107a+ NK cells 
Donor KIR HLA-C CD158b+a- CD158b+a+ CD158b-a+ CD158b-a- 
1 L2/L2 C2/C2 5.30 5.01 21.40 20.40 
2 L2/L2 C1/C1 4.32 4.56 41.63 42.66 
3 L3/L3 C1/C1 5.40 4.89 38.00 37.90 
4 L3/L3 C1/C2 4.79 5.14 43.65 41.89 
5 L3/L3 C1/C1 3.23 3.68 39.84 40.10 
 
 
Table 3.1 Inhibition of CD158b+ NK cells by HLA-C1 between donors with 
different KIR and HLA-C types 
PBMCs from 5 donors homozygous for KIR2DL2 (L2/L2) or KIR2DL3 (L3/L3) with 
different HLA-C type were co-incubated with HLA-Cw*0304-expressing .221 cells 
and CD107a assay was performed as previously described. Samples were analysed 
directly using a FACSCanto analytical flow cytometer. CD107a expression in the four 
defined NK cell subpopulations is shown. No significant differences were observed 
between the five donors (one way ANOVA). 
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As no differences in HLA-C1 mediated inhibition was observed between the two 
defined CD158b+ NK cell populations, for subsequent analysis the frequency of 
degranulating NK cells was analysed in two populations; CD158b+ NK cells and 
CD158b- NK cells (Figure 3.11a). For all donors, inhibition of CD158b+ NK cells 
was observed following co-incubation of PBMCs with target cells expressing HLA-
Cw*0304, compared to untransfected .221 cells, and no inhibition was observed in the 
CD158b- population (Figure 3.11b). The data from this functional assay therefore 
reproduced the HLA-C1 specificity of KIR2DL2-Ig and KIR2DL3-Ig in binding 
assays. Although differences in binding between KIR2DL2 and KIR2DL3 using 
soluble KIR-Ig proteins were observed, comparison between KIR2DL2 and KIR2DL3 
homozygote donors did not reveal any significant differences in HLA-C1-mediated 
inhibition. 
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Figure 3.11 Inhibition of CD158b+ NK cells by HLA-C1 in KIR2DL2 and 
KIR2DL3 homozygous donors 
a. NK cells were divided into two populations based on CD158b staining; CD158b+ and 
CD158b-, and the percentage of CD107a+ NK cells was determined for each population 
following co-incubation of PBMCs from a healthy donor with .221 cells or HLA-Cw*0304-
.221 cells. b. Analysis of CD107a expression in the two NK cell populations from 5 healthy 
donors homozygous for either KIR2DL2 or KIR2DL3 following co-incubation of PBMCs 
with .221 cells or HLA-Cw*0304-transfected .221 cells. No significant differences were 
observed between donors (One way ANOVA).  
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3.4 Effect of single amino acid substitutions on KIR binding. 
 
Distinguishing the KIR2DL2 and KIR2DL3 alleles used in this study (KIR2DL2*001 
and KIR2DL3*001 respectively) are four polymorphisms in the extracellular Ig-like 
domains and one in the stem region. To identify whether these polymorphisms could 
affect binding of KIR to HLA-C1, mutant fusion proteins were made (C. Brooks, 
unpublished data). A series of single substitutions were made in the KIR2DL2 
extracellular Ig domains or stem region, where residues present in KIR2DL2*001 
were substituted with those present in KIR2DL3*001. Table 3.2 shows the five 
polymorphisms, and their locations within the extracellular domains that distinguish 
KIR2DL2*001 and KIR2DL3*001 and the nomenclature for the mutant KIR2DL2-Ig 
proteins generated. 
 
Table 3.2 Polymorphisms distinguishing KIR2DL2*001 and KIR2DL3*001 
 
Amino 
acid 
residue 
Location in 
extracellular 
domain 
Residue in 
KIR2DL2*001 
Residue in 
KIR2DL3*001 
Mutant 
KIR2DL2 
nomenclature 
16 D1 Arginine (R) Proline (P) R16P 
35 D1 Glutamic acid (E) Glutamine (Q) E35Q 
148 D2 Cysteine (C) Arginine (R) C148R 
200 D2 Isoleucine (I) Threonine (T) I200T 
216 Stem Lysine (K) Glutamic acid (E) K216E 
 
 
Soluble wild type KIR2DL2-Ig, KIR2DL3-Ig, KIR2DS4-Ig fusion proteins as well as 
the 5 mutant KIR2DL2-Ig fusion proteins were incubated at increasing concentrations 
with 721.221 cells or 721.221 cells transfected with the HLA-C1 allele HLA-
Cw*0304 (Figure 3.12). 
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Figure 3.12 Effect of substitutions in KIR2DL2-Ig and binding to HLA-C1 
a. Histogram plots of .221 cells (grey fill) and .221-Cw*0304 (solid lines) incubated with 
50µg/ml KIR-Ig fusion proteins. MFI values for KIR-Ig binding to HLA-Cw*0304 are 
shown. b. Increasing concentrations of KIR-Ig fusion proteins (KIR2DS4-Ig (negative 
control; cIg), KIR2DL2-Ig (solid lines), KIR2DL3-Ig (dashed lines), or the 5 mutant 
KIR2DL2-Ig (solid lines)), were incubated with .221 cells or .221-Cw*0304. Data is 
expressed as MFI. One experiments out of three separate experiments is shown. 
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Binding of all KIR2DL-Ig fusion proteins to 721.221 cells expressing HLA-Cw3 
again consistently failed to reach saturation even at 100µg/ml. KIR2DL2-Ig again 
reproducibly bound to HLA-Cw*0304 more avidly than KIR2DL3-Ig. Single 
substitutions at the extracellular positions 16, 35, 148 and 200 did not weaken the 
interaction of KIR2DL2 with HLA-C1; stronger binding of KIR2DL2 to HLA-C1 to 
any one of these single residues could not be attributed. Binding of the soluble 
proteins to 721.221 untransfected cells was again negligible. These binding data were 
reproducible amongst different protein preparations (at least two different protein 
preparations for each KIR-Ig).  
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3.5 Discussion 
 
KIR-Ig fusion proteins and CD107a assays were used to investigate KIR binding to 
HLA-C. Soluble KIR2DL2-Ig and KIR2DL3-Ig proteins bound to group 1 HLA-C 
allotypes (HLA-C1; HLA-Cw*0304 and HLA-Cw*0702), but not to group 2 HLA-C 
allotypes (HLA-C2; HLA-Cw*0401) or MHC class I-negative .221 cells. Similar to 
published observations (Winter et al, 1998), binding of KIR-Ig to HLA-C1 
consistently failed to reach saturation even at 100µg/ml, which may reflect 
aggregation of these receptors. Binding of KIR to HLA-C has been reported to induce 
clustering of KIR mediated by zinc and other bivalent cations. The KIR-Ig binding 
experiments were performed in the presence of DMEM, which contains the divalent 
cations Mg2+ and Ca2+, which may explain the aggregation observed. 
 
We showed that KIR2DL2-Ig bound more avidly to HLA-C1 than KIR2DL3-Ig. 
KIR2DL2 and KIR2DL3 segregate as alleles of the same locus, and the alleles used in 
this study (KIR2DL2*001 and KIR2DL3*001) differ by only five amino acids in the 
extracellular domains. The crystal structures of KIR2D alone and bound to HLA-C 
have shown these amino acid polymorphisms are not located within the region that 
interacts with HLA-C (Snyder et al, 1999; Boyington et al, 2000). Given that 
KIR2DL2 and KIR2DL3 bind their ligands with different avidity, it seems likely that 
these polymorphisms may modify receptor function. KIR2DL2 may have increased 
inhibitory activity and affect an individual’s ability to mount an immune response. 
Our mutational analysis of single amino acid polymorphisms between KIR2DL2 and 
KIR2DL3 did not explain the difference in avidity between these two receptors. 
Therefore, we were not able to attribute stronger binding of KIR2DL2 to HLA-C1 to 
any of these single residues.  
 
Subsequent to these experiments, a study by Moesta et al (2008) was published 
investigating polymorphisms between KIR2DL2*001 and KIR2DL3*001. Consistent 
with our data, single amino acid substitutions in the D1 and D2 domain of 
KIR2DL2*001 did not decrease the avidity of KIR2DL2 for HLA-C1. Further 
mutational analysis revealed that the combination of polymorphisms at positions 16 
and 148 in the D1 and D2 domain respectively act synergistically to alter the avidity 
of KIR for HLA-C1. Arginine 16 and cysteine 148 synergistically increase avidity of 
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KIR2DL2 for HLA-C1, whereas proline 16 and arginine 148 weakens the KIR2DL3 
binding site. Residues 16 and 148 are located near the highly conserved hinge region 
that links the D1 and D2 domain, facing each other from complementary locations on 
the internal aspect of their respective domains (Figure 3.13). Moesta et al (2008) 
therefore suggested that residues 16 and 148 in KIR2DL2 alter the hinge angle and / 
or its flexibility, increasing its avidity for HLA-C1. Sequence alignment for all known 
KIR2DL2 (5 alleles) and KIR2DL3 alleles (7 alleles) show that all KIR2DL2 alleles, 
except KIR2DL2*004, have the same residues at position 16 and 148 as 
KIR2DL2*001, and are therefore predicted to bind more avidly to KIR2DL3 alleles 
that all share the same amino acid residues at these positions as KIR2DL3*001. 
KIR2DL2*004 has a proline at position 16, however due to a polymorphism at 
position 41 (threonine) is retained within the cell and cannot interact with HLA-C 
(VandenBussche et al, 2006). 
 
 
 
 
 
 
 
 
 
 
Taken from Moesta et al. J Immunol 2008; 180: 3969-3979 
 
Figure 3.13 Polymorphisms at residues 16 and 148 are predicted to alter the 
hinge angle and orientation of D1 and D2 domains.  
Polymorphisms distinguishing the KIR2DL2 and KIR2DL3 in the D1 and D2 domains are 
coloured red on the KIR2DL2 structure (green). Arginine 16 and cysteine 148 of KIR2DL2 
are located immediately below the highly conserved hinge region linking the D1 and D2 
domains synergistically make KIR2DL2 a stronger receptor for HLA-C1. Crystallographic 
evidence and mutational analyses predict these two residues alter the hinge angle and the 
relative orientation of the two domains.  
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The binding assays performed using soluble fusion proteins provides many 
advantages. They can be used to screen a wide coverage of receptor-ligand 
interactions rapidly, and avoids having to use bacterial expression systems, that may 
need further steps of glycosylation and correct folding. Fusion proteins are expressed 
as homodimers linked via disulphide bridges in the hinge region of the Fc (Winter and 
Long, 2000), which enhances the ability to detect binding than that obtained using a 
monomeric soluble receptor, therefore allowing visualisation of subtle differences in 
binding that may exist between different receptors. KIR-Ig fusion proteins however 
do not provide direct affinity measurements between receptor-ligand complexes. 
 
The specificity of KIR2DL2 and KIR2DL3 was reproduced in functional CD107a 
experiments, where HLA-C1-mediated inhibition of CD158b+ NK cells, but not 
CD158b- NK cells, was observed amongst different donors. Despite observed 
differences in binding assays between KIR2DL2 and KIR2DL3, CD158b+ NK cells 
from KIR2DL2 and KIR2DL3 homozygous donors inhibited HLA-C1 transfected 
target cells to an equal amount. Other studies have shown stronger inhibition of 
KIR2DL2+ NK cells than KIR2DL3+ NK cells (Winter et al, 1998; Moesta et al, 
2008) in response to HLA-C1-transfected cell lines. These studies used the vaccinia 
virus system where KIR proteins were overexpressed in KIR- NK cell lines. High 
inhibitory receptor expression on NK cell lines may allow to look for more subtle 
functional differences between the two receptors compared to using freshly isolated 
PBMCs from individuals expressing multiple receptors. Due to the variegated 
expression of KIR, only a subset of NK cells express the inhibitory receptor of 
interest. NK cell lines transfected with single KIR receptors rules out the possibility of 
interactions between other KIR: MHC: peptide interactions would, and differences 
between the two receptors would be more readily observed compared to using intact 
NK cells. 
 
As KIR-Ig binding to HLA-C1 is reflective of inhibitory function, we would expect 
KIR-Ig binding to correlate with the functional specificity of KIR for HLA-C1. 
However, it is difficult to directly compare these two methods. KIR-Ig binding assays 
measure the avidity of interactions between KIR and HLA-C1, whereas the CD107a 
assay does not directly measure receptor-ligand interactions, but looks at the 
frequency of NK cells within a population responding to HLA-C1-expressing target 
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cells. For the donors tested, not all NK cells within a population responded to MHC 
class I-deficient target cells, and not all CD158b+ NK cells were inhibited by HLA-
C1, suggesting that NK cells expressing a particular receptor are balanced slightly 
differently. Although functional differences between KIR2DL2 and KIR2DL3 donors 
may exist, this may be difficult to observe due to variability within the same 
population to respond to target cells. Assessment of a larger group of donors is 
required.  
 
Studies in human and mice have shown that during NK cell development, engagement 
of inhibitory receptors with self-MHC class I molecules provides a positive signal that 
leads to licensing of fully competent peripheral NK cells that can sense and lyse 
autologous targets that lose MHC class I (Kim et al, 2005; Anfossi et al, 2006). A 
recent study by Brodin et al (2009) showed that the strength of inhibitory signals 
received during NK cell licensing was directly proportional to functional 
responsiveness; NK cells licensed on stronger interactions between inhibitory receptor 
and ligand responded more strongly and with increased frequency than NK cells 
licensed on weaker inhibitory receptor-ligand combinations. Therefore, differences in 
interaction between inhibitory KIR2DL receptors and different HLA-C1 allotypes 
during development may affect the strength of functional recognition of HLA-C1 by 
mature NK cells.  
 
Despite differences in avidity between KIR2DL2 and KIR2DL3 for HLA-C1, there 
may be no observable functional differences between the two receptors. NK cells 
receiving stronger inhibitory signals during development through engagement with 
self MHC class I have been shown to mount a stronger response to MHC class I 
negative cells (Brodin et al, 2009). Mature KIR2DL2+ NK cells may therefore be able 
to respond to MHC class I negative cells with higher frequency, but not be able to 
respond to as readily as KIR2DL3+ NK cells, licensed on a weaker inhibitory signal. 
Functional differences between the two receptors may therefore be balanced out and 
not observable. Although differences are observed in NK cells licensed on different 
KIR-self HLA interactions for missing self, the effect of NK cell licensing by 
different KIR and self-HLA on NK cell inhibition has not been investigated.  
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We showed that KIR2DL2-Ig and KIR2DL3-Ig bound more avidly to HLA-Cw*0304 
than HLA-Cw*0702. These differences may be attributable to the higher expression 
of HLA-Cw*0304 than HLA-Cw*0702 on .221 cells observed. However, the 
possibility that KIR2DL2-Ig and KIR2DL3-Ig bind more avidly to HLA-Cw*0304  
than HLA-Cw*0702 cannot be ruled out. In a study of 58 unrelated individuals, 
KIR2DL3-mediated IFN-γ production in response to .221 cells was strongest for 
individuals with an HLA-Cw*07 allotype than for other HLA-C1 allotypes including 
HLA-Cw*0304 (Yawata et al, 2008). The observations by Yawata et al (2008) and 
Brodin et al (2009) are difficult to reconcile with our observations that HLA-Cw*07 
may be a weaker ligand for KIR, as KIR2DL3-mediated IFN-γ production in response 
to .221 cells was strongest for individuals with an HLA-Cw*07 allotype, and not 
HLA-Cw*0304. Due to differences in cell surface expression between the two HLA-
C1 alleles tested, we cannot attribute the weaker binding of KIR-Ig to HLA-Cw*0702 
to a weaker affinity of KIR for HLA-Cw*0702. A direct affinity measurement 
between KIR receptor-HLA ligand pairs is required to determine how differences in 
affinity between HLA-C alleles can modulate functional responses of mature NK 
cells. 
 
KIR and HLA types for the individual donors tested revealed some interesting 
observations. One of the five donors tested is homozygous for KIR2DL2, HLA-C2, 
HLA-Bw6 and does not express KIR2DL1. This donor has no cognate HLA-C 
ligands for KIR, and NK cells from this donor are solely licensed on CD94/NKG2A. 
All other donors tested had cognate HLA-C ligands for KIR. No differences were 
observed between donors in CD158b-mediated inhibition of HLA-Cw*0304-
expressing target cells, suggesting that engagement of CD158b for cognate HLA-C is 
not required for receptor function. However donors with cognate HLA-C ligands for 
KIR were able to respond with higher frequency to MHC class I-deficient .221 cells 
than the donor with no cognate HLA ligands for KIR. Human NK cells expressing 
inhibitory KIR with cognate HLA have been shown to be more responsive by CD16 
cross-linking, cytokine production and CD107a expression to class I-negative targets 
compared with other NK cell subsets (Anfossi et al, 2006). Furthermore, a hierarchy 
of responses to class I-negative cells by NK subsets has been observed that is directly 
proportional to the number of different inhibitory KIRs for self-HLA (Yu et al, 2007). 
This suggests a model of NK cell licensing whereby increased inhibitory KIR-cognate 
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HLA interactions during development results in NK cells with higher effector 
capacity toward cells that have downregulated MHC class I. This may explain the 
decreased responses to class I-negative targets for the donor with no cognate HLA for 
inhibitory KIR. As CD158b-mediated inhibition however is not impaired, the 
functional consequences of decreased inhibitory KIR-self HLA interactions during 
development seem to be related to missing self responses and not self-tolerance. 
 
In contrast to the observations by Yu et al (2007), we observed that co-expression of 
CD158a and CD158b in donors expressing cognate HLA-C ligands for one or both 
HLA-C-specific inhibitory KIR did not affect CD158b-mediated inhibition of HLA-
C1+ target cells, or the ability to respond to class I-deficient targets. Further analysis 
of these individuals is required to look at other inhibitory KIR and HLA interactions 
for each donor to assess the functional consequences between donors expressing 
different numbers of inhibitory KIR-cognate HLA pairs. 
 
Further assessment of the interaction between KIR2DL2 and KIR2DL3 and HLA-C1 
would provide more detailed analysis of KIR allelic polymorphisms. A direct affinity 
measurement comparing binding of KIR2DL2 and KIR2DL3 to HLA-C1 in a 1:1 
stoichiometry using Surface Plasmon Resonance studies would provide Kd values 
between the different receptor-ligand interactions, whilst analysis of singly positive 
KIR2DL2+ or KIR2DL3+ NK cells may provide insights into functional differences 
between the two receptors.  
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Chapter 4. The peptide preference for KIR binding to HLA-C1 
 
The crystal structure of KIR2DL2 bound to HLA-Cw3 revealed that KIR2DL2 makes 
direct contact with residues 7 and 8 of the peptide bound in the MHC class I groove. 
KIR recognition has been shown to be both dependent and influenced by the peptide 
bound to HLA, although there is no specificity for a single peptide, since KIR can 
bind to the same HLA molecules carrying rather different peptides (Correa and 
Raulet, 1995; Peruzzi et al, 1996 Rajagopolan and Long, 1997; Zappacosta et al, 
1997).  
 
Functional studies have shown that lysis of target cells by NK clones exhibit peptide 
specificity (Zappacosta et al, 1997; Rajagopalan and Long, 1997). Different 
endogenous peptides known to bind HLA-Cw*0304 were shown to mediate different 
degrees of peptide-mediated protection against lysis by NK cell clones expressing 
KIR2DL2/KIR2DL3 (Zappacosta et al, 1997), whilst Surface Plasmon Resonance 
(SPR) analysis showed that the affinity of soluble KIR2DL3 binding to HLA-Cw7: 
peptide was dramatically affected by the nature of the bound peptide (Maenaka et al, 
1999). Recognition of HLA-Cw4 by KIR2DL1 was observed to be dependent on 
peptides (Rajagopalan and Long, 1997), and peptides that no longer allowed 
recognition of HLA-Cw4 by KIR2DL1-Ig were those with a negatively charged 
residue at p8. Indeed the crystal structure of KIR2DL1 complexed with HLA-Cw4 
and peptide revealed that although minimal interactions were observed between HLA-
Cw4-bound peptide and KIR2DL1, KIR2DL1 has an electronegatively charged polar 
surface around the peptide p8 Lys side chain (Fan et al, 2001). It therefore does not 
tolerate acid residues at this position. In the KIR2DL2/Cw3 complex, Gln71 of 
KIR2DL2 is hydrogen bonded to the main-chain nitrogen atom of p8 Ala (Boyington 
et al, 2000) which is thought to restrict the size of the side chain that can be 
accommodated. Indeed, there is a preference for the small amino acid residues alanine 
or serine in the p8 position. Recognition of HLA-B*2705 by KIR3DL1 is dependent 
on residues 7 and 8 of the peptide, whilst binding of KIR3DL2 to HLA-A3 and HLA-
A11 is also dependent on the presence of specific peptides (Hansasuta et al, 2004; 
Peruzzi et al, 1996).  
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KIR2DL2 and KIR2DL3 bind the same HLA-C1 allotypes with Asn at position 80 
(Vitale et al, 1995), and make direct contact with the HLA-C1 bound peptide at 
residues 7 and 8 of the peptide (Boyington et al, 2001). KIR2DL2 and KIR2DL3 
segregate as alleles of the same locus (Keaney et al, 2004), are similar in sequence, 
and vary by no more than six amino acids in their extracellular domains between any 
two allelic products (VandenBussche et al, 2006). The amino acid differences 
observed are not located within the region that interacts with HLA-C1 and bound 
peptide. In Chapter 3, binding assays with KIR-Ig fusion proteins showed that 
KIR2DL2 binds more strongly to HLA-C1-transfected cell lines than KIR2DL3, 
although no functional differences between KIR2DL2 or KIR2DL3 homozygote 
donors were observed. The role of peptide however was not addressed. Given that 
different peptides bound to the same HLA-C1 allele have been shown to confer 
different degrees of protection against NK cell lysis, the recognition of HLA-C1 by 
KIR2DL2 and KIR2DL3 appears to be both selective and dependent on the peptide 
bound (Maenaka et al, 1999; Zappacosta et al, 1997; Rajagopalan and Long, 1997). 
 
As the affinity for HLA-C can be dramatically altered by both the specific HLA allele 
studied and by the specific peptide presented by the HLA molecule, we hypothesised 
that the observed differences between KIR2DL2 and KIR2DL3 in HCV infection may 
be in part due to the receptors exhibiting peptide selectivity. The influence of peptide 
on binding of KIR2DL2 and KIR2DL3 was investigated by exploiting a cell line that 
is deficient in Transporter associated with Antigen Processing (TAP) that expresses 
the HLA-C1 allele HLA-Cw*0102, to determine the peptide specificity and 
selectivity for these two receptors. Peptides that promoted weak, intermediate and 
strong KIR binding to HLA-C1 were selected from a previous screen of a large panel 
of VAPWNSLSL peptides, a peptide know to bind HLA-Cw*0102, with mutations at 
the residues critical for KIR binding; residues 7 and 8.  A sample of peptides screened 
is shown in Figure 4.1. 
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Figure 4.1 Peptide screen of VAPWNSLSL with mutations at residues 7 and 8 
A panel of VAPWNSLSL peptides with mutations at residues 7 and 8 were screened for 
binding to HLA-Cw*0102 to KIR2DL2-Ig and KIR2DL3-Ig (Khakoo, SI; unpublished 
observations). Peptides promoting strong, intermediate or weak binding of KIR-Ig to HLA-
Cw*0102 were used for further studies. 
 
 
Binding assays were performed using KIR2DL2-Ig and KIRDL3-Ig fusion proteins to 
investigate the influence of peptide on binding of KIR to HLA-C1. Furthermore, 
CD107a functional assays were performed to look at NK cell activation and target cell 
lysis, to determine the effect of peptides differing in residues critical for KIR binding 
(residues 7 and 8) on CD158b+  NK cell activation/inhibition.  
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4. Results 
 
4.1 The peptide preference for KIR2DL2 and KIR2DL3 binding to HLA-C1 
 
To investigate the influence of peptide on KIR binding to HLA-C1, the T2 cell line 
originally described by Salter et al (1985) was used for loading exogenous peptide 
onto HLA-C1. T2 cells are deficient in TAP1 and TAP2, which are responsible for 
importing peptides generated in the cytoplasm to the endoplasmic reticulum (ER) for 
loading onto MHC class I molecules (Salter et al, 1985). Due to deficiency in TAP, 
MHC class I is loaded with a low affinity peptide, causing an unstable MHC class I: 
β2-microglobulin: peptide trimeric complex on the cell surface (Henderson et al, 
1992; Correa and Raulet, 1995). TAP-deficient cells can be loaded with exogenous 
peptide, resulting in stabilisation of the class I molecule and a subsequent increase in 
MHC class I complexes on the cell surface when incubated at 26°C (Correa and 
Raulet, 1995). T2 cells express the HLA-C1 allotype HLA-Cw*0102 (Andersen et al, 
1999).   
 
To determine whether KIR2DL2 and KIR2DL3 have different peptide specificities for 
binding to HLA-C1, a cell surface stabilisation assay was performed. T2 cells were 
exogenously loaded with the peptide VAPWNSLSL, an endogenous, natural eluted 
peptide known to bind HLA-Cw*0102 (Andersen et al, 1999), or peptides with 
mutations of VAPWNSLSL at residues 7 and 8, and incubated at 26°C overnight. The 
following day, cells were stained with KIR2DS4-Ig (negative control), KIR2DL2-Ig 
or KIR2DL3-Ig fusion proteins to assess the ability of different peptides to promote 
binding of HLA-Cw*0102 to these KIR. A panel of seven peptides were selected 
from a previous screen of a large panel of VAPWNSLSL peptides that were observed 
to exhibit strong, intermediate or weak recognition of HLA-Cw*0102 by KIR2DL2 
and KIR2DL3 (Figure 4.1); VAPWNSLSL (VAP-LS), VAPWNSFAL (VAP-FA), 
VAPWNSDAL (VAP-DA), VAPWNSRAL (VAP-RA), VAPWNSWSL (VAP-WS), 
VAPWNSYSL (VAP-YS) and VAPWNSVSL (VAP-VS).  
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All peptides induced an increase in HLA-Cw*0102 complexes by approximately 
equal amounts resulting in an approximately two-fold increase in peptide: MHC 
complexes on the cell surface of T2 cells, as detected by the HLA-Cw*0102-specific 
antibody VP6G3 (Figure 4.2). In the absence of peptide, unstable HLA-Cw*0102 can 
still be detected, probably reflecting binding of suboptimal TAP-independent HLA-
Cw*0102 peptides to the HLA-C1 binding groove, or may represent ‘empty’ HLA-
Cw*0102 (Henderson et al, 1992).  
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a. 
 
 
 
 
 
 
 
 
 
b.  
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Peptide stabilisation of HLA-Cw*0102 on the cell surface of T2 cells 
following overnight incubation with peptide at 26°C 
T2 cells were exogenously loaded with 100µM peptide overnight at 26°C before staining with 
the HLA-Cw*0102-specific VP6G3 antibody. a. Histogram plot showing stabilisation of 
HLA-Cw*0102 following overnight incubation at 26°C in absence of peptide, 100µM VAP-
FA or 100µM VAP-DA. MFI values are shown. b. Stabilisation of HLA-Cw*0102 for the 
panel of seven peptides investigated following overnight incubation at 26°C in either absence 
of peptide, or 100µM indicated peptide. A single experiment of 8 separate experiments is 
shown.   
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To determine whether KIR2DL2 and KIR2DL3 have different peptide specificities for 
binding to HLA-C1, HLA-Cw*0102 was stabilised on the surface of T2 cells by the 
addition of 100µM of the seven different peptides described earlier. The following 
day, binding of KIR2DL2 and KIR2DL3 to HLA-Cw*0102: peptide complexes was 
assessed by staining T2 cells with increasing concentrations of KIR2DL2-Ig and 
KIR2DL3-Ig conjugated to protein A-Alexa 488. KIR was conjugated to protein A-
Alexa 488 at a ratio of 12:1 (KIR: Alexa), and the concentration of protein A Alexa-
488 to use for conjugation with KIR was determined through titration of Alexa-488 
(Figure 4.3a).  The differences between the slopes of KIR2DL2-Ig and KIR2DL3-Ig 
conjugated to protein A are not significant (Figure 4.3b; p = 0.7008) indicating that 
KIR2DL2-Ig and KIR2DL3-Ig conjugate to protein A Alexa-488 by equivalent 
amounts. 
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Figure 4.3 KIR2DL2-Ig and KIR2DL3-Ig conjugate to protein-A Alexa-488 at an 
optimum ratio of 12:1 KIR: protein-A Alexa-488 
a. T2 cells were incubated overnight at 26°C in the presence or absence of 100µM VAP-FA, 
before staining with 60µg/ml KIR2DL2-Ig (block line) or KIR2DL3-Ig (dashed line) fusion 
proteins conjugated with different concentrations of protein-A Alexa-488. Data are expressed 
as mean fluorescence intensity (MFI). For subsequent experiments, a ratio of 12:1 KIR: Alexa 
was used. b. Linear regression analysis of transformed data is shown. The slopes of 
KIR2DL2-Ig and KIR2DL3-Ig lines do not differ (ANCOVA; p = 0.7008). 
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4.1.1 Differential influence of peptide on binding of KIR2LD2-Ig and KIR2DL3-
Ig to HLA-Cw*0102 
 
In the absence of peptide, KIR2DL2-Ig and KIR2DL3-Ig did not bind to HLA-
Cw*0102 (Figure 4.4a), confirming that peptide is required for KIR binding. 
Moreover, the peptide VAPWNSDAL resulted in no or very weak recognition of 
HLA-Cw*0102 by KIR2DL2-Ig and KIR2DL3-Ig, despite stabilisation of peptide: 
MHC complexes to similar amounts as all other peptides tested (Figure 4.2a). The 
peptide VAPWNSFAL however promoted strong recognition of HLA-Cw*0102 by 
KIR2DL2-Ig and KIR2DL3-Ig (Figure 4.4a). These results were observed at all 
concentrations of KIR-Ig tested (Figure 4.4b). 
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Figure 4.4 KIR2DL2-Ig and KIR2DL3-Ig binding to HLA-Cw*0102 in the 
absence of peptide, to HLA-Cw*0102: VAP-DA and HLA-Cw*0102: VAP-FA 
a. Flow cytometry histogram plots showing KIR-Ig binding to T2 cells incubated overnight at 
26°C without peptide, in the presence of 100µM VAP-DA or 100µM VAP-FA following 
staining with 60µg/ml isotype control (KIR2DS4-Ig; black fill), KIR2DL2-Ig (block line) or 
KIR2DL3-Ig (dashed line) fusion proteins conjugated to protein-A Alexa-488. b. Titration of 
KIR-Ig (7.5µg/ml-120µg/ml) on T2 cells incubated with and without indicated peptide 
overnight at 26°C. 
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With the exception of VAP-DA, KIR2DL2-Ig bound to HLA-Cw*0102: peptide 
significantly more avidly than KIR2DL3-Ig at all concentrations (7.5µg/ml-120µg/ml) 
for all peptides tested. This observation was consistent in three separate experiments. 
To standardise KIR2DL2 data to KIR2DL3, subsequent data where indicated was 
expressed as the increase in binding relative to the binding of KIR2DL2-Ig and 
KIR2DL3-Ig to VAP-DA. 
 
The avidity of KIR for HLA-Cw*0102 was influenced by different peptides and a 
peptide hierarchy for binding of KIR2DL2-Ig and KIR2DL3-Ig to HLA-Cw*0102: 
peptide was observed (Figure 4.5). HLA-Cw*0102 presenting the VAP-FA peptide 
resulted in the strongest recognition of HLA-Cw*0102 by KIR2DL2-Ig and 
KIR2DL3-Ig of the peptides tested, followed by strong recognition of HLA-
Cw*0102: VAP-LS and HLA-Cw*0102: VAP-VS by KIR-Ig. Three peptides, VAP-
RA, VAP-WS and VAP-YS promoted intermediate recognition of HLA-Cw*0102 by 
KIR2DL2-Ig, whilst recognition of HLA-Cw*0102 by KIR2DL3-Ig mediated by 
these three peptides was very weak. 
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Figure 4.5 Influence of peptide on binding of KIR2DL2-Ig and KIR2DL3-Ig to 
HLA-Cw*0102 
T2 cells were incubated overnight at 26°C in the presence of 100µM indicated peptide before 
staining with increasing concentrations of KIR2DL2-Ig (block line) or KIR2DL3-Ig (dashed 
line) fusion proteins Data is expressed as increase in binding relative to VAP-DA peptide 
(MFI/VAP-DA). Data shown are means of triplicates with Mean +/- SEM shown. 
Significance was determined by Mann-Whitney test. 
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Figure 4.6a shows the peptide hierarchy observed for binding of KIR2DL2-Ig and 
KIR2DL3-Ig to HLA-Cw*0102: peptide at one concentration of KIR-Ig (60µg/ml). 
Data is again expressed as the increase in binding relative to binding of KIR-Ig to 
HLA-Cw*0102: VAP-DA (this peptide resulted in weak/no recognition of HLA-
Cw*0102 by KIR2DL2-Ig and KIR2DL3-Ig). A hierarchy of strong, intermediate and 
weak KIR2DL2- and KIR2DL3-binding peptides was established, with more avid 
binding of KIR2DL2-Ig to HLA-Cw*0102: peptide compared with KIR2DL3-Ig for 
all peptides (p<0.05). VAP-RA, VAP-WS and VAP-YS may represent peptides that 
are recognised by KIR2DL2 but not KIR2DL3, as these peptides promoted 
intermediate recognition of HLA-Cw*0102 by KIR2DL2-Ig, with only weak 
recognition of HLA-Cw*0102 by KIR2DL3-Ig. This suggests that KIR2DL2 and 
KIR2DL3 may exhibit a degree of peptide selectivity.  
 
Histogram plots for KIR2DL2-Ig and KIR2DL3-Ig binding to HLA-Cw*0102 
mediated by VAP-FA and VAP-RA peptides are shown in Figure 4.6b. At 60µg/ml 
KIR-Ig, both KIR2DL2-Ig and KIR2DL3-Ig bind with strong avidity to HLA-
Cw*0102: VAP-FA (MFI = 101.50 and 82.13 respectively). KIR2DL2-Ig bound more 
avidly to HLA-Cw*0102: VAP-FA than KIR2DL3-Ig. KIR2DL2-Ig bound to HLA-
Cw*0102: VAP-RA with intermediate avidity (MFI = 42.78) with weak recognition 
of HLA-Cw*0102: VAP-RA by KIR2DL3-Ig (MFI = 15.87). These observations 
were consistent in three separate experiments.  
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Figure 4.6. Peptide hierarchy for binding of KIR2DL2-Ig and KIR2DL3-Ig to 
HLA-Cw*0102 
a. T2 cells were incubated overnight at 26°C in the presence of 100µM indicated peptide 
before staining with 60µg/ml KIR2DL2-Ig (black fill) or KIR2DL3-Ig (horizontal lines) 
fusion proteins conjugated to protein-A Alexa-488 Data is expressed as increase in binding 
relative to VAP-DA peptide and are means of triplicates with Mean +/- SEM shown. 
Significance was determined by Mann-Whitney test (indicated by *). b. Flow cytometry 
histogram plot from one experiment is shown. T2 cells were incubated with 100µM 
VAP-FA or VAP-RA before staining with 60µg/ml KIR2DS4-Ig (fill), KIR2DL2-Ig (block 
line) or KIR2DL3-Ig (dashed line). 
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Binding of KIR2DL2-Ig and KIR2DL3-Ig fusion proteins to HLA-Cw*0102: peptide 
consistently failed to reach saturation even at 100µg/ml except for VAP-FA. Non-
linear regression curve analysis and scatchard analysis was performed to fit a binding 
curve to obtain Bmax (maximum specific binding) values and ½ max values for KIR-
Ig binding to different HLA-Cw*0102: peptide complexes, where ½ max is the 
concentration of KIR2DL2-Ig or KIR2DL3-Ig required to reach half-maximal binding 
to HLA-Cw*0102: peptide complexes (Figure 4.7; Table 4.1). A stronger peptide has 
a lower ½ max than a weaker peptide. For the three peptides that mediate intermediate 
recognition of HLA-Cw*0102 by KIR2DL2-Ig - VAP-WS, VAP-RA, and VAP-YS , 
½ max values for KIR2DL3-Ig binding to HLA-Cw*0102 were high – 155.3, 109.1 
and 142.4 respectively, suggesting minimal or no binding of these peptide: MHC 
complexes to KIR2DL3. Thus KIR2DL2 and KIR2DL3 may exhibit a degree of 
peptide selectivity.  
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Figure 4.7 Non-linear regression curve analysis to obtain Bmax and ½ max 
values  
Non-linear regression curve analysis was performed to fit a binding curve for VAP-
FA binding to HLA-Cw*0102 to obtain Bmax and ½ max values. Scatchard analysis 
to visualise saturation binding data is shown. 
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 KIR2DL2-Ig (µg/ml) KIR2DL3-Ig (µg/ml) 
VAP-FA 8.338 20.14 
VAP-VS 11.37 56.09 
VAP-LS 22.810 73.68 
VAP-WS 43.190 155.3 
VAP-RA 38.790 109.1 
VAP-YS 61.220 142.4 
 
 
Table 4.1 Non-linear regression curve analysis showing ½ max values of different 
peptide: HLA-Cw*0102 complexes for binding KIR2DL2-Ig and KIR2DL3-Ig 
Nonlinear regression curve analysis was performed as described in Materials and Methods to 
obtain ½ max  values for different peptide: HLA-Cw*0102 complexes for binding KIR2DL2-
Ig and KIR2DL3-Ig, where ½ max is the concentration of KIR2D-Ig required to reach half-
maximal binding to peptide: HLA-Cw*0102.  
 126 
4.2 Differential inhibition of NK cell degranulation by exogenous peptide 
 
To assign functional relevance to the peptide-binding hierarchy observed for both 
KIR2DL2 and KIR2DL3, the seven peptides described above were incorporated into 
the CD107a assay described previously (Section 3.3.1). The CD107a marker was 
used to detect NK cell activity in NK cell populations expressing CD158b to 
determine whether the peptide hierarchy observed for the binding assays described 
above could be observed in functional assays. T2 cells loaded with exogenous peptide 
were used as target cells and PBMCs from healthy donors were used as effector cells.  
 
4.2.1 Optimisation of CD107a assay using T2 cells as target cells 
 
TAP-deficient cells T2 cells loaded with exogenous peptide overnight results in 
stabilisation of the MHC class I molecule and a subsequent increase in MHC class I: 
peptide complexes on the cell surface when cells are incubated at 26°C. The CD107a 
assay described in Section 3.3 was performed at 37°C for 4 hours. When T2 cells 
were loaded overnight with exogenous peptide at 26°C, and the following day 
incubated at 37°C up to a maximum of 5 hours, the rate of decay of HLA-Cw*0102: 
VAP-FA complexes from the cell surface of T2 cells occurred very rapidly (Figure 
4.8). Stabilisation of HLA-Cw*0102: VAP-FA as detected by the HLA-Cw*0102-
specific VP6G3 antibody dropped to half between 2 and 3 hours following incubation 
at 37°C.   
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Figure 4.8 Stability of HLA-Cw*0102: peptide at 37°C 
T2 cells were incubated in the presence or absence of 100µM VAP-FA overnight at 26˚C 
before incubation at 37°C. Stability of HLA-Cw*0102 was detected at the indicated time 
points with the HLA-Cw*0102-specific antibody VP6G3. Data are expressed as mean 
fluorescence intensity (MFI). 
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As the CD107a assay requires incubation of effector cells with target cells for 4 hours 
to see maximum CD107a expression by NK cells (Figure 3.7), these experiments 
needed to be performed at 26°C, and not 37°C, to prevent a decay of HLA-Cw*0102: 
peptide complexes over the 4 hour time period. K562 cells do not express MHC class 
I molecules, therefore are excellent targets for NK cell lysis, whereas the T2 cell line 
expresses HLA-Cw*0102 as well as HLA-A*0201 and HLA-B*5101 (Andersen et al, 
1999). To determine whether NK cells are able to degranulate in response to T2 target 
cells at 26°C, and whether degranulation is comparable to that at 37°C, CD107a 
assays were performed at the two temperatures using K562 cells and T2 cells as target 
cells. The frequency of degranulating NK cells was quantitated by multi-parameter 
flow cytometry (Figure 4.9). NK cells were able to degranulate in response to both 
K562 and T2 target cells at 26°C and 37°C, and the frequency of degranulating NK 
cells was comparable between the two temperatures. NK cells were able to 
degranulate in response to T2 cells (Figure 4.9) with an optimal E:T of 5:1. 
Therefore, for subsequent experiments, this ratio was used.  
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Figure 4.9 NK cell degranulation in response to K562 cells and T2 cells at 26°C 
and 37°C  
CD107a assays were performed as described in Materials and Methods. K562 cells and T2 
cells were used as target cells and added at increasing concentrations to PBMCs. PBMCs 
were co-incubated with target cells for 4 hours at either 26°C or 37°C. 
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4.2.2 Inhibition of NK cell degranulation by exogenous peptide 
 
To determine whether the same peptide hierarchy observed in binding assays (Section 
4.1) could be observed in a functional assay, CD107a assays were performed using T2 
cells loaded with exogenous peptides as target cells to look at the effect of exogenous 
peptide on CD158b+ NK cells. T2 cells were loaded with exogenous peptide up to a 
maximum concentration of 10-5M peptide. At this concentration of peptide, maximal 
expression of HLA-Cw*0102: peptide complexes on the surface of T2 cells can be 
detected following overnight incubation at 26°C (Figure 4.10). HLA-Cw*0102 
stabilisation was determined for each experiment. For subsequent experiments, 
titrations of peptide were performed at a maximum concentration of 10-5M. 
 
 
 131 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10 Expression of HLA-Cw*0102: peptide complexes detected on surface 
of T2 cells following incubation with exogenous peptide 
T2 cells were incubated overnight at 26°C in the presence or absence of increasing 
concentrations of VAP-DA (block line), VAP-FA (dashed) or VAP-RA (dotted) to a 
maximum concentration of 20µM peptide.  Stabilisation of HLA-Cw*0102 was detected 
using the VP6G3 antibody. Data are expressed as mean fluorescence intensity (MFI).  
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Degranulation of CD158b+ NK cells in response to T2 cells loaded with the different 
HLA-Cw*0102-specific peptides was examined in a CD107a assay. CD3-CD56+ NK 
cells were divided into four populations based on staining with anti-CD158b (anti-
KIR2DL2/KIR2DL3/KIR2DS2) and anti-CD158a (anti-KIR2DL1/KIR2DS1) 
antibodies, as described in Figure 3.6. Within the different NK cells populations, the 
expression of CD107a was noted in either unstimulated controls, or following 
stimulation with T2 cells in the absence or presence of peptide.  
 
Histogram plots from a healthy KIR2DL2/KIR2DL3 heterozygote donor showing 
CD107a expression in the four defined NK cell populations in response to T2 cells in 
the absence of exogenous peptide, T2 cells loaded with 10-5M VAP-DA or 10-5M 
VAP-FA are shown in Figure 4.11a. In the absence of peptide, T2 cells express 
unstable class I MHC at the cell surface, and do not bind KIR-Ig. NK cells in all four 
defined NK cell populations degranulate in response to T2 cells, ranging from 29.5%-
43.3% of NK cells expressing CD107a for the donor shown. Degranulation of 
CD158b+ NK cells was inhibited by addition of exogenous VAP-FA but not VAP-DA 
peptide. For the donor shown in Figure 4.11a, 30.2% and 35.9% of 
CD158b+CD158a- and CD158b+CD158a+ NK cells were activated in response to T2 
cells in the presence of 10-5M VAP-DA peptide, at similar levels to the percentage of 
NK cells degranulating in response to T2 cells in the absence of peptide for these two 
populations (29.5% and 37.8% respectively). This is consistent with the observed 
weak binding of HLA-Cw*0102: VAP-DA by KIR2DL2-Ig and KIR2DL3-Ig. 
However, for target cells incubated overnight with 10-5M VAP-FA, the percentage of 
degranulating CD158b+ NK cells dropped to 5.9% and 6.8% in the CD158b+CD158a- 
and CD158b+CD158a+ NK cell populations respectively. This is consistent with our 
binding assays where VAP-FA promoted strong binding of KIR2DL2-Ig and 
KIR2DL3-Ig to HLA-Cw*0102. The frequency of NK cells degranulating in the two 
CD158b- NK cell populations in response to T2 cells loaded with VAP-DA and VAP-
FA as expected was not altered by the presence of peptide, with approximately equal 
percentages of NK cells from these populations degranulating in response to T2 
targets, and comparable to T2 cells where no peptide was loaded.  This shows that 
response to peptide is specific for NK cells expressing CD158b.  
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For the two defined NK cell populations expressing CD158b, the presence or absence 
of CD158a did not affect CD158b-mediated inhibition of HLA-Cw*0102: VAP-FA. 
For the donor shown in Figure 4.11a NK cells expressing CD158b in the presence or 
absence of CD158a were inhibited to a similar amount be T2 cells expressing HLA-
Cw*0102: VAP-FA (5.9% and 6.8% respectively). Therefore, for NK cells expressing 
both receptors, the lack of engagement of CD158a by peptide: MHC in the presence 
of engagement of CD158b by peptide: MHC results in similar levels of inhibition. For 
all subsequent experiments to look at the effect of exogenous peptide on CD158b+ 
NK cells, CD107a expression was analysed in two NK cell populations; CD158b+ and 
CD158b- NK cells (Figure 4.11b). CD107a expression was detected in CD158b+ and 
CD158b- NK cells in response to T2 cells in the absence of peptide, T2 cells loaded 
with 10-5M VAP-DA or 10-5M VAP-FA peptide. Degranulation of CD158b+ NK cells 
was inhibited by T2 cells loaded with VAP-FA but not VAP-DA or unloaded T2 cells 
(Figure 4.11b). Analysis on the same KIR2DL2/L3 donor as in Figure 4.11a showed 
that 33.5% of CD158b+ NK cells expressed CD107a in response to T2 cells loaded 
with VAP-DA peptide, which is similar to the percentage of NK cells degranulating in 
response to T2 cells in the absence of peptide (33.9%). CD158b+ NK cell 
degranulation was inhibited by T2 cells loaded with exogenous VAP-FA with only 
6.7% of KIR2DL2/KIR2DL3+ NK cells expressing CD107a in response to these 
targets. Addition of either peptide did not affect degranulation of CD158b- NK cells. 
Figure 4.11c compares CD107a expression for the same donor in the three CD158b+ 
NK cell populations; CD158b+a-, CD158b+a+, and CD158b+ NK cells. Inhibition of 
NK cells by CD158b is not affected by the presence or absence of CD158a. 
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Figure 4.11 CD158b+ NK cell degranulation in response to T2 cells in the absence 
of exogenous peptide, loaded with VAP-DA or VAP-FA peptide. 
a. Histogram plots from one KIR2DL2/KIR2DL3 heterozygote donor showing CD107a 
expression in response to T2 cells in the absence of peptide, T2 cells loaded with 10-5M VAP-
DA or T2 cells loaded with 10-5M VAP-FA in the four NK cell populations defined by 
CD158b and CD158a antibody staining. b. Gating of NK cells into CD158b+ or CD158b- NK 
cells and histogram plots showing CD107a expression in response to T2 cells in the absence 
or presence of 10-5M indicated peptide at 26°C. c. CD107a expression in three defined 
CD158b populations; CD158b+a-, CD158b+a+, and CD158b+ in response to T2 cells loaded in 
the absence or presence of 10-5M indicated peptide. 
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4.2.3 Differential inhibition of CD158b+ NK cells by different concentrations of 
exogenous peptide. 
 
To determine whether the peptide hierarchy observed in binding assays could be 
reproduced in functional CD107a assays, peptide titrations were performed 
incorporating peptides that promoted strong (VAP-FA) and intermediate (VAP-RA, 
VAP-WS and VAP-YS)  binding of KIR2DL2-Ig and KIR2DL3-Ig to HLA-
Cw*0102. Exogenous peptide was added to a maximum final concentration of 10-5M 
peptide. Donor variability is observed in the percentage of NK cells responding to 
peptide: T2 cells, with a range of lysis in response to HLA-Cw*0102 presenting VAP-
DA between 26.1-47%, with a mean of 33.7%. Due to donor variability, the data is 
normalised to the percentage of NK cells degranulating in response to T2 cells loaded 
with VAP-DA (peptide that resulted in weak KIR-Ig binding to HLA-Cw*0102; 
%VAP-DA). The hierarchy observed in the binding assays was reproduced in 
functional assays (Figure 4.12). At a maximum concentration of exogenous peptide 
(10-5M), addition of VAP-FA resulted in strongest inhibition of NK cell degranulation 
by the CD158b+ NK cells. At the same concentration of peptide, more CD107a-
expressing CD158b+ NK cells were observed with the weaker binding peptides VAP-
WS, VAP-RA and VAP-YS. As the peptide concentration decreased, the frequency of 
degranulating CD158b+ NK cells increased due to lower levels of HLA-Cw*0102 on 
target cells. CD107a expression by CD158b- subsets as before was not affected by 
exogenous peptide.  
 
Linear regression analysis was performed to interpolate the graphs of transformed 
data to obtain values for the concentration of peptide required to reach 50% inhibition 
(Table 4.2). For all peptides promoting weaker binding of KIR to HLA-C1, the 
peptide concentration required to reach 50% inhibition by CD158b+ NK cells was 
higher than for VAP-FA (4.4x10-7M), consistent with the model that peptides that 
mediate weaker binding to HLA-Cw*0102 require quantitatively more HLA-C: 
peptide interactions than HLA-C: VAP-FA to mediate the same level of inhibition. 
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Figure 4.12 CD158b+ NK cell degranulation is inhibited to a greater extent by 
VAP-FA than intermediate KIR-binding peptides 
CD107a assays were performed using PBMCs from one healthy KIR2DL2/KIR2DL3 
heterozygous donor. Exogenous peptide was added at increasing concentrations to a 
maximum final concentration of 10-5M peptide. Left-hand panels show titration curves for 
intermediate binders of KIR2DL; VAP-RA, VAP-WS and VAP-YS compared with VAP-FA 
(strong binder). The transformed data is shown in right-hand panels indicating by arrows the 
concentration of either peptide to achieve 50% inhibition. Data is expressed as the percentage 
of CD158b+CD107a+ NK cells normalised to VAP-DA. Data shown are means of triplicates 
with Mean +/- SEM shown. 
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Peptide 
 
½ max values obtained 
for KIR2DL2-Ig in 
binding assays (µg/ml) 
½ max values obtained for 
KIR2DL3-Ig in binding 
assays (µg/ml) 
Peptide 
concentration 
required to reach 
50% inhibition (M) 
VAP-FA 8.338 20.14 4.4x10-7 
VAP-RA 38.79 109.1 5.96x10-5 ** 
VAP-WS 43.19 155.3 1.87x10-6 * 
VAP-YS 61.22 142.4 2.8x10-4 ** 
 
Table 4.2 Peptide concentration required to reach 50% NK cell inhibition by 
CD158b+ subset is higher for weaker binding peptides 
Linear regression analysis of transformed data was performed to determine the peptide 
concentrations of the different peptides to mediate 50% inhibition by CD158b+ NK cells. 
Statistical analysis showed that transformed slopes of VAP-RA, VAP-YS and VAP-WS were 
significantly different from that of VAP-FA (strong KIR2DL binder) (p<0.05; ANCOVA). 
Statistically significant results indicated by *. 
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The analyses shown above were for one KIR2DL2/KIR2DL3 heterozygous donor. To 
show that data can be reproduced in different donors, and that KIR genotype and 
HLA-C type does not affect the ability of KIR2DL2/KIR2DL3+ cells to respond to 
exogenous peptide, VAP-FA peptide titrations were performed for 14 different donors 
with different KIR (KIR2DL2/L2; KIR2DL2/L3 or KIR2DL3/L3) and HLA-C types 
(HLA-C1/C1, HLA-C2/C2, or HLA-C1/C2) to determine the peptide concentration 
required to reach 50% inhibition for each donor (Table 4.3). No statistical difference 
was observed for the fourteen donors differing in KIR and HLA-C type in the 
concentration of VAP-FA required to mediate 50% inhibition by CD158b+ NK cells, 
suggesting the results obtained for the donor in Figure 4.12 and Table 4.2 are not 
donor dependent. 
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 KIR type   
Donor KIR2DL2 KIR2DL3 HLA-C Peptide concentration required to reach 
50% inhibition (M) 
1 + - C2/C2 2.7x10-7 
2 - + C1/C1 1x10-7 
3 - + C1/C2 1.9x10-7 
4 - + ? 1x10-7 
5 - + C2/C2 2x10-7 
6 - + C1/C2 3.62x10-7 
7 - + C1/C2 2.79X10-7 
8 - + ? 1.75x10-7 
9 - + C1/C1 3.1x10-7 
10 + + C1/C2 3.39x10-7 
11 + + ? 3.35x10-7 
12 + + C1/C1 3.26x10-7 
13 + + C1/C2 2.89x10-7 
14 + + C1/C2 1.74x10-7 
 
Table 4.3 VAP-FA concentration required to reach 50% NK cell inhibition by 
CD158b+ NK cells for donors with different KIR and HLA-C types 
 
Linear regression analysis of transformed data was performed to determine the peptide 
concentrations of the VAP-FA required to mediate 50% inhibition by the KIR2DL2/L3+ NK 
cell population. Statistical analysis showed that values did not differ significantly between 
donors; one way ANOVA p>0.05.   
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T2 cells are known to express other HLA alleles including HLA-A*0201. HLA-A2 
and HLA-C1 possess similar peptide binding motifs and a number of HLA-Cw*0102-
binding peptides have been shown to bind to HLA-A*0201 (Anderson et al, 1999). In 
order to determine whether the exogenous peptides loaded onto T2 cells were binding 
to and upregulating HLA-A2, contributing to the binding and functional data shown, 
unloaded T2 cells or T2 cells loaded with exogenous VAP-FA were stained with the 
HLA-Cw*0102 or HLA-A*0201-specific antibodies. HLA-A*0201 was not found to 
be upregulated on the cell surface of T2 cells upon addition of peptide (Figure 4.13). 
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Figure 4.13 HLA-A*0201 is not upregulated on the cell surface of T2 cells by 
HLA-Cw*0102-specific peptides 
T2 cells were incubated in the presence or absence of 10-5M VAP-FA peptide overnight at 
26˚C before staining with the HLA-Cw*0102-specific antibody (VP6G3) or HLA-A*0201-
specific antibody (BB7.2). Samples were directly analysed by flow cytometry using a 
FACSCanto analytical flow cytometer. Data are expressed as mean fluorescence intensity 
(MFI). One experiment of three separate experiments is shown.  
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4.3 Inhibition of KIR2DL2+ and KIR2DL3+ NK cells by exogenous peptide 
 
Binding assays with KIR-Ig fusion proteins suggested that HLA-Cw*0102 presenting 
VAP-RA, VAP-WS or VAP-YS may be recognised by KIR2DL2-Ig but not 
KIR2DL3-Ig. To address whether KIR2DL2+ and KIR2DL3+ NK cells exhibit the 
same peptide selectivity, CD107a assays were performed using PBMCs from two 
healthy KIR2DL2 homozygote donors (KIR2DL2/L2) and three healthy KIR2DL3 
homozygote donors (KIR2DL3/L3). KIR types for the donors were assessed by PCR-
SSP (Figure 3.9). T2 cells incubated with 10-5M peptide were used as target cells, and 
all seven peptides described were tested. At this peptide concentration, HLA-
Cw*0102 is expressed at a maximum levels on the surface of T2 cells. A similar 
peptide hierarchy was observed in CD107a assays for KIR2DL2/L2 donors and 
KIR2DL3/L3 donors as for binding assays, with addition of exogenous VAP-FA 
resulting in the strongest inhibition by both KIR2DL2+ and KIR2DL3+ NK cells 
(Figure 4.14). All peptides that inhibited NK cells in KIR2DL2+ donors inhibited NK 
cells from KIR2DL3+ donors by similar amounts, and no significant differences were 
observed between the donors. This therefore did not correlate with previous binding 
data as KIR2DL3+ NK cells were inhibited by addition of exogenous VAP-WS, VAP-
RA and VAP-YS. HLA-Cw*0102 loaded with these three peptides showed very weak 
binding of KIR2DL3 in the binding assays described earlier. 
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Figure 4.14 Inhibition of CD158b+ NK cells from KIR2DL2 and KIR2DL3 
homozygous donors by exogenous peptide 
CD107a assays were performed using PBMCs from healthy KIR2DL2/L2 (n=2) and 
KIR2DL3/L3 (n=3) homozygous donors. T2 cells were loaded with exogenous peptide 
overnight at 26°C at a final concentration of 10-5M peptide. CD107a degranulation is shown 
in CD158b+ and CD158b- NK cells for all donors, and data is normalised to VAP-DA. Data 
shown are means of triplicates with Mean +/- SEM shown. No significant differences were 
observed between donors (p>0.05; one way ANOVA).  
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To further address whether KIR2DL2+ and KIR2DL3+ NK cells require a 
quantitatively different number of inhibitory HLA-C1:peptide interactions to mediate 
NK cell inhibition, peptide titrations were performed for VAP-FA (strong KIR2DL 
binding peptide) and VAP-RA (intermediate weak KIR2DL2-binding peptide that 
may exhibit peptide selectivity) with PBMCs from three KIR2DL3/KIR2DL3+ donors 
and one KIR2DL2/KIR2DL2+ donor (Figure 4.15a).  
 
Linear regression analysis was performed on these peptide titrations to interpolate 
graphs of transformed data to obtain values for the concentration of peptide required o 
reach 50% inhibition for VAP-FA and VAP-RA for the four donors (Figure 4.15b; 
Table 4.3). For all weaker binding peptides, the peptide concentration required to 
reach 50% inhibition by CD158b+ NK cells was significantly higher than for VAP-FA 
(p<0.05), supporting earlier data that weaker peptides require quantitatively more 
HLA-C: peptide interactions than HLA-C: VAP-FA to mediate the same level of 
inhibition. However, no significant differences were observed between KIR2DL2/L2 
and KIR2DL3/L3 donors (p>0.05; one way ANOVA). These data suggest that 
CD158b+ NK cells from KIR2DL2 and KIR2DL3 homozygote donors do not require 
quantitatively different numbers of HLA-C: peptide interactions to mediate inhibition. 
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Figure 4.15 KIR2DL2+ NK cells do not require a quantitatively different number 
of HLA-C: peptide interactions for CD158b+- mediated inhibition 
a CD107a assays were performed using PBMCs from KIR2DL2 (n=1) and KIR2DL3 (n=3) 
homozygous donors as effector cells and T2 cells loaded with different concentrations of 
VAP-FA and VAP-RA as target cells. Data shown are means of triplicates with Mean +/- 
SEM shown. b. Linear regression analysis for the 4 donors is shown to determine peptide 
concentration required to reach 50% inhibition for each peptide. 
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KIR type HLA-C type VAP-FA concentration 
required to reach 50% 
inhibition (M) 
VAP-RA concentration 
required to reach 50% 
inhibition (M) 
2DL3/L3 Donor 1 C1/C1 2.79x10-7 9.2x10-6 
2DL3/L3 Donor 2 C1/C2 2.08x10-7 2.1x10-5  
2DL3/L3 Donor 3 ? 3.12x10-7 8.1x10-6  
2DL2/L2 Donor 1 C2/C2 2.86x10-7 1.2x10-5  
 
Table 4.4 Peptide concentration required to reach 50% NK cell inhibition does 
not differ between KIR2DL2/L2 and KIR2DL3/L3 donors 
Linear regression analysis of transformed data was performed to determine the peptide 
concentrations of VAP-FA and VAP-RA required to mediate 50% inhibition by the 
KIR2DL2/L2+ (n=1) KIR2DL3/L3+ (n=3) NK cells. Statistical analysis showed that 
transformed slopes of VAP-RA were significantly different from that of VAP-FA (p<0.05; 
ANCOVA). No significant differences were observed between KIR2DL3/L3 and 
KIR2DL2/L2 donors (one way ANOVA; p>0.05). 
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4.4 Validation of peptide experiments 
 
The experiments described above were performed using PBMCs from healthy donors. 
NK cells from individual donors are a highly heterogenous population. To rule out the 
possibility of interactions between other NK cell receptors and ligands on target cells, 
we wanted to set up a different assay using KIR- NKL cell lines, which had previously 
been transfected with either KIR2DL2 or KIR2DL3 (NKL-KIR2DL2 and NKL-
KIR2DL3 respectively). The ability of NKL-KIR2DL3 cells to respond to T2 cells in 
the absence of peptide were tested in a sandwich IFN-γ ELISA, Lactate 
Dehydrogenase Assay, CD107a assay, and Chromium release assay. NKL-KIR2DL3 
did not produce IFN-γ, did not degranulate in response to T2 target cells and no 
specific LDH activity could be detected. As T2 cells need to be incubated at 26°C for 
stable peptide: MHC complexes, NKL, NKL-KIR2DL2 and NKL-KIR2DL3 were 
assessed for their ability to kill T2 target cells at 26°C and 37°C by a Chromium 
release assay. T2 cells were labelled with 51Cr and incubated with NKL cells 
(untransfected, or expressing KIR2DL2 or KIR2DL3) for 5 hours at 26°C and 37°C. 
All tested NKL cells were able to kill T2 target cells in the absence of peptide at 
37°C, but not 26°C (Figure 4.16). Therefore, we were not able to validate the peptide 
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Figure 4.16 Chromium release assay using NKL, NKL-KIR2DL2 and NKL-
KIR2DL3 effector cells and T2 target cells at 26°C and 37°C 
51-Cr Cytotoxicity assays were performed using NKL, NKL-L2 or NKL-L3 cells stimulated 
with T2 target cells for 5hrs at 37°C or 26°C at different E:T ratios. The release of 51-Cr was 
detected in harvested supernatants. Samples were repeated in triplicate and mean +/- SEM is 
shown. 
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4.5 Discussion 
 
A panel of seven peptides differing in the residues that contact KIR2DL2 and 
KIR2DL3 (residues 7 and 8; Boyington et al, 2000), were assessed for their ability to 
promote binding of HLA-C1 to KIR-Ig fusion proteins, and inhibit CD158b+ NK cells 
in CD107a assays. We observed a peptide hierarchy of strong, intermediate or weak 
recognition of HLA-C1 by KIR-Ig in binding assays, and this peptide hierarchy was 
reproduced in functional assays.  
 
The KIR-Ig binding assays inversely correlated with CD107a assays. HLA-Cw*0102 
loaded with VAP-FA peptide promoted strong recognition of HLA-C1 by KIR2DL2-
Ig and KIR2DL3-Ig, and mediated strong inhibition of CD158b+ NK cells. Inhibition 
of CD158b+ NK cells was specific for the interaction of CD158b with HLA-
Cw*0102: peptide as addition of exogenous peptide did not inhibit CD158b- NK cells, 
and did not upregulate HLA-A*0201, which possesses a similar peptide-binding motif 
to HLA-Cw*0102. Increased frequency of degranulating CD158b+ NK cells was 
observed with peptides that promoted intermediate binding of KIR2DL2-Ig and 
KIR2DL3-Ig to HLA-C1 (VAP-RA, VAP-WS and VAP-YS), compared to peptides 
that promoted stronger recognition of HLA-Cw*0102. HLA-Cw*0102 loaded with 
VAP-DA peptide resulted in weak or no recognition by either KIR-Ig and did not 
inhibit CD158b+ NK cells. The ½ max values calculated for binding of KIR-Ig to 
different HLA-C: peptide complexes correlated with peptide concentrations required 
for 50% inhibition of CD158b+ NK cells. Peptides that promoted weaker interaction 
of KIR-Ig to HLA-C had higher ½ max values and required more peptide to inhibit 
50% of CD158b+ NK cells than peptides which promoted stronger KIR binding to 
HLA-C and inhibition of CD158b+ NK cells. 
 
The crystal structure of KIR2DL2 bound to HLA-Cw*0304: GAVDPLLAL peptide 
showed that a hydrophobic residue 7 allowed for contact with KIR through 
hydrophobic interactions with Leu 104 and Tyr 105 of KIR2DL2 (Boyington et al, 
2000). For the panel of peptides tested, VAP-FA which has the hydrophobic residue 
phenylalanine at position 7 promoted the strongest binding of KIR to HLA-Cw*0102, 
whilst the VAP-DA peptide with an aspartic acid at residue 7 resulted in very weak 
interaction of KIR-Ig with HLA-C1.  
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KIR2DL2-Ig bound with intermediate avidity to HLA-Cw*0102 presenting the 
peptides VAP-RA, VAP-WS or VAP-YS, indicated by both binding curves and ½ 
max values. Binding of KIR2DL3-Ig to HLA-Cw*0102 presenting these three 
peptides was only observed at high concentrations of KIR2DL3-Ig, and high ½ max 
values were obtained indicating weak recognition of HLA-Cw*0102 by KIR2DL3-Ig. 
These results can be explained in two ways. Firstly, as KIR2DL2-Ig binds more 
avidly to HLA-C1 than KIR2DL3-Ig for all peptides, the binding assay may not be 
sensitive enough to detect weak but clear binding of HLA-Cw*0102 to KIR2DL3 
mediated by these peptides. An alternative explanation would be to propose that 
KIR2DL2 and KIR2DL3 exhibit different peptide specificities for binding to HLA-
C1. VAP-RA, VAP-WS or VAP-YS presented by HLA-Cw*0102 may be recognised 
by KIR2DL2 but not KIR2DL3. NK cells from individuals homozygous for 
KIR2DL3 encountering such HLA-C: peptide complexes would not be inhibited, 
however recognition of these complexes by NK cells from KIR2DL2 homozygote 
donors would inhibit NK cells. Incorporation of saturating concentrations of VAP-
RA, VAP-WS or VAP-YS in CD107a assays however did not reveal differences in 
peptide specificities between the two receptors, as CD158b+ NK cells from KIR2DL2 
or KIR2DL3 homozygote donors were inhibited by HLA-C: peptide by equivalent 
amounts.  
 
To validate the results of CD107a assays and KIR-Ig binding assays, we tried to set 
up functional assays using KIR- NKL cells transfected with single KIR receptors; 
NKL-KIR2DL2 and NKL-KIR2DL3. Using this cell line in functional experiments 
would be advantageous as the possibility of interactions between other NK cell 
receptors and ligands could be ruled out. Although we were not able to validate our 
results, the CD107a assay has been previously validated for NK cells and correlates 
with both a loss of perforin and target cell death (Alter et al, 2004).  
 
For all peptides, KIR2DL2-Ig bound more avidly to HLA-C1 than KIR2DL3-Ig. 
However, no functional differences between KIR2DL2 and KIR2DL3 homozygote 
donors could be attributed to differences in avidity observed between the two 
receptors. A recent study by Almeida and Davis (2006) found a strong correlation 
between the level of expression of HLA-C2 alleles on target cells and inhibition by 
KIR2DL1-expressing NK cells with a sharp threshold in the number of HLA-C 
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complexes required to mediate inhibition. We investigated whether CD158b+ NK 
cells from KIR2DL2 and KIR2DL3 homozygote donors require a different number of 
HLA-C: peptide complexes to achieve 50% inhibition i.e. have a different threshold 
for inhibition. Linear regression analysis showed that CD158b+ NK cells from 
KIR2DL2 homozygote donors did not require quantitatively less HLA-C1: peptide 
interactions to achieve 50% inhibition than CD158b+ NK cells from KIR2DL3 
homozygote donors. Stabilisation of HLA-Cw*0102 was detected by an HLA-
Cw*0102-specific antibody, therefore the number of HLA-C1: peptide complexes 
was not quantified accurately. More accurate quantification of HLA-C: peptide 
complexes may reveal whether KIR2DL2+ and KIR2DL3+ NK cells have different 
threshold for inhibition. Future studies would use a similar method described by 
Almeida and Davis (2006) to quantify HLA-C: peptide, where GFP-tagged MHC 
molecules were transfected into MHC class I-negative cell lines, and cells expressing 
different amounts of GFP were selected by flow cytometry. The brightness of GFP 
fluorescence would correlate with the level of cell surface MHC class I expression.  
 
Important directions for future studies would be to obtain direct affinity 
measurements of the interactions of KIR2DL2 and KIR2DL3 with different HLA-C: 
peptide complexes. An understanding of how peptides can affect interactions between 
these two receptors and their ligands may provide insight into NK cell calibration and 
lead to a greater understanding of how pathogens can modulate NK cell function.  
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Chapter 5. The effect of changing the peptide repertoire on NK cell activation 
 
KIR recognition is both dependent and influenced by the peptide bound to MHC class 
I, and functional studies have shown that lysis of target cells by NK clones exhibit 
peptide selectivity (Correa and Raulet, 1995; Peruzzi et al, 1996; Rajagopolan and 
Long, 1997; Zappacosta et al, 1997). In Chapter 4, we showed that peptides differing 
in residues 7 and 8 only resulted in differential recognition of HLA-Cw*0102 by 
KIR2DL2-Ig and KIR2DL3-Ig. A peptide hierarchy was established for KIR-Ig 
binding which inversely correlated with CD107a assays. Peptides that promoted 
strong recognition of HLA-Cw*0102 by KIR-Ig resulted in strong inhibition of 
CD158b+ NK cells, whilst peptides that resulted in weak or no recognition of HLA-
Cw*0102 by KIR-Ig did not inhibit CD158b+ NK cells. The peptide selectivity 
observed for KIR interactions with HLA may be relevant as they may influence NK 
cell recognition of infected cells. 
 
Several viruses express genes that downregulate expression of class I MHC proteins 
This provides them with a means of escaping attack from cytotoxic T lymphocytes 
(CTLs), however renders them susceptible to attack by NK-mediated lysis. The 
almost ubiquitous expression of MHC class I provides one means by which NK cells 
are able to discriminate between target cells that have lost or downregulated MHC 
class I, and is known as the “missing-self” hypothesis (Kärre et al, 1986). Thus cells 
that have lost self MHC class I become susceptible to NK-mediated lysis. Conversely, 
an induction of self MHC class I molecules on such a target cell should be sufficient 
to prevent rejection mediated by NK cells (Storkus et al, 1989). Although it seems 
unlikely that peptides provided by viruses are predominantly of a type that prevent 
recognition of MHC class I molecules, a study by Liberatore et al (1999) showed that 
transfection of a cell line with a plasmid vector containing the neo antibiotic-
resistance gene resulted in susceptibility to NK lysis, conferred by the neo gene, 
which was restricted to NK cells expressing KIR3DL1. Analysis of neo protein 
peptides identified several nonamer sequences that could bind to the HLA-Bw4 allele, 
HLA-B27, but interfered with KIR3DL1-mediated recognition of HLA-B27, making 
these cells susceptible to NK cell lysis by KIR3DL1+ NK cells. 
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Viral infection may therefore change the repertoire of peptides bound to MHC class I 
molecules such that they are no longer recognised by inhibitory receptors present on 
NK cells, resulting in lysis of the infected target cell. Indeed, a study by Hickman et al 
(2003) showed that HIV infection altered the presentation of host-encoded self 
peptides. Mass spectrometric mapping of peptides from uninfected and HIV-infected 
cells were compared and 15 host-derived peptides uniquely presented on HIV-
infected cells were identified.  As all functional inhibitory KIR receptors have been 
shown to be peptide selective (Correa and Raulet, 1995; Peruzzi et al, 1996; 
Rajagopolan and Long, 1997; Zappacosta et al, 1997), alterations in presentation of 
either viral proteins, or in host protein presentation on MHC class I molecules may 
render an infected cell susceptible to NK cell lysis. This may be of great importance 
and asks the question whether healthy HLA molecules present a proportion of 
peptides that are permissive for binding, and that changes in peptide repertoire may 
trigger NK cell activation. 
 
Using the peptide hierarchy defined in Chapter 4, we generated in vitro peptide 
repertoires containing peptides that mediate strong and weak recognition of HLA-
Cw*0102 by KIR, to look at the effect of changing the peptide repertoire on NK cell 
activation. Furthermore, we imaged KIR aggregation at the NK cell inhibitory 
immune synapse to determine whether the presence of a peptide mediating weak 
recognition of HLA-Cw*0102 by KIR could disrupt formation of the inhibitory 
immune synapse by a peptide that promotes strong recognition of HLA-Cw*0102 by 
KIR. 
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5. Results 
 
5.1 Changes in peptide repertoire release CD158b+ NK cells from inhibition 
 
To investigate how alterations in peptide repertoire can affect NK cell activation, in 
vitro peptide repertoires were generated containing peptides that were shown to 
mediate strong and weak recognition of HLA-Cw*0102 by KIR2DL2-Ig and 
KIR2DL3-Ig; VAP-FA and VAP-DA respectively. HLA-Cw*0102 was stabilised to a 
maximum level on T2 cells by loading VAP-FA and VAP-DA to a final peptide 
concentration of 10µM (10-5M) peptide. Different ratios of strong: weak KIR-binding 
peptides were used such that HLA-Cw*0102 levels remained constant throughout the 
experiments (Figure 5.1a) but the concentration of VAP-FA or VAP-DA was altered 
by 10% increments each time. HLA-Cw*0102 expression was maximal at 10µM 
peptide as detected by the HLA-Cw*0102-specific antibody VP6G3 (Figure 5.1b). 
T2 cells loaded with either VAP-FA or VAP-DA stabilised HLA-Cw*0102 to 
approximately equivalent amounts, although VAP-DA stabilisation of HLA-Cw*0102 
was slightly greater than VAP-FA. This may reflect increased HLA stabilisation by 
VAP-DA, although VAP-FA and VAP-DA do not differ in anchor residues required 
for binding to HLA-Cw*0102 (residues 2 and 9). It is possible that despite similar 
stabilisation VP6G3 recognises HLA-Cw*0102: VAP-DA more strongly than HLA-
Cw*0102: VAP-FA. HLA-Cw*0102 stabilisation with different ratios of VAP-DA 
and VAP-FA at a final peptide concentration of 10µM was not significantly altered at 
the different ratios (Figure 5.1b). 
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Figure 5.1 HLA-Cw*0102 stabilisation following overnight incubation with 
exogenous peptide at 26°C 
a. Histogram plots showing HLA-Cw*0102 stabilisation detect by VP6G3 antibody following 
overnight incubation of T2 cells with 10µM VAP-DA or 10µM VAP-FA alone, or with 5µM 
VAP-FA + 5µM VAP-DA together. b. Left-hand panel - Maximum stabilisation of HLA-
Cw*0102 is detected following incubation with 10-5M VAP-FA or VAP-DA peptide. Right-
hand panel – Stabilisation of HLA-Cw*0102 is not significantly altered at the different ratios 
of VAP-FA and VAP-DA loaded together onto T2 cells. HLA-Cw*0102 stabilisation was 
determined for each experiment.  
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To observe the effect of changing the peptide repertoire on NK cell activation, T2 
cells loaded with different ratios of VAP-FA and VAP-DA were used as target cells in 
CD107a assays. CD107a expression was detected on CD3-CD56+ CD158b+ NK cells. 
The frequency of degranulating CD158b+ NK cells were normalised to the percentage 
of CD158b+ NK cells degranulating in response to T2 cells loaded with 10µM VAP-
DA, as similar frequencies of degranulating CD158b+ NK cells are observed in 
response to these target cells and T2 cells in the absence of peptide (Figure 5.2a). For 
T2 cells loaded with 10µM VAP-FA alone, strong inhibition of CD158b+ NK cells 
was observed. In peptide titration experiments for VAP-FA alone, as the VAP-FA 
concentration loaded onto T2 cells decreases, less HLA-Cw*0102: VAP-FA are 
expressed on T2 cells, and the frequency of degranulating CD158b+ NK cells 
increases (Figure 5.2b). Here, CD158b+ NK cells are responding to MHC class I 
downregulation on T2 cells. Linear regression analysis of transformed data was 
performed for VAP-FA titrations, and for the donor shown in Figure 5.2, the VAP-
FA concentration required to reach 50% inhibition of CD158b+ NK cells was 
3.87x10-7M. 
 
For peptide mix experiments, T2 cells were loaded with different ratios of VAP-FA 
and VAP-DA together. There was a higher frequency of activated CD158b+ NK cells 
in response to T2 cells loaded with VAP-FA in the presence of VAP-DA compared 
with in the absence of VAP-DA (Figure 5.2). At 5µM VAP-FA alone, strong 
inhibition of CD158b+ NK cells is observed, with approximately 30% of CD158b+ 
NK cells expressing CD107a (data normalised to VAP-DA). At the same 
concentration of VAP-FA in the presence of 5µM VAP-DA, the frequency of 
degranulating NK cells increases to approximately 70%. Performing linear regression 
analysis of transformed data, the VAP-FA peptide concentration required to reach 
50% inhibition of CD158b+ NK cells in the presence of VAP-DA was 7.6x10-6M, as 
opposed to 3.87x10-7M for VAP-FA in the absence of VAP-DA. Therefore VAP-DA 
seems to perturb inhibition by CD158b+ NK cells by VAP-FA; at concentrations of 
VAP-FA where we would expect to see inhibition by CD158b+ NK cells, the presence 
of VAP-DA results in NK cell activation. This loss of inhibition in the presence of 
VAP-DA occurred at more than one log higher concentration of VAP-FA than in the 
absence of VAP-DA. The difference between the slopes for peptide titrations and 
peptide mix experiments were significantly different (p<0.001; ANCOVA). 
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Figure 5.2 The effect of VAP-DA on VAP-FA-mediated inhibition of CD158b+ 
NK cells  
T2 cells loaded with increasing concentrations of VAP-FA alone, VAP-DA alone, or with 
different ratios of VAP-FA and VAP-DA to a maximum concentration of 10µM peptide were 
used as target cells in CD107a assays, using PBMCs from one KIR2DL2/L3 heterozygote 
donor. a. Histogram plots showing the frequency of CD158b+ CD107a+ NK cells in response 
to T2 cells loaded with indicated peptides. b. VAP-FA peptide titration and VAP-FA/VAP-
DA peptide mix experiments are shown. Data shown are means of triplicates with Mean +/- 
SEM shown. 
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The peptide repertoire expressed by MHC class I+ cells will be composed of peptides 
that mediate strong, intermediate or weak recognition of KIR to MHC class I 
molecules. The majority of HLA-Cw*0102-binding peptides screened in Figure 4.1 
were not recognised by KIR2DL2-Ig or KIR2DL3-Ig. To look at the effect of having 
strong, intermediate and weak KIR-binding peptides presented by MHC class I on 
CD158b+ NK cell degranulation, simulated peptide repertoires were investigated. T2 
cells loaded with the intermediate KIR-binding peptide VAP-RA with the weak KIR-
binding VAP-DA were used as target cells in peptide mix experiments (Figure 5.4). 
The effect of strong and intermediate KIR-binding peptides presented by MHC class I 
molecules on target cells was examined in peptide mix experiments using T2 cells 
loaded with VAP-FA and VAP-RA together (Figure 5.5). For all peptide mix 
experiments, the HLA-C stabilisation was determined for peptides loaded onto T2 
cells alone, or together (Figure 5.3) 
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Figure 5.3 HLA-Cw*0102 stabilisation for Peptide Titration and Peptide mix 
experiments.  
HLA-Cw*0102 stabilisation was detected by the HLA-Cw*0102-specific antibody VP6G3 
for T2 cells loaded with a. VAP-DA and VAP-RA, alone or together and b. VAP-FA and 
VAP-RA, alone or together. 
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T2 cells loaded with VAP-RA in the presence of VAP-DA resulted in increased 
frequency of CD158b+ NK cells than in the absence of VAP-DA (Figure 5.4). The 
increased activation of CD158b+ NK cells in the presence of VAP-DA is less 
pronounced for VAP-RA than for VAP-FA, as the frequency CD158b+ NK cells in 
response to T2 cells loaded with VAP-RA alone at 10µM peptide is higher than for 
T2 cells loaded with VAP-FA alone at the same peptide concentration. However, the 
presence of VAP-DA perturbs inhibition of CD158b+ NK cells by VAP-RA, and the 
slopes of the curves are significantly different (p<0.005; ANCOVA). The presence of 
the weak KIR-binding peptide VAP-DA can therefore perturb the inhibition of 
CD158b+ NK cells by strong and intermediate KIR-binding peptides. 
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Figure 5.4 The effect of VAP-DA on VAP-RA-mediated inhibition of CD158b+ 
NK cells  
CD107a assays were performed using T2 cells loaded with VAP-RA, VAP-DA or VAP-RA 
and VAP-DA together using PBMCs from one KIR2DL2/L3 heterozygote donor. a. 
Histogram plots showing the frequency of CD158b+ CD107a+ NK cells in response to T2 
cells loaded with indicated peptides. b. VAP-RA peptide titration and VAP-RA/VAP-DA 
peptide mix experiments are shown. Data shown are means of triplicates with Mean +/- SEM 
shown. 
10 -10 10 -9 10 -8 10 -7 10 -6 10 -5 10 -4
0
25
50
75
100
VAP-RA
VAP-RA/VAP-DA mix
VAP-RA concentration (M)
%
 
C
D
15
8b
+
 
C
D
10
7a
+
 
N
K
 
ce
ll
s 
(%
VA
P-
D
A)
R5
100 101 102 103 104
PE Log Comp
0
8
17
26
35
C
o
u
nts R6
100 101 102 103 104
PE Log Comp
0
8
17
26
35
C
o
u
nts
10µM VAP-DA 5µM VAP-RA
30.05% 19.12%
R7
100 101 102 103 104
PE Log Comp
0
8
17
26
35
C
o
u
nts
5µM VAP-RA + 5µmVAP-DA
30.01%
CD107a-PE
C
o
u
nts
C
o
u
nts
C
o
u
nts
C
o
u
nts
 163 
Simulated peptide repertoires incorporating strong and intermediate KIR-binding 
peptides were investigated. T2 cells loaded with VAP-FA and VAP-RA were used as 
target cells in CD107a assays to determine the effect on CD158b-mediated inhibition 
(Figure 5.5). T2 cells loaded with VAP-FA or VAP-RA differentially inhibit 
CD158b+ NK cells, with a higher frequency of degranulating NK cells is observed 
when T2 cells are loaded with VAP-RA alone (Figure 5.5).  
 
T2 cells loaded with VAP-FA in the presence of VAP-RA resulted in increased 
frequency of CD158b+ NK cells than in the absence of VAP-RA (Figure 5.5). 
However compared to peptide mix experiments with VAP-DA, activation of 
CD158b+ NK cells was not as readily observed. In response to T2 cells loaded with 
5µM VAP-FA alone, approximately 30% of CD158b+ NK cells expressed CD107a, 
whilst for T2 cells loaded with 5µM VAP-RA, approximately 65% of CD158b+ NK 
cells expressed CD107a. For T2 cells loaded with 5µM VAP-FA and 5µM VAP-RA 
together, approximately 40% of CD158b+ NK cells expressed CD107a. Although an 
increased frequency of degranulating CD158b+ NK cells was observed for VAP-FA 
in the presence of VAP-RA, changing the peptide repertoire so that 80% of HLA-
Cw*0102 was presenting VAP-RA resulted in activation of 50% of CD158b+ NK 
cells. However, for peptide mix experiments incorporating VAP-FA and VAP-DA, 
changing the peptide repertoire so that only 30% of HLA-Cw*0102 was presenting 
VAP-DA resulted in activation of 50% of CD158b+ NK cells. Therefore, a large 
change in peptide repertoire is required to perturb inhibition of strong KIR-binding 
peptide in the presence of an intermediate KIR-binding peptide, whilst target cells 
expressing strong and weak KIR-binding peptides require only a small amount of 
weak KIR-binding peptide to perturb inhibition mediated by a strong KIR-binding 
peptide. 
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Figure 5.5 The effect of VAP-RA on VAP-FA-mediated inhibition of CD158b+ 
NK cells  
CD107a assays were performed using T2 cells loaded with VAP-RA, VAP-FA or VAP-RA 
and VAP-FA together using PBMCs from one KIR2DL2/L3 heterozygote donor. a. 
Histogram plots showing the frequency of CD158b+ CD107a+ NK cells in response to T2 
cells loaded with indicated peptides. b. VAP-RA and VAP-FA peptide titrations and VAP-
RA/VAP-FA peptide mix experiments are shown. Data shown are means of triplicates with 
Mean +/- SEM shown. 
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To investigate whether this unexpected activation of NK cells mediated by VAP-DA 
in the presence of VAP-FA could be observed in the presence of a second weak KIR-
binding peptide, in vitro peptide repertoires were generated incorporating VAP-FA 
and the weak KIR-binding peptide VAP-DY. The VAP-DY peptide was selected from 
the original peptide screen shown in Figure 4.1 where weak or no recognition of 
HLA-Cw*0102 by KIR2DL2-Ig or KIR2DL3-Ig in the presence of this peptide was 
observed (Figure 5.6a) despite stabilisation of HLA-Cw*0102 comparable to all 
other peptides tested (Figure 5.6b). Although HLA-Cw*0102 stabilisation was 
slightly greater for VAP-DA than VAP-FA (Figure 5.1), this was not observed for 
VAP-DY. In CD107a assays, CD158b+ NK cells were not inhibited by T2 cells 
loaded with VAP-DY, and a comparable frequency of degranulating CD158b+ NK 
cells were observed for T2 cells loaded with VAP-DA, VAP-DY or in the absence of 
peptide (Figure 5.6c). 
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Figure 5.6 VAP-DY binding to KIR, stabilisation of HLA-C and inhibition of 
CD158b+ NK cells 
a. T2 cells in the absence of peptide or incubated in the presence of 10-5M VAP-DY or 10-5M 
VAP-FA were stained with 60µg/ml KIRDS4-Ig (cIg; black fill), KIR2DL2-Ig (block line), or 
KIR2DL3-Ig (dashed line) fusion proteins conjugated to Protein A-Alexa 488. b. HLA-
Cw*0102 stabilisation was detected for T2 cells loaded with indicated peptide with VP6G3 
antibody. c. CD107a assays were performed incorporating T2 cells loaded in the absence of 
peptide, with 10-5M VAP-DA, 10-5M VAP-DY, or 10-5M VAP-FA, and the frequency of 
degranulating NK cells is observed for CD158b+ NK cells. Data shown are means of 
triplicates with Means +/- SEM shown. 
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CD158b+ NK cells inhibition of T2 cells loaded with VAP-FA was perturbed in the 
presence of the weak KIR-binding peptide VAP-DY (Figure 5.7). An increased 
frequency of CD158b+ NK cells was observed in response to T2 cells loaded with 
VAP-FA in the presence of VAP-DY than in the absence of VAP-DY. At 5µM VAP-
FA alone, strong inhibition of CD158b+ NK cells is observed, with approximately 
30% of CD158b+ NK cells expressing CD107a. At the same concentration of VAP-
FA in the presence of 5µM VAP-DY, the frequency of degranulating NK cells 
increases to approximately 70%. The difference between the slopes for VAP-FA in 
the absence or presence of VAP-DY were significantly different (p<0.001; 
ANCOVA).  
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Figure 5.7 The effect of VAP-DY on VAP-FA-mediated inhibition of CD158b+ 
NK cells  
T2 cells loaded with increasing concentrations of VAP-FA alone, VAP-DA alone, VAP-DY 
alone, or with different ratios of VAP-FA and VAP-DY to a maximum concentration of 
10µM peptide were used as target cells in CD107a assays, using PBMCs from one 
KIR2DL2/L3 heterozygote donor. a. Histogram plots showing the frequency of CD158b+ 
CD107a+ NK cells in response to T2 cells loaded with indicated peptides. b. VAP-FA peptide 
titration and VAP-FA/VAP-DY peptide mix experiments are shown. Data shown are means 
of triplicates with Mean +/- SEM shown. 
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The anti-CD158b antibody recognises the inhibitory receptors KIR2DL2 and 
KIR2DL3, but also recognises the activating receptor KIR2DS2. The peptide mix 
experiments were performed for one KIR2DL2/L3 heterozygous donor. As KIR2DL2 
and KIR2DS2 are in strong linkage disequilibrium, this donor is likely to express the 
activating KIR2DS2 receptor. Binding of KIR2DL2-Ig fusion protein to HLA-C1 has 
not been observed (Winter et al, 1998). However to exclude the possibility that 
activation of CD158b+ NK cells by HLA-Cw*0102: VAP-DA was due to interaction 
with KIR2DS2, CD107a assays were performed with PBMCs from two donors with a 
KIR2DL3+KIR2DL2-KIR2DS2- genotype, and two donors with a KIR2DL3-
KIR2DL2+KIR2DS2+ genotype. T2 cells loaded with different ratios of VAP-FA and 
VAP-DA were used as target cells. Linear regression analysis was performed for each 
donor, and the VAP-FA concentration required to reach 50% inhibition was 
determined for VAP-FA in the presence or absence of VAP-DA (Table 5.1). No 
significant differences were observed between the different donors (one way 
ANOVA; p>0.05), suggesting that expression of KIR2DS2 does not contribute to the 
observed results, but that the presence of VAP-DA perturbs KIR2DL2/L3+ NK cell-
mediated inhibitory signals through interaction with HLA-Cw*0102:VAP-FA. 
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 KIR type 
VAP-FA 
concentration 
required to reach 
50% inhibition (M) – 
VAP-FA alone 
 
VAP-FA concentration 
required to reach 50% 
inhibition (M) – VAP-
FA/VAP-DA mix 
 
Donor 1 KIR2DL3+/L2+/S2+ 3.87x10-7 7.8x10-6 
Donor 2 KIR2DL3+/L2+/S2+ 2.79x10-7 7.2x10-6 
Donor 3 KIR2DL3+/L2-/S2- 3.08x10-7 7.7x10-6 
Donor 4 KIR2DL3+/L2-/S2- 2.96x10-7 7.6x10-6 
 
 
Table 5.1 Results of VAP-FA/VAP-DA peptide mix experiments for four 
different donors 
The VAP-FA concentration required to inhibit 50% of CD158b+ NK cells in the absence and 
presence of the weak KIR-binding peptide VAP-DA was determined for four donors. No 
significant differences were observed between the different donors (one-way ANOVA). 
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All the above peptide mix experiments were performed at a concentration of peptide 
where all available HLA-Cw*0102 was presenting peptide. To determine if the 
observed activation of CD158b+ NK cells in the presence of VAP-FA and VAP-DA 
was due to displacement of VAP-FA by VAP-DA, peptide mix experiments were 
performed at final concentration of 1µM peptide, where free HLA-Cw*0102 is 
available for unbound VAP-FA and VAP-DA to bind. Peptide mix experiments were 
also performed at a final concentration of 10µM peptide where all HLA-Cw*0102 is 
occupied by VAP-FA or VAP-DA (Figure 5.8).  
 
The presence of VAP-DA perturbed the inhibition of CD158b+ NK cells by VAP-FA 
for peptide experiments performed at 1µM and 10µM peptide (Figure 5.8). At a 
50:50 ratio of VAP-FA: VAP-DA at both peptide concentrations, approximately 75-
80% of CD158b+ NK cells were activated (Figure 5.8a). The slopes of the curves 
were not significantly different for the two peptide concentrations (ANCOVA; 
p>0.05) (Figure 5.8b). This data indicates that the activation of CD158b+ NK cells by 
VAP-FA in the presence of VAP-DA is not due to total displacement of VAP-FA by 
VAP-DA, but dependent on the ratio of strong: weak KIR-binding peptides. 
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Figure 5.8 VAP-FA/VAP-DA peptide mix experiments at a final concentration of 
1µM and 10µM peptide 
CD107a assays were performed using PBMCs from one KIR2DL3 homozygous donor. T2 
cells loaded with different ratios of VAP-FA and VAP-DA to a final concentration of 1µM or 
10µM peptide were used as target cells a. Histogram plots showing the frequency of CD158b+ 
CD107a+ NK cells in response to T2 cells loaded with indicated peptides. b. VAP-FA peptide 
titration and VAP-FA/VAP-DA peptide mix experiments are shown, with transformed data in 
the right-hand panel. Data shown are means of triplicates with Mean +/- SEM shown. 
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The peptide mix experiments described above show that the presence of a weak KIR-
binding peptide perturbs the inhibition of CD158b+ NK cells by a strong KIR-binding 
peptide. To determine whether the activation of NK cells mediated by the weak KIR-
binding peptide was due to the generic upregulation of MHC class I which may 
disrupt interaction of KIR with HLA-Cw*0102: VAP-FA through steric hindrance, or 
due to the specific upregulation of HLA-Cw*0102, peptide mix experiments were 
performed for VAP-FA in the presence of VAP-DA or in the presence of an HLA-
A*0201-specific peptide, GILGFVFTL. Overnight incubation of T2 cells with 10-5M 
GILG does not upregulate HLA-Cw*0102, but does upregulate HLA-A*0201 as 
determined by staining with VP6G3 and BB7.2 antibody respectively (Figure 5.9).  
 
 175 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9 Peptide stabilisation of HLA-Cw*0102 and HLA-A*0201 by specific 
peptides 
T2 cells were incubated in the absence (block line) or presence of 10-5M VAP-FA (dashed 
line) or 10-5M GILG (dotted line) overnight before staining with the HLA-Cw*0102-specific 
antibody VP6G3 or the HLA-A*0201-specific antibody BB7.2. Histogram plots and bar 
charts with MFI values are shown.  
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The frequency of degranulating CD158b+ NK cells in response to target cells loaded 
with VAP-FA was increased in the presence of VAP-DA. CD158b+ NK cells were not 
inhibited by T2 cells presenting GILG alone (Figure 5.10a). However, when target 
cells were loaded with VAP-FA in the presence of the GILG, CD158b+ NK cells were 
not activated, but inhibited to the same degree as when T2 cells were loaded with 
VAP-FA alone (Figure 5.10). This data indicates that the activation of CD158b+ NK 
cells seen in the presence of VAP-FA with VAP-DA is due to the specific 
upregulation of HLA-Cw*0102, and not the generic upregulation of MHC class I on 
the cell surface. This suggests that the loss of inhibition when VAP-FA and VAP-DA 
are co-expressed on T2 cells is not due to the inability of HLA-Cw*0102: VAP-FA 
complexes to aggregate at the inhibitory synapse in the presence of generic HLA: 
peptide complexes due to steric hindrance, but due to HLA-Cw*0102: VAP-DA 
specifically disrupting the KIR2DL2/L3-derived inhibitory signals mediated by HLA-
Cw*0102: VAP-FA. This therefore suggests specific interaction of HLA-Cw*0102: 
VAP-DA with KIR2DL2/L3. This interaction is not sufficient to inhibit NK cells, but 
is able to disrupt inhibition in the presence of an inhibitory peptide. In binding assays 
using KIR-Ig fusion proteins, very weak binding of KIR2DL2-Ig and KIR2DL3-Ig to 
HLA-Cw*0102: VAP-DA can be detected, which is consistently higher than binding 
of KIR-Ig to T2 cells in the absence of peptide (Figure 5.11). 
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Figure 5.10 The effect of GILG on VAP-FA-mediated inhibition of CD158b+ NK 
cells  
CD107a assays were performed using PBMCs from one KIR2DL3 homozygous donor. T2 
cells loaded with different ratios of VAP-FA and VAP-DA or VAP-FA and GILG were used 
as target cells a. Histogram plots showing the frequency of CD158b+ CD107a+ NK cells in 
response to T2 cells loaded with indicated peptides. b. VAP-FA peptide titration and VAP-
FA/GILG peptide mix experiments are shown. Data shown are means of triplicates with 
Mean +/- SEM shown. 
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Figure 5.11 Binding of KIR2DL2-Ig and KIR2DL3-Ig to HLA-Cw*0102: VAP-
DA 
T2 cells were incubated with (a) 60µg/ml (b) increasing concentrations of KIR2DS4-Ig (cIg; 
black fill), KIR2DL2-Ig (block line), or KIR2DL3-Ig (dashed line). Bound fusion proteins 
were detected by flow cytometry. Data shown are means of triplicates with Mean +/- SEM 
shown. 
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The peptide concentration required to reach 50% inhibition was determined for the 
peptide mix experiments shown above. The results are shown in Table 5.2 below. 
 
Peptide mix Peptide for which 50% 
inhibition is calculated 
Peptide concentration 
required to reach 50% 
inhibition (M) 
VAP-FA alone VAP-FA 3.87x10-7 
VAP-FA/VAP-DA VAP-FA 7.6x10-6 
VAP-FA/VAP-RA VAP-FA 2x10-6 
VAP-FA/VAP-DY VAP-FA 7.1x10-6 
VAP-FA/GILG VAP-FA 3.76x10-7 
VAP-RA alone VAP-RA 8.4x10-4 
VAP-RA/VAP-DA VAP-RA 1.44x10-4 
 
Table 5.2 Peptide concentration required to reach 50% inhibition by CD158b+ 
NK cells for different peptide mix experiments 
The peptide concentration required to inhibit 50% of CD158b+ NK cells was determined for 
the indicated peptide mix experiments. 
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5.2 The effect of changing the peptide repertoire on formation of the NK cell 
Inhibitory Immune Synapse 
 
As we have shown the need for cognate MHC to perturb inhibition of NK cells by a 
strong KIR-binding peptide, we investigated the effect of VAP-DA on formation of 
the NK cell inhibitory immune synapse in the presence of VAP-FA. Synapse 
formation was imaged for NKL-KIR2DL3 co-incubated with T2 cells loaded with 
VAP-FA alone, or in the presence of VAP-DA or GILG at a 50:50 peptide ratio 
(Figure 5.12a). Quantification of the intensity of KIR2DL3 at the immune synapse 
showed that T2 cells loaded with VAP-DA alone or in the presence of VAP-FA leads 
to KIR accumulation to the same extent as VAP-FA alone (Figure 5.12b),  and the 
percentage of conjugates with KIR aggregation at the point of contact between NKL-
KIR2DL3 and T2 cells were counted (Figure 5.12c). KIR2DL3 aggregation was 
observed in approximately 70-80% of conjugates for T2 cells loaded with 5µM VAP-
DA, 5µM VAP-FA alone or together at a 50:50 peptide ratio. A similar percentage of 
conjugates with KIR2DL3 aggregation at the point of contact between NKL-
KIR2DL3 and T2 cells was observed for T2 cells incubated with VAP-FA in the 
presence of GILG at a 50: 50 peptide ratio, but not in the presence of GILG alone or 
in the absence of peptide. No significant differences between the percentages of 
conjugates forming an inhibitory synapse were observed following overnight 
incubation of T2 cells with VAP-DA, VAP-FA, VAP-FA/VAP-DA or VAP-
FA/GILG.  
 
These data indicated that VAP-DA in the presence or absence of VAP-FA is recruited 
to the immunological synapse through specific interaction with KIR2DL3. This 
interaction is not sufficient to inhibit CD158b+ NK cells, but is able to disrupt 
inhibition by a strong KIR-binding peptide. 
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Figure 5.12 The weak KIR-binding peptide VAP-DA is recruited into the NK cell 
inhibitory synapse  
a. NKL-KIR2DL3 co-incubated with T2 cells loaded with 5µM indicated peptide were 
imaged by confocal microscopy. Images of the bright field image of typical cell conjugates 
are shown in the left hand column; right hand column shows KIR2DL3 distribution. b. Mean 
intensity of KIR2DL3 aggregation was measured for conjugates at the immune synapse and 
compared to mean intensity of KIR2DL3 outside the synapse (background). Data is expressed 
as a fold increase of mean intensity compared to the background, with Mean +/- SEM shown. 
Mean values of fold increase are shown. c. The percentages of conjugates forming an 
inhibitory synapse were counted for T2 cells in the absence or presence of exogenous peptide 
at the different conditions. Between 10 and 20 conjugates were analysed for each condition.  
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5.3 Discussion 
 
CD107a assays were used to determine the effect of changing the peptide repertoire 
on CD158b+ NK cell activation. In vitro peptide repertoires were generated 
incorporating peptides defined in Chapter 4 that mediated strong, intermediate or 
weak binding of KIR-Ig to HLA-C1. We observed that the presence of a weak KIR-
binding peptide could perturb the inhibition of CD158b+ NK cells by a strong KIR-
binding peptide. This loss of inhibition was specific for inhibitory CD158b receptors, 
and occurred at more than one log higher concentration in the presence of a weak 
KIR-binding peptide than in the absence of a weak KIR-binding peptide. This 
indicates that changes in peptide repertoire are significantly more efficient than MHC 
class I downregulation at releasing NK cells from inhibition. Changing the peptide 
repertoire by approximately 25% in this system was able to push NK cells from 
inhibition to activation. Similar activation of CD158b+ NK cells was observed for the 
intermediate KIR-binding peptide VAP-RA in the presence of VAP-DA. For peptide 
mix experiments incorporating strong and intermediate KIR-binding peptides; VAP-
FA and VAP-RA respectively, although NK cells were not as readily activated by 
VAP-FA in the presence of VAP-RA, inhibition of CD158b+ NK cells was perturbed. 
 
It is possible that HLA-C molecules on healthy target cells presenting a range of 
strong, intermediate and weak KIR-binding peptides derived from host proteins may 
bind KIR just above the threshold for NK cell activation. Therefore a small change in 
peptide repertoire that can occur during viral infection may disrupt this inhibition if 
the viral or host-derived peptide that is not usually presented by MHC class I is not 
permissive for binding of KIR to HLA-C. Several studies have shown that NK cells 
are able to preferentially lyse virally-infected cells with unaltered amounts of MHC 
class I expression (Kaufman et al, 1992; Malnati et al, 1993), indicating a role for 
MHC in regulating NK cell-mediated killing of virus-infected cells. Recognition of 
MHC: peptide may be disrupted due to occupancy of MHC class I molecules by viral 
peptides or host-derived peptides that are uniquely expressed on infected cells. Viral 
peptides from coxsackie virus have been shown to abrogate the inhibition of HLA-
Cw7-expressing target cells (Mandelboim et al, 1997), which was suggested to be due 
to replacement of self peptide that are permissive for NK cell inhibition with viral 
peptides. Analysis of peptides eluted from HLA-B*0702 molecules produced in HIV-
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infected or uninfected cells revealed 15 host-derived peptides uniquely presented on 
HIV-infected cells (Hickman et al, 2003). It would be interesting to determine 
whether these upregulated peptides can trigger NK cell activation through weak 
interaction with KIRs. Sequencing of over 200 endogenously-loaded HLA-B*1801 
peptides in an MHC class I-deficient cell line showed that for this cell line, a single 
MHC class I molecule can access proteins from a large portion, if not all, of the 
proteomic content of the cell (Hickman et al,2004). Importantly, this suggests that 
virus or tumour-induced changes in virtually any cellular component is expected to be 
presented by MHC class I for immune recognition.  
 
Peptides that disrupt NK cell-mediated inhibition are not restricted to KIR receptors, 
and has been shown for the CD94/NKG2A inhibitory receptor. CD94/NKG2A is 
expressed on a large proportion of human NK cells, and interacts with the 
nonclassical HLA-E molecule (Brooks et al, 1997). HLA-E displays limited 
polymorphism and its peptide binding groove is occupied by peptides derived from 
the signal sequence of certain HLA-A, -B, -C and –G molecules (Braud et al, 1998). It 
has been demonstrated that HLA-E can bind a diverse array of peptides derived from 
random peptide libraries (Stevens et al, 2001). A study by Michaëlsson et al (2002) 
demonstrated that HLA-E can present a peptide derived from the signal sequence of 
cellular derived heat shock protein 60 (hsp60). Increased hsp60 levels have been 
observed in response to a variety of stress stimuli. HLA-E: hsp60 complexes were not 
efficiently recognised by inhibitory CD94/NKG2A receptor shown by lack of binding 
of HLA-E: hsp60 tetramers to cells expressing CD94/NKG2A, and by NK cell-
mediated lysis of cells expressing HLA-E: hsp60 complexes. The authors proposed 
that the proportion of HLA-E: hsp60 is increased during stress leading to a shift in the 
HLA-E peptide repertoire from NK cell protective to NK cell unprotective complexes. 
It may therefore be a general mechanism for NK cells to detect stressed cells in a 
peptide selective manner. It would be of interest to determine whether the 
simultaneous expression of hsp60 with an HLA-E-inhibitory peptide on target cells 
can abrogate inhibition by an HLA-E: inhibitory peptide of CD94/NKG2A+ NK cells 
as we observed for KIR2DL2 and KIR2DL3.  
 
Peptide mix experiments performed with VAP-FA and an HLA-A2 binding peptide 
did not disrupt inhibition of NK cells, suggesting that activation of CD158b+ NK cells 
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by T2 cells loaded with VAP-DA and VAP-FA is due to the specific upregulation of 
HLA-Cw*0102. We observed KIR2DL3 aggregation at the point of contact with T2 
cells loaded with VAP-DA peptide both in the presence or absence of VAP-FA, 
inferring that VAP-DA does not mediate CD158b+ NK cell activation by interfering 
with formation of the inhibitory immune synapse. This indicates that the presence of a 
weak KIR-binding peptide disrupts inhibition by a strong KIR-binding peptide 
through specific interactions with KIR2DL2 or KIR2DL3. Weak KIR-binding 
peptides seem to be recruited to the point of contact between NK cells and target cells, 
and disrupt the generation of inhibitory signals mediated by strong KIR-binding 
peptides. Using KIR-Ig fusion proteins, VAP-DA mediated very weak recognition of 
HLA-Cw*0102 by KIR2DL2-Ig and KIR2DL3-Ig, and MFI values were consistently 
higher in the presence of VAP-DA than in the absence of peptide. This weak binding  
detected by KIR-Ig fusion proteins is not enough to inhibit CD158b+ NK cells. Direct 
affinity measurements to investigate the interaction of KIR2DL receptors to HLA-C1: 
VAP-DA in a 1:1 stoichiometry using Surface Plasmon Resonance studies may be a 
better method to determine the nature of this interaction. 
 
That a weak KIR-binding peptide can abrogate inhibition of NK cells by a strong 
KIR-binding peptide is similar to the described phenomenon of TCR antagonism for 
T cells. T lymphocytes recognise peptides presented by MHC molecules; peptides that 
elicit full T cell responses including proliferation, cytokine secretion, cytolysis etc. are 
know as fill agonist ligands. Altered peptide ligands (APLs) are variants of wild-type 
TCR-activating (agonist) peptides that produce a range of effects from differential 
cytokine production to null peptides which elicit no T cell activity (Sloan-Lankaster 
and Allen, 1996). Antagonist peptides are a rare subset of APLs that block T cell 
activation to otherwise stimulatory concentrations of agonist ligands (De Magistris et 
al, 1992). TCR antagonists do not act by competing for binding to MHC molecules, 
but at the level of the TCR, and interact with the TCR without inducing activation 
(Lacioppi et al, 1993). TCR antagonism occurs when T cells are simultaneously 
exposed to stimulatory and antagonist ligands. Consistent with their inability to elicit 
T cell functions, antagonist peptides fail to induce full TCR-dependent signalling 
(Jameson et al, 1993; Lacciopi et al, 1993; Reis e Sousa, 1996).  
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Although early studies showed that 100- to 1000- fold excess of antagonist peptides 
are required to observe T cell inhibition (Alexander et al, 1993), some “natural” TCR 
antagonist peptides derived from Human Immunodeficiency virus (HIV) and 
Hepatitis B virus (HBV) have been shown to act at 10- or even 100-fold lower 
concentration than the agonist peptide to antagonise T cell responses (Klenerman et 
al, 1994; Bertoletti et al, 1994; Purbhoo et al, 1998). These antagonist peptides 
therefore clearly have physiological relevance and may be an effective immune 
evasion mechanism for these pathogens. The mechanism for T cell antagonism is not 
completely understood, but a kinetic model suggests that decreasing the half-life of an 
agonist peptide creates antagonist peptides that can induce partial signalling and 
inhibit T cell activation (Matsui et al, 1994; Kersh et al, 1998; Wulfing et al, 2002).  
 
The model of TCR antagonism may fit with our observations. Weak KIR-binding 
peptides act similar to antagonist peptides, however do not disrupt activation, but 
disrupt NK cell inhibition by a strong KIR-binding peptide. Further investigation to 
determine the half-life of interactions of HLA-Cw*0102: VAP-DA compared to 
HLA-Cw*0102: VAP-FA is required. Similar to investigations with “natural” HIV 
and HBV antagonist peptides, low concentrations of VAP-DA could antagonise 
CD158b+ NK cell-mediated inhibition by VAP-FA. It may be possible that “natural” 
antagonist peptides may provide a viral escape mechanism to inhibit activation of 
CTL, however weak recognition of MHC: antagonist peptides by NK cell inhibitory 
receptors may activate NK cells.  
 
Antagonist peptides have been shown to be recruited into T cell synapses, but these 
synapses display reduced MHC density compared to null peptides (Sumen et al, 
2004). We did not observe differences between synapse formation when T2 cells were 
presenting HLA-Cw*0102: VAP-FA alone compared with co-presentation of HLA-
Cw*0102: VAP-FA and HLA-Cw*0102: VAP-DA. Further analysis to determine 
whether immune synapses differ in the presence of VAP-DA with VAP-FA, 
compared with VAP-FA alone is required.  Finally, antagonist peptides have been 
shown to induce partial T cell signalling that can inhibit T cell activation (Reis e 
Sousa et al, 1996). Inhibitory KIR receptors possess two consecutive ITIMs in their 
cytoplasmic domain (Lanier, 1998 and Long, 1999). Engagement of inhibitory 
receptors by MHC class I results in rapid clustering and tyrosine phosphorylation of 
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KIR. Future work would be to determine whether the presence of a weak KIR-binding 
peptide can induce partial phosphorylation of ITIMs, to disrupt inhibition mediated by 
a strong KIR-binding peptide. 
 
The peptide repertoire experiments performed presumed that the ratio of peptides 
loaded onto T2 cells was equivalent to the proportion of peptides presented by HLA-
Cw*0102. Although peptide stabilisation of HLA-Cw*0102 was shown to be 
equivalent for all peptides tested, the weak KIR-binding peptide VAP-DA appeared to 
stabilise HLA-Cw*0102 at slightly higher levels than VAP-FA. Although we cannot 
rule out the possibility that VAP-DA has a higher affinity for HLA-Cw*0102 than 
VAP-FA, similar results were obtained when peptides were loaded at concentrations 
that induced stabilisation of HLA-C1 to maximum levels or at lower levels. This 
indicates that the activation of NK cells was not observed due to VAP-DA 
outcompeting VAP-FA for binding to HLA-Cw*0102, but due to the ratio of strong: 
weak KIR-binding peptides. Furthermore, stabilisation of VAP-DY and VAP-FA 
were equivalent with similar CD158b+ NK cell activation observed in the presence of 
VAP-DY. Measuring the kinetics of different peptides for HLA-Cw*0102 binding 
would be a more accurate method to determine if the peptides have different affinities 
for HLA-Cw*0102.  
 
We have attempted to simulate a peptide repertoire, using different ratios of two 
peptides which mediate differential recognition of HLA-Cw*0102 by KIR. However, 
healthy cells will present a diverse range of strong, intermediate and weak KIR-
binding peptides on MHC class I molecules, and are protected from NK cell lysis. It 
would be interesting to investigate the changes in peptide presentation during viral 
infection that induce susceptibility to NK lysis by specific NK cell subsets, without 
downregulation of MHC class I. Characterising differences in peptide presentation 
between infected and uninfected cells may define NK cell “antagonist” peptides that 
can activate NK cells. 
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Chapter 6. Discussion 
 
Natural Killer cells play pivotal roles in immune defence against invading viruses and 
cellular transformation leading to cancer, and are important regulators of immune 
responses. Their functional role extends beyond killing of infected or transformed 
cells. Interactions with dendritic cells (DCs) (Andoniou et al, 2005), macrophages, 
and fetal trophoblast cells (Loke and King, 2000) are critical for anti-tumour and 
antiviral immunity, and can regulate NK cell activity by influencing cytokine 
production, cytotoxicity and stimulation of T helper-1 (Th1) responses that can shape 
and influence the subsequent adaptive immune response.  
 
NK cells are regulated in part by inhibitory receptors recognising MHC class I 
molecules on normal cells, of which KIR receptors play a major role. The 
consequence of KIR diversity and the contribution of individual KIRs to signalling in 
NK cells and T cells is not completely understood, but their importance has been 
highlighted by several genetic studies that have linked combinations of KIR and HLA 
genes with the outcome of various diseases including viral infections, malignant 
transformation and autoimmune diseases (Khakoo et al, 2004; Martin et al, 2002a; 
Martin et al, 2002b; Carrington et al, 2005; Nelson et al, 2004). This points to the 
functional effect of the genes encoding KIR, and the clinical correlation with the 
presence or absence of KIR/HLA combinations indicates that disease can be modified 
by KIR-ligand interactions rather than by global responsiveness of NK cells or T 
cells. One feature of KIR genes is their lack of conservation among species, and their 
rapid evolution, which cannot be accounted for solely by divergence in MHC class I 
molecules (Vilches and Parham, 2002). As several genetic studies of viral infection 
have revealed an influence of HLA-KIR gene interaction on disease outcome (Martin 
et al, 2002a; Khakoo et al, 2004), KIR gene evolution is likely to be pathogen driven.  
 
Understanding the basis for observed genetic associations in disease is complicated by 
the large repertoire of receptors used by NK cells to sample their environment. KIR 
haplotypes exhibit extensive polymorphism differing in both gene and allelic content 
(Uhrberg et al, 1997; Wilson et al, 2000). Different haplotypes carry different 
numbers of KIR genes. Group A haplotypes have few or no activating KIRs, whilst 
Group B haplotypes have several activating KIRs. The stochastic nature of KIR 
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expression is such that each NK cell carries it own repertoire of KIR receptors, and 
the frequency at which KIR are expressed within the NK cell population as well as the 
intensity with which they are expressed can diverge (Valiante et al, 1997). The 
frequency of expression of a given KIR is likely to be important in determining the 
strength of an NK cell response against viral infection. Evidence for this is suggested 
by the observation that the number of NK cells expressing a given MHC-specific NK 
cell receptor has been shown to affect the degree of graft rejection (Johannson et al, 
2005). 
 
In the case of HCV infection, homozygosity for KIR2DL3 and HLA-C1 is associated 
with resolution of infection (Khakoo et al, 2004, Romero et al, 2008). One hypothesis 
proposed by the authors is that KIR2DL3 binds HLA-C1 with lower affinity than 
KIR2DL1 and KIR2DL2 receptors, therefore reducing NK cell inhibition and 
favouring resolution of infection. Similar to published observations (Winter et al, 
1998; Moesta et al, 2008), we have shown that KIR2DL2 binds to HLA-C1 more 
avidly than KIR2DL3. Homozygosity for both KIR2DL3 and HLA-C1 may not only 
be protective due to absence of the stronger binding KIR2DL2, but also the absence 
of HLA-C2, the ligand for KIR2DL1. Indeed an association between HLA-Cw*04, a 
group 2 HLA-C allotype and a chronic course of hepatitis C infection in a single 
source outbreak has been reported (Fanning et al, 2004). Individuals who are 
heterozygous for KIR2DL2/KIR2DL3 lose the protective effect observed for HCV, 
suggesting a quantitative model for protection against HCV.  
 
Binding and functional studies have observed interaction of KIR2DL2 and KIR2DL3 
with HLA-C2 (Winter et al, 1998; Moesta et al, 2008). Using an in vitro system 
involving NKL cells expressing a single KIR2DL receptor and target cells expressing 
a single MHC class I allotype, strong inhibition of cytotoxicity was observed 
mediated by KIR2DL2 and HLA-C2. However, no inhibition of cytotoxicity could be 
attributed to the interaction of KIR2DL3 with HLA-C2 (Moesta et al, 2008) suggested 
to be due to lower avidity of KIR2DL3 which may be insufficient to reach the 
threshold required to trigger inhibitory signals. This data suggests that the avidity 
difference between KIR2DL2 and KIR2DL3 becomes a difference in specificity, and 
could represent another functional difference between KIR2DL2 and KIR2DL3 
receptors. Interactions between HLA-C2 and KIR2DL2 could have a physiological 
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role in NK cell repertoire development and the NK cell response to infection, 
malignancy and allogeneic cells, and may in part contribute to disease susceptibility 
in HCV infection. 
 
In cytotoxicity assays using NKL cell lines transfected with single KIR2DL, 
KIR2DL2+ NK cells exerted stronger inhibition than KIR2DL3+ NK cells in response 
to HLA-C1-expressing target cells (Winter et al, 1998; Moesta et al, 2008). However, 
in CD107a assays, we observed no functional differences in inhibition between 
KIR2DL2 and KIR2DL3 homozygote donors in response to HLA-C1 allotypes. The 
interplay of other receptor-ligand interactions is likely to play a role in these 
observations, and recent studies have shown that differences in the avidity of 
interactions between NK cell MHC class I-specific inhibitory receptors and MHC 
class I during development can affect functional responsiveness of mature NK cells 
(Brodin et al, 2009). Therefore functional differences between KIR2DL2 and 
KIR2DL3 may not be observable. Complicating the interpretation of the clinical 
correlations is the strong linkage disequilibrium that is characteristic of the KIR locus. 
Associations made with activating receptor genes may be caused by alleles of other 
KIR that are in linkage disequilibrium. KIR2DL2 for example is in strong linkage 
disequilibrium with KIR2DS2, and KIR2DS2 may contribute to susceptibility in HCV 
infection. 
 
Several of the genetic studies have suggested a model where inhibition of NK cells by 
some KIR-HLA interactions is stronger than others. Inhibition by KIR2DL1-HLA-C2 
is strongest, followed by KIR2DL2-HLA-C1 and finally KIR2DL3-HLA-C1 (Khakoo 
et al, 2004; Parham, 2004b; Hiby et al, 2004). Weaker inhibitory signals, and 
therefore stimulation of NK cells may be beneficial and provide better protection 
against viral infection and cellular transformation, but may result in greater 
susceptibility to autoimmunity. Various clinical correlations have pointed to the effect 
of genes encoding activating KIR. Interaction between KIR3DS1 and HLA-Bw4 
alleles with isoleucine at position 80 is associated with delayed progression to AIDS 
in HIV-infected individuals (Martin et al, 2002a). In patients with acute myeloid 
leukemia (AML), lack of HLA ligands in the recipient for donor-inhibitory KIRs can 
contribute to improved clinical outcome (Hsu et al, 2005). KIR2DS1 and KIR2DS2 in 
the absence of HLA-C1 confer susceptibility to psoriatic arthritis (Martin et al, 
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2002b). KIR2DS2 in combination with the ligand for the homologous inhibitory 
receptors (KIR2DL2 and KIR2DL3), HLA-C1 was also found to be associated with 
diabetes (van der Slik, 2003) and vasculitis as a complication of rheumatoid arthritis 
(Yen et al, 2001). 
 
The role of KIR receptors in disease outcome may be due to the expression of a 
particular KIR receptor in combination with its HLA ligand, or may be due to the 
expression of other KIR receptors on a particular KIR haplotype. Differences between 
KIR2DL2 and KIR2DL3 receptors interacting with HLA-C1 may have contrasting 
roles in susceptibility or resolution to antiviral or anti-tumour immunity versus 
autoimmunity. Weaker interaction of KIR2DL3 with HLA-C1 may be beneficial for 
viral infection, with enhanced NK cells activation, as compared to KIR2DL2. 
However, KIR2DL3-HLA-C1 interaction may be associated with enhanced 
susceptibility to autoimmunity, with stronger KIR2DL2-HLA-C1 interactions to 
prevent NK cell activation conferring protection in this setting. KIR2DL2 and 
KIR2DL3 may also exhibit different outcomes with disease as the genes encoding 
KIR2DL2 and KIR2DL3 segregate on different KIR haplotypes. KIR2DL3 is present 
on a Group A haplotype that are devoid of stimulatory KIR, except KIR2DS4. Group 
A haplotypes that lack stimulatory KIR may be associated with susceptibility to 
infection, but protective in autoimmunity. KIR2DL2 however is present on a Group B 
haplotype. Group B haplotypes generally possess more KIR genes than Group A, and 
the gene content is biased towards activating KIR, which may be protective in the 
context of viral infection or tumour transformation, but not in autoimmunity. Indeed 
stimulatory KIR characteristic of Group B haplotypes are associated with 
susceptibility in autoimmunity (Martin et al, 2002b; van der Silk, 2003; Yen et al, 
2001), but protection in viral infection (Martin et al, 2002a). KIR expression is not 
restricted to NK cells, and has been reported on T cells subsets including γδ T cells, 
effector memory CD8+ αβ+ T lymphocytes and CD4+ T cells (Uhrberg et al, 2001; 
Parham, 2004a). Since T-lymphocytes express inhibitory and activating KIR (Philips 
et al, 1995; Namekawa et al, 2000; Yen et al, 2001), antigen-specific immune 
responses could vary among individuals expressing different KIR receptors and 
different KIR receptors may lower or raise the activation threshold of T-lymphocytes, 
inhibiting or promoting adaptive immune responses.   
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The observation that certain antigenic peptides favour or prevent KIR recognition of 
MHC class I raised the possibility that NK cells could discriminate between cells 
presenting self and foreign peptides. Peptide specificity has been observed for all the 
functional inhibitory KIRs; KIR2DL1 (Rajagopalan and Long, 1997), KIR2DL2 and 
KIR2DL3 (Zappacosta et al, 1997), KIR3DL1 (Malnati et al, 1995; Peruzzi et al, 
1996) and KIR3DL2 (Hansasuta et al, 2004), and for one activating KIR; KIR2DS1 
(Stewart et al, 2005). We showed that KIR binding and function was dependent on the 
peptide bound to HLA-C1. Individual peptides differing in residues 7 and 8 only 
affected the avidity of interaction between HLA-C1 and KIR2DL2 or KIR2DL3, and 
activation of NK cells expressing KIR2DL2 and KIR2DL3. Peptide specificity adds 
another complexity to KIR recognition of MHC class I, although there is no peptide-
specific recognition, as KIR receptors can bind to the same MHC class I molecule 
carrying different peptides, and are able interact with different MHC class I 
molecules. KIR receptors that lose recognition of MHC class I molecules presenting 
peptides non-permissive for binding would activate NK cells.  
 
In the context of HCV infection, KIR2DL2 and KIR2DL3 may exhibit differences in 
peptide selectivity. Certain HLA-C1: peptide complexes may be permissive for 
KIR2DL2 binding, preventing KIR2DL2+ NK cell activation, but may be non-
permissive for KIR2DL3 binding, resulting in specific activation of KIR2DL3+ NK 
cells. In binding assays using KIR-Ig fusion proteins, we observed some peptide 
selectivity between KIR2DL2 and KIR2DL3 receptors, however these differences 
were not observed in functional assays. Direct affinity measurements investigating 
whether differences in peptide specificity exist between KIR2DL2 and KIR2DL3 may 
provide insight into a further mechanism for the observed differences in HCV disease 
association studies.  
 
Binding of CD94/NKG2A to HLA-E is also governed by peptide specificity 
(Michaelsson et al, 2002). HLA-E normally binds peptides derived from signal 
sequences of other MHC class I molecules (Braud et al, 1998), and recognition of 
HLA-E by CD94/NKG2A is lost when HLA-E binds a peptide derived from the 
signal sequence of heat shock protein 60 (hsp60) (Michaelsson et al, 2002). These 
data indicate that this “modified self” situation where peptides non-permissive for 
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binding to NK cell receptors could induce the killing of cells undergoing a stress 
response by NK cells that are normally inhibited by MHC class I. 
 
The role of NK cells in detecting cells that have reduced surface expression of MHC 
class I is well characterised (Karre et al, 1986). Downregulation of MHC class I is a 
common consequence of tumour transformation and intracellular infection. Many 
pathogens and tumours have evolved mechanisms that interfere with MHC class I 
expression and antigen presentation to CD8+ T cells and subsequent CTL responses 
(Brodsky et al, 1999; Farrell et al, 1999; Tortorella et al, 2000; Algarra et al, 2000). 
NK cells are also able to detect cells with unaltered amounts of MHC class I 
(Kauffman et al, 1992; Malnati et al, 1993; Liberatore et al, 1999). The concept that 
peptides can be permissive or non-permissive to KIR recognition of MHC class I 
molecules shown in this study and in previous cited experiments (Malnati et al, 1995; 
Zappacosta et al, 1997; Rajagopalan and Long, 1997; Peruzzi et al, 1996; Hansasuta 
et al, 2004; Stewart et al, 2005) indicates that peptides can influence NK cell 
recognition of infected cells. The set of peptides presented by healthy cells may 
contain a proportion of peptides that are permissive for KIR binding that are tuned 
just above the threshold required to inhibit NK cells. MHC class I molecules could 
gradually change its peptide repertoire from NK cell protective to non-protective 
complexes during infection and inflammatory responses, and this mechanism may be 
important to decrease the threshold of NK cell activation. 
 
Sequence analysis of the native peptide repertoire presented by a single MHC class I 
molecule revealed that peptides from a large portion, if not all, or the proteomic 
content of the cells were represented on the cell surface (Hickman et al, 2004). Virus- 
or tumour-induced protein changes in any cellular component would therefore be 
expected to be presented by MHC class I.  HIV infection has been shown to alter the 
peptide repertoire of presented peptides with unique presentation of 15 host-derived 
peptides on HIV-infected cells (Hickman et al, 2003). We showed that the presence of 
a weak KIR2DL2- or KIR2DL3-binding peptide can disrupt the inhibition of 
CD158b+ NK cells mediated by a strong KIR2DL2- or KIR2DL3-binding peptide, 
and NK cell activation was observed in the presence of few KIR-non-protective 
complexes relative to KIR-protective complexes. This data indicates that alteration in 
virus-derived or host-derived peptides presented by MHC class I molecules during 
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infection can trigger NK cell activation in a KIR-dependent manner if the presented 
peptides are non-permissive for KIR binding, in the absence of MHC class I 
downregulation.   
 
Interestingly, we observed that the weak KIR-binding peptide did not interfere with 
formation of the inhibitory immune synapse in the presence of a strong KIR-binding 
peptide. This indicates specific interaction between KIR and non-protective MHC 
class I: peptide complexes, which aggregate at the point of contact between NK cells 
and target cells, where they disrupt inhibition by KIR-protective MHC class I 
complexes that aggregate at the same contact site. These observations have 
similarities with TCR antagonism where T cell activation by peptides that alone elicit 
full T cell responses is disrupted by the simultaneous presentation of antagonist 
peptides that interact with the TCR without inducing activation. Antagonist peptides 
are predicted to interact with the TCR more weakly and with faster kinetics than 
agonist peptides that elicit full T cell activation. Natural T cell antagonist peptides 
have been described for HBV and HCV that act at 10- to 100-fold lower concentration 
than agonist peptide to antagonise T cell responses (Klenerman et al, 1994; Bertoletti 
et al, 1994; Purbhoo et al, 1998). As these weak KIR-binding peptides promote NK 
cell activation, peptide repertoire changes that occur during infection or tumour 
transformation it may be more suitable to describe them as NK “agonist” peptides. 
These NK “agonist” peptides that interact weakly with inhibitory KIR receptors may 
be of viral or host origin. A model for the mechanism by which alterations in peptide 
repertoire can activate NK cells is shown in Figure 6.1. As peptide specificity has 
been described for KIR receptors as a requirement for recognition of MHC class I 
molecules, the NK cell activation observed by NK agonist peptides is unlikely to be 
specific for KIR2DL2 and KIR2DL3, but may be a common mechanism for NK cell 
receptors to detect infected or tumour transformed cells. This is indicated by the 
observation that CD94/NKG2A recognition of HLA-E is disrupted by an hsp60-
derived peptide (Michaelson et al, 2002), which may disrupt inhibition in the presence 
of inhibitory HLA-E: peptide complexes. It would be interesting to determine the 
effect of viral infection on changing the peptide repertoire and whether “natural” NK 
“agonist” peptides exist.  
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Figure 6.1 The effect of NK cell “agonist” peptides on NK cell inhibition 
a. The set of peptides presented by MHC class I molecules on healthy cells derived from 
endogenous self proteins may contain a proportion of peptides that are permissive for KIR 
binding tuned just above the threshold required to inhibit NK cells. Interaction of KIR 
receptors on NK cells with MHC class I: inhibitory peptide results in clustering of KIR and 
MHC class I and formation of an inhibitory immune synapse. Subsequently, SHP-1 is 
recruited. Recruitment of SHP-1 to KIR ITIMs results in ITIM phosphorylation and inhibition 
of NK cell function. b. Viral infection may alter the peptide repertoire from NK cell-
protective to non-protective. Alteration in virus-derived or host-derived peptides presented by 
MHC class I molecules by even 25% can trigger NK cell activation in a KIR-dependent 
manner if the presented peptides are non-permissive for KIR binding (NK “agonist” peptide). 
NK “agonist” peptides are recruited with inhibitory peptides to the NK cell synapse, but 
activate NK cells. The effect of an NK “agonist” peptide on NK cell signalling in the presence 
of an inhibitory peptide has not yet been characterised. 
Inhibitory peptide
NK cell “agonist” peptide
SHP-1
Healthy cells expressing MHC: permissive 
peptides above threshold for inhibition 
results in NK cell INHIBITION
Target cell
NK cell
Healthy cells
KIR
MHC 
class I
Activating 
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Activating 
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25% change in peptide repertoire towards 
MHC: peptide non-permissive for KIR 
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Individual susceptibility to disease is strongly influenced by the genetic profile of the 
host. The HLA class I loci is genetically diverse and KIR receptors exhibit allelic 
polymorphism. Each HLA allotype has its own rules for peptide binding, although 
KIR receptors can bind to different HLA-B or HLA-C molecules. The observations 
that KIR receptors exhibit peptide specificity indicate that a particular HLA allotype 
can markedly contribute to susceptibility or resistance to disease and may place 
selective pressure on that HLA allotype. It may be possible that a particular HLA 
allotype is selected for that can present peptides that mediate weak interaction with 
KIR receptors i.e. that can bind NK “agonist” peptides, resulting in NK cell activation 
during viral infection or tumour transformation. The functional importance of KIR 
and HLA polymorphism is not completely understood, but precise analysis of KIR 
and HLA alleles, rather than overall genotypes may result in stronger associations 
with disease or loss of statistical significance. Indeed, the protective effect of 
KIR2DL3 with HLA-C1 in HCV infection highlights the value of discriminating 
between KIR alleles in disease association studies. Without distinguishing between 
KIR2DL2 and KIR2DL3, no protective effect would have been observed. Further 
analysis of HLA-C1 alleles may reveal stronger or weaker protective association, 
which in may in part be due to the specific peptide that they present. Several HLA 
class I alleles are known to have either beneficial or deleterious consequences, 
depending on the type of disease. HLA-B*5301 contributes to susceptibility in AIDS 
progression, while protecting against severe malaria (Gao et al, 2001; Hill et al, 
1991), and HLA-Cw*06 in combination with KIR2DS1 is protective in psoriatic 
arthritis (Martin et al, 2002b).  
 
The peptide specificity observed by KIR receptors may play an important role in anti-
tumour and anti-viral immunity. NK cells are abundant in inflamed and non-inflamed 
human lymph nodes (Ferlazzo et al, 2004; Fehniger et al, 2003) and thus may exert a 
rapid viral effect on recognition of altered self, such as MHC class I molecules 
presenting non-protective peptides. In addition to its anti-viral effect, NK cell 
responses promote early CD8+ T cell responses against viruses and depletion of NK 
cells from mice results in inefficient priming of virus-specific T cells (Liu et al, 2000). 
The function of NK cells extends beyond direct killing of target cells. NK cells 
control and shape adaptive responses in response to viral infection, tumours, 
autoimmunity, and transplantation. Through interaction with DCs, NK cells promote 
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Th1 polarisation of CD4+ T cells through secretion of IFN-γ (Mailliard et al, 2003), 
which in turn promotes priming and expansion of CD8+ T cells. NK cells therefore 
play central responses in innate and adaptive immunity. NK cells are regulated by 
inhibitory and activating receptors, to which KIR make a major contribution, and the 
interaction between KIR receptors and MHC class I molecules may be critical in 
mounting an immune response against viruses or tumours. A further understanding of 
the interactions between KIR receptors and MHC class I: peptide and how virus- or 
tumour- induced changes in peptide repertoire can affect the functional consequences 
of NK cells is required.  
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Chapter 7. Conclusion 
 
In summary, we have demonstrated that KIR2DL2 binds more avidly than KIR2DL3 
to HLA-C1-transfected cells and HLA-Cw*0102: peptide complexes. Analysis of a 
panel of seven peptides showed that the nature of the bound peptide affects 
recognition of HLA-Cw*0102 by these two KIR receptors; mutations at residues 7 
and 8 only affect recognition. A peptide hierarchy was observed for binding of HLA-
C1 to KIR2DL2 and KIR2DL3, with KIR2DL2 consistently binding more avidly than 
KIR2DL3. These observations may provide an explanation for the protective effect of 
KIR2DL3-HLA-C1 homozygosity observed in HCV infection; weaker binding 
KIR2DL3 may provide less inhibition than KIR2DL2, resulting in increased NK 
activity against hepatitis C-infected cells. Functional assays to look at the effect of 
exogenous peptide on degranulation by CD158b+ NK cells confirmed the peptide 
hierarchy observed in binding assays. Using NK cells from KIR2DL2 homozygotes 
and KIR2DL3 homozygotes, no differences were observed between donors in NK cell 
activation in response to HLA-C1: peptide complexes, which may reflect a true 
observation, although further investigation is required. To look at the effect of peptide 
repertoire changes on NK cell activation, in vitro peptide repertoires were generated 
incorporating strong and weak KIR-binding peptides. We observed that in the 
presence of a weak KIR-binding peptide, inhibition mediated by a strong KIR-binding 
peptide was perturbed, without disrupting formation of the inhibitory immune 
synapse.  
 
Important directions for future studies will be to obtain direct affinity measurements 
of interaction of KIR2DL2 and KIR2DL3 with different HLA-C: peptide complexes. 
It would be interesting to investigate how viral infection can alter the peptide 
repertoire, and whether upregulation of host- or virus-derived peptides includes weak-
binding peptides for KIR or other NK cell inhibitory receptors. Finally, investigating 
the mechanism by which weak KIR-binding peptides can disrupt NK cell inhibition is 
required to look at the effect on intracellular signalling. An understanding of the 
interactions between KIR receptors and their ligands may provide insight into NK cell 
calibration and lead to a greater understanding of how pathogens can modulate NK 
function. 
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